---
document_datetime: 2023-12-11 10:21:39
document_pages: 96
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/vyxeos-liposomal-epar-assessment-report-variation_en.pdf
document_name: vyxeos-liposomal-epar-assessment-report-variation_en.pdf
version: success
processing_time: 92.7356992
conversion_datetime: 2025-12-24 01:14:54.146464
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 March 2022 EMA/665588/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Vyxeos liposomal

International non-proprietary name: daunorubicin / cytarabine

Procedure No. EMEA/H/C/004282/II/0018/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 6                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6    |                                                                                                            |
| 1.2. Steps taken for the assessment of the product                                                                        | ........................................................7                                                  |
| 1.3. Introduction                                                                                                         | ........................................................................................................8  |
| 1.3.1. Problem statement                                                                                                  | ............................................................................................8              |
| 1.3.2. About the product                                                                                                  | .............................................................................................9             |
| 1.3.3. The development programme/compliance with CHMP guidance/scientific advice........9                                 |                                                                                                            |
| 1.3.4. General comments on compliance with GCP........................................................                    | 10                                                                                                         |
| 1.4. Non-clinical aspects............................................................................................     | 10                                                                                                         |
| 1.4.1. Ecotoxicity/environmental risk assessment.........................................................                 | 10                                                                                                         |
| 1.4.2. Conclusion on the non-clinical aspects                                                                             | ............................................................... 13                                         |
| 1.5. Clinical aspects                                                                                                     | .................................................................................................. 13      |
| 1.5.1. Introduction....................................................................................................   | 13                                                                                                         |
| 1.5.2. Pharmacokinetics                                                                                                   | ............................................................................................ 14            |
| 1.5.3. Pharmacodynamics..........................................................................................         | 19                                                                                                         |
| 1.5.4. PK/PD modelling                                                                                                    | ............................................................................................. 19           |
| 1.5.5. Discussion on clinical pharmacology...................................................................             | 44                                                                                                         |
| 1.5.6. Conclusions on clinical pharmacology.................................................................              | 46                                                                                                         |
| 1.6. Clinical efficacy .................................................................................................. | 46                                                                                                         |
| 1.6.1. Dose response studies .....................................................................................        | 46                                                                                                         |
| 1.6.2. Main study                                                                                                         | ..................................................................................................... 50   |
| 1.6.3. Discussion on clinical efficacy............................................................................        | 66                                                                                                         |
| 1.6.4. Conclusions on the clinical efficacy ....................................................................          | 69                                                                                                         |
| 1.7. Clinical safety                                                                                                      | .................................................................................................... 70    |
| 1.7.1. Discussion on clinical safety..............................................................................        | 87                                                                                                         |
| 1.7.2. Conclusions on clinical safety............................................................................         | 90                                                                                                         |
| 1.7.3. PSUR cycle                                                                                                         | ..................................................................................................... 90   |
| 1.8. Risk management plan                                                                                                 | ....................................................................................... 90                 |
| 1.9. Update of the Product information........................................................................            | 90                                                                                                         |
| 2. Benefit-Risk Balance.............................................................................                      | 90                                                                                                         |
| 2.1.1. Disease or condition                                                                                               | ........................................................................................ 90                |
| 2.1.2. Available therapies and unmet medical need.......................................................                  | 90                                                                                                         |
| 2.1.3. Main clinical studies.........................................................................................     | 91                                                                                                         |
| 2.2. Favourable effects (study AAML1421)...................................................................               | 91                                                                                                         |
| 2.3. Uncertainties and limitations about favourable effects.............................................                  | 91                                                                                                         |
| 2.4. Unfavourable effects...........................................................................................      | 92                                                                                                         |
| 2.5. Uncertainties and limitations about unfavourable effects                                                             | ......................................... 93                                                               |
| 2.6. Effects Table......................................................................................................  | 94                                                                                                         |
| 2.7. Benefit-risk assessment and discussion.................................................................              | 94                                                                                                         |
| 2.7.1. Importance of favourable and unfavourable effects..............................................                    | 94                                                                                                         |
| 2.7.2. Balance of benefits and risks ............................................................................         | 95                                                                                                         |
| 2.7.3. Additional considerations on the benefit-risk balance                                                              | ........................................... 95                                                             |
| 2.8. Conclusions                                                                                                          | ....................................................................................................... 95 |

<div style=\"page-break-after: always\"></div>

3. Recommendations  ................................................................................. 95

4. EPAR changes ....................................................................................... 96

<div style=\"page-break-after: always\"></div>

## List of abbreviations

7 + 3

7-day continuous infusion of cytarabine at a dose of 100 to 200 mg/m2/day in combination with administration of an anthracycline for 3 days

AE

adverse event

AESI

adverse events of special interest

AML

acute myeloid leukemia

AML-MRC

AML with myelodysplasia-related changes

ANC

absolute neutrophil count

Ara-U

1- β -d-arabinofuranosyluracil

AUC

area under the plasma concentration-time curve

BSA

body surface area

CCH

Cincinnati Children's Hospital

CL

clearance

Cmax

maximum concentration

COG

Children's Oncology Group

CPX-351

daunorubicin and cytarabine powder for concentrate for solution for infusion

CR

complete remission

CR1

first complete remission

CR2

second complete remission

CRF

case report form

CRi

complete remission with incomplete hematologic recovery

CRp

complete remission with incomplete platelet recovery

CSR

clinical study report

DLT

dose limiting toxicity

DNX

daunoxome

ECG

electrocardiogram

ECHO

echocardiogram

EEA

European Economic Area

EFS

event-free survival

EMA

European Medicines Agency

ERA

Environmental risk assessment

E-R

exposure-response

EU

European Union

FDA

Food and Drug Administration

PEC

Predicted environmental concentration

FLAG

fludarabine, cytarabine, and G-CSF

FLAG-IDA

FLAG in combination with idarubicin

Fpen

Market penetration

G-CSF

granulocyte-colony stimulating factor

HSCT

hematopoietic stem cell transplant

IV

intravenous

log P

Octanol-water partition coefficient

LVEF

left ventricular ejection fraction

LVSF

left ventricular shortening fraction

MEC

mitoxantrone, cytarabine and etoposide

MLFS

morphologic leukemia-free state

MTD

maximum tolerated dose

ORR

overall response rate

OS

overall survival

PBRER

Periodic Benefit-risk Evaluation Report

PIP

pediatric investigational plan

PK

pharmacokinetic(s)

PT

preferred term

RP2D

recommended phase 2 dose

RR-AML

relapsed or refractory AML

SAE

serious adverse event

SOC

system organ class

TEAE

treatment-emergent adverse event

t-AML

therapy-related AML

UK

United Kingdom

US

United States

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Jazz Pharmaceuticals Ireland Limited submitted to the European Medicines Agency on 26 November 2020 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                                          | Type    | Annexes affected   |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                | Type II | I, II and IIIB     |
| C.I.13                 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | Type II | None               |

Extension of indication to add treatment of relapsed/refractory AML in paediatric patients with subsequent updates to Sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC based on the new safety and efficacy data from the paediatric clinical study AAML1421. The Package leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the PI is updated in line with the latest QRD template 10.2. Submission of the final data from paediatric clinical study CPX-MA-1201 in support of the extension of indication.

However, during the procedure the marketing authorisation holder revised the requested scope of the variation and no longer sought an extension of the indication, instead proposing inclusion of relevant paediatric data in the product information based on results from study AAML1421. See Section 4. for details.

## Information relating to orphan designation

Vyxeos liposomal, was designated as an orphan medicinal product (EU/3/11/942) on 11 January 2012 in the following indication: Treatment of acute myeloid leukaemia.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision EMEA001858-PIP02-16-M03 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP EMEA-001858-PIP02-16-M03 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No

<div style=\"page-break-after: always\"></div>

847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Protocol assistance

The MAH did not seek Protocol Assistance at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Johanna Lähteenvuo

Co-Rapporteur:

Janet Koenig

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 26 November 2020 |
| Start of procedure:                                  | 20 February 2021 |
| CHMP Rapporteur Assessment Report                    | 16 April 2021    |
| CHMP Co-Rapporteur Assessment Report                 | 22 April 2021    |
| PRAC Rapporteur Assessment Report                    | 22 April 2021    |
| PRAC members comments                                | 28 April 2021    |
| Updated PRAC Rapporteur Assessment Report            | 29 April 2021    |
| PRAC Outcome                                         | 6 May 2021       |
| CHMP members comments                                | 10 May 2021      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 18 May 2021      |
| Request for supplementary information (RSI)          | 20 May 2021      |
| CHMP Rapporteur Assessment Report                    | 12 October 2021  |
| PRAC Rapporteur Assessment Report                    | 13 October 2021  |
| PRAC members comments                                | 20 October 2021  |
| Updated PRAC Rapporteur Assessment Report            | 21 October 2021  |
| PRAC Outcome                                         | 28 October 2021  |
| CHMP members comments                                | 29 October 2021  |
| Updated CHMP Rapporteur Assessment Report            | 4 November 2021  |
| Request for supplementary information (RSI)          | 11 November 2021 |
| CHMP Rapporteur Assessment Report                    | 22 February 2022 |
| PRAC Rapporteur Assessment Report                    | 22 February 2022 |

<div style=\"page-break-after: always\"></div>

| Timetable                                 | Actual dates   |
|-------------------------------------------|----------------|
| PRAC members comments                     | 02 March 2022  |
| Updated PRAC Rapporteur Assessment Report | 3 March 2022   |
| PRAC Outcome                              | 10 March 2022  |
| CHMP members comments                     | 14 March 2022  |
| Updated CHMP Rapporteur Assessment Report | 17 March 2022  |
| Opinion                                   | 24 March 2022  |

## 1.3. Introduction

## 1.3.1. Problem statement

Vyxeos  liposomal  is  approved  for  the  treatment  of  adults  with  newly-diagnosed  therapy-related  acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

## State the claimed the therapeutic indication

The MAH is proposing the following extension of the approved AML indication: the treatment of relapsed or refractory AML in paediatric and young adult patients aged 1 to 21 years old.

## Clinical presentation, diagnosis and stage/prognosis

Acute myeloid leukaemia is a form of leukaemia - i.e., cancer of the white blood cells - characterised by infiltration  of  proliferative,  clonal,  abnormally  differentiated,  and  occasionally  poorly  differentiated haematopoietic cells of myeloid lineage in the bone marrow, blood, and other tissues.

In AML, leukaemic blasts replace normal blood cells in bone marrow and peripheral blood, which leads to anaemia, neutropenia, and thrombocytopenia. This is associated with symptoms of fatigue, shortness of breath, disturbed wound healing, infections and bleedings. If left untreated, AML results in death within a few weeks to months.

AMLs are classified according to the World Health Organisation (WHO) classification from 2001, revised in 2008 and in 2016 (2). The classification incorporates morphological criteria, cytogenetic data, molecular genetics, immunophenotype data and clinical information into a diagnostic algorithm to delineate clinically significant disease entities.

## Management

Leukaemia accounts for approximately 30% of all paediatric malignancies, of which 15-20% comprises AML. Long-term survival rates of pediatric AML patients are currently 70% or even higher. Compared to adults, children with AML have superior outcomes due to fewer adverse genetic mutations and the ability to  tolerate  the  high-intensity  chemotherapy  currently  necessary  for  cure.  Regarding  novel  agents  and treatment  modalities,  drugs  such  as  venetoclax,  monoclonal  antibodies,  and  cellular  therapies  are investigated in AML.

<div style=\"page-break-after: always\"></div>

Treatment decisions, namely the need for hematopoietic stem-cell transplantation (HSCT) in pediatric AML are primarily driven by genetic risk classification which is quickly evolving. However, in 24 - 40% of children the AML relapses, with a probability of long-term survival of approximately 40%. These poor outcomes indicate the need for improved treatment, including innovative drugs and treatment modalities. Due to a relatively small patient population, studies on pediatric relapsed AML mostly consist of case reports and only a few large cohort-based studies have been performed.

For  patients  who  relapse,  or  are  refractory  to  first-line  therapy,  there  is  a  limited  number  of  effective therapeutic agents available. Optimal treatment for paediatric relapsed AML is not well defined, regarding optimal chemotherapy, the need for allogeneic HSCT (allo-HSCT), the timing of an allo-HSCT and risk group stratified treatment based on prognostic factors. However, allo-HSCT in the second complete remission after reinduction chemotherapy is associated with better outcome than chemotherapy only, and once a paediatric patient relapses, working towards an allo-HSCT is currently a rule.

## 1.3.2. About the product

Vyxeos liposomal is a liposomal formulation of a fixed combination of daunorubicin and cytarabine in a 1:5 molar ratio. The 1:5 molar ratio has been shown in vitro and in vivo to maximise synergistic antitumour activity in AML.

Daunorubicin has antimitotic and cytotoxic activity, which is achieved by forming complexes with DNA, inhibiting  topoisomerase  II  activity,  inhibiting  DNA  polymerase  activity,  affecting  regulation  of  gene expression, and producing DNA-damaging free radicals.

Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division.  Intracellularly,  cytarabine  is  converted  into  cytarabine-5-triphosphate  (ara-CTP),  which  is  the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition  of  DNA  synthesis.  Incorporation  into DNA  and  RNA  may  also  contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to proliferating mammalian cells in culture.

Based on data in animals, Vyxeos liposomes accumulate and persist in high concentration in the bone marrow, where they are preferentially taken up intact by leukaemia cells in an active engulfment process. In leukaemia-bearing mice, the liposomes are taken up by leukaemia cells to a greater extent than by normal  bone  marrow  cells.  After  internalisation,  Vyxeos  liposomes  undergo  degradation,  releasing daunorubicin and cytarabine within the intracellular environment, enabling the medicinal products to exert their synergistic antineoplastic activity.

The currently approved indication is the treatment of adults with newly-diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

## 1.3.3. The development programme/compliance with CHMP guidance/scientific advice

No scientific advice was given by CHMP with regard to paediatric studies CPX-MA-1201, AAML1421 and 1831.

A paediatric investigational plan (PIP) for CPX-351 (EMA-001858-PIP01-15) was approved on 23 June 2018 (P/0200/2017).  There  have  been  3  PIP  modifications  submitted  to  the  EMA.  The  current  PIP  strategy

<div style=\"page-break-after: always\"></div>

includes Study CPX-MA-1201, and Study AAML1421, which are both included in this application. It also includes a newly initiated paediatric Study 1831 in paediatrics patients with newly-diagnosed AML.

## 1.3.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

No scientific advice was given by CHMP with regard to paediatric studies CPX-MA-1201, AAML1421 and 1831.

A paediatric investigational plan (PIP) for CPX-351 (EMA-001858-PIP01-15) was approved on 23 June 2018 (P/0200/2017).  There  have  been  3  PIP  modifications  submitted  to  the  EMA.  The  current  PIP  strategy includes Study CPX-MA-1201, and Study AAML1421, which are both included in this application. It also includes a newly initiated paediatric Study 1831 in paediatrics patients with newly-diagnosed AML.

A PIP compliance report was approved by PDCO 29.1.2021 (EMA/656343/2020).

## 1.4. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 1.4.1. Ecotoxicity/environmental risk assessment

The MAH submitted an updated ERA for Vyxeos liposomal according to the active CHMP 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' and the Questions and Answers on the  Guideline  (EMEA/CHMP/SWP/4447/00  corr2,  2006;  EMA/CHMP/SWP/44609/2010  Rev.,  2016).  It includes both active components of Vyxeos liposomal (cytarabine and daunorubicin) and updates regarding the dosing regimen in adults and the addition of the paediatric population to include the sought paediatric indication in relapsed/refractory (R/R) AML.

## Phase I: Estimation of Exposure

Screening for Persistence, Bioaccumulation, and Toxicity

The octanol-water partition coefficient (log Kow log P) of cytarabine was determined by the shake-flask method. The log Kow of cytarabine at 21°C, determined for 3 different water:octanol ratios from 0.5 to 2 using the shake flask method, was determined to be -2.02 ± 0.04. For daunorubicin, the experimental value of log Kow reported in the literature is 1.83. The experimental log Kow values for the drug substances cytarabine and daunorubicin are below 4.5; therefore, further screening is not considered necessary for persistence, bioaccumulation, and toxicity.

Calculation of the Predicted Environmental Concentration (PEC)

Only a maximum number of doses of Vyxeos liposomal can be received over a lifetime by adult patients (n=9 doses), and by children and adolescent patients (n=3 doses) according to the approved and proposed labelling. The use of daunorubicin (and other anthracycline preparations) as monotherapy is also limited

<div style=\"page-break-after: always\"></div>

primarily due to the intrinsic cardiotoxicity associated with daunorubicin, one of Vyxeos liposomal active components. Therefore, the fraction of market penetration (Fpen) calculations accounts for the limited number  of  doses  that  can  be  received  by  patients  over  their  lifetime.  The  predicted  environmental concentration (PEC) was calculated for each of the active components (cytarabine and daunorubicin) for the adults and children/adolescent patient populations separately, and was then be summed to obtain the overall PEC. The Fpen was refined based on prevalence of the disease and treatment regime among each patient population.

## Adult Patients

The approved regimen for Vyxeos liposomal is 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine on days 1, 3, and 5 for the first induction; 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine on days 1 and 3, for the second induction; and 29 mg/m 2  daunorubicin and 65 mg/m 2  cytarabine on days 1 and 3 for up to 2 consolidation  cycles.  The  maximum  lifetime  number  of  doses  in  adults  is  9  (5  induction  doses  and  4 consolidation doses), corresponding to a total maximum lifetime dose of 336 mg/m 2  daunorubicin and 760 mg/m 2  cytarabine. Using a maximum body surface area of 2.5 m 2  these doses correspond to 840 mg daunorubicin and 1900 mg cytarabine.

## Fpen Calculation

Fpen  was  calculated  using  the  formula  given  in  EMA/CHMP/SWP/44609/2010  Rev.,  2016  and  yearly incidence of disease (39881 cases in 2017, a conservative assumption that includes all adult AML patients).

Fpen Daunorubicin = 1.9 x 10 -6

Fpen Cytarabine = 1.9 x 10 -6

## PECSW Calculation

Because the doses used for the induction and consolidation cycles are different, the defined daily dose is the average of the maximum total dose (i.e., induction plus consolidation) divided by the maximum total of dosing days (for daunorubicin 840 mg/9 days = 93.3 mg/day and for cytarabine 1900 mg/9 days = 211.1 mg/day).

Using the formula given in EMEA/CHMP/SWP/4447/00 corr 2:

PECSW Daunorubicin = 0.000090 µg/L

PECSW Cytarabine = 0.00020 µg/L

## Paediatric Patients

In children and adolescents, the regimen consists of a single induction cycle with 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine on days 1, 3, and 5. Therefore, the maximum number of lifetime doses in children is 3 (3 induction doses) for a maximum total dose of 177 mg/m 2  daunorubicin and 405 mg/m 2 cytarabine. Assuming a body surface area of 2 m 2  the maximum daily doses on dosing days are 118 mg daunorubicin and 270 mg cytarabine.

## Fpen Calculation

Fpen  was  calculated  using  the  formula  given  in  EMA/CHMP/SWP/44609/2010  Rev.,  2016  and  yearly incidence of disease (R/R paediatric AML yearly incidence is estimated to a maximum of 40% of 2 cases per  million  inhabitants,  or  approximately  410  cases  per  year  and  a  conservative  assumption  that  all paediatric R/R AML patients take Vyxeos liposomal).

Fpen Daunorubicin = 6.6 x 10 -9

<div style=\"page-break-after: always\"></div>

## Fpen Cytarabine = 6.6 x 10 -9

## PECSW Calculation

Because the doses used for the induction cycles in children are constant, it corresponds to the defined daily dose.

Using the formula given in EMEA/CHMP/SWP/4447/00 corr 2:

PECSW Daunorubicin = 0.00000039 µg/L

PECSW Cytarabine = 0.00000089 µg/L

## Daunorubicin Use with Other Patients

The QuintilesIMS database search provided an estimate of daunorubicin use (in mg) from 23 different European Union countries for 2Q2017. The QuintilesIMS used data for daunorubicin for 1 quarter (37390 mg), which was then multiplied by 4 in order to predict the yearly use of daunorubicin (149560 mg) in medicinal products other than  Vyxeos  liposomal.  Based  on  the  SmPC  for  Cerubidin  20  mg  Powder  for Solution for Injection (daunorubicin hydrochloride), daunorubicin is used for the induction of remission in acute lymphoblastic or lymphatic leukaemias (ALL) and acute myeloid leukaemias (AML). The maximum lifetime cumulative dose for daunorubicin is 550 mg/m 2  due to the potential for cardiotoxicity. Per the SmPC, the recommended daily dose in adults is 45 mg/m 2  and the maximum dose is 60 mg/m 2 . Assuming a  body  surface  area  of  2.5  m 2  the  recommended  and  maximum  doses  are  112  mg  and  150  mg  of daunorubicin, respectively for one treatment day.

## Fpen Calculation

Fpen was calculated using the formula given in EMA/CHMP/SWP/44609/2010 Rev., 2016, the daily dose of 45 mg/m 2  and consumption of 149560 mg/year.

Fpen Daudorubicin = 1.1 x 10 -8 .

## PECSWr Calculation

Using the formula given in EMEA/CHMP/SWP/4447/00 corr 2:

PECSW Daunorubicin = 0.0000006 µg/L.

## Total PECsurfacewater

PECSW Daunorubicin = PECSW for adults + PECSWr for children and adolescents + PECSWr for other use

## PECSW Daunorubicin = 0.000090 μ g/L + 0.00000039 μ g/L + 0.0000006 μ g/L = 0.000091 μ g/L

PECSW Cytarabine = PECSW for adults + PECSW for children and adolescents

PECSW Cytarabine = 0.00020 μ g/L + 0.00000089 μ g/L = 0.00020 μ g/L

Therefore, the PECSW for either drug substances are below the action limit threshold of 0.01 μ g/L and a Phase II environmental-fate and effect analysis is not required.

<div style=\"page-break-after: always\"></div>

## 1.4.2. Conclusion on the non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of daunorubicin and cytarabine.

Considering the above data, daunorubicin and cytarabine are not expected to pose a risk to the environment.

## 1.5. Clinical aspects

## 1.5.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| StudyIdlentifier Status Report Location Report Type          | Type of Study           | Study Design and Type of Control   | Objective(s) ofthe Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Product,Route,Doseand Durationof Treatment                                                                                                                                                                 | Subject Population Mean age (range)                                                                                                                                                                                    |
|--------------------------------------------------------------|-------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CPX-MA-1201 Complete Module 5.3.5.2 Full CSR and CSR Erratum | Safety, Efficacy and PK | Phase 1 OL, SC, Pilot study        | To determine a safe and tolerable dose of CPX-351 in children and adolescents (≤ 21 years of age) with relapsed or refractory hematopoietic malignancies and to recommend a dose for future studies. To describe the toxicity and tolerability of CPX-351in childrenand young adults (≤ 30 years of age) with hematopoietic malignancies. To recommend a dose of CPX-351 for future studies in young patients with previously untreated AML. To describe the PK of plasma cytarabine and daunorubicin after CPX-351 administration to young patients with recurrent or refractory hematologic malignancies. | ●CPX-351100 or 134 units/m² by CVC over90 minutes on Days 1, 3 and 5 ·IT cytarabine at the Investigator's discretion in subjects with microscopic disease in CSF and in those at high risk for CNS failure | 13 male subjects and 14 female subjects ≥1 year and≤ 21 years for the Dose Exploration Phase and ≥ 1 year and ≤ 30 years for the Expanded Phase with pathologically confirmed relapsed AML or ALL; 6.7 years (1 to 19) |

<div style=\"page-break-after: always\"></div>

| Study Idlentifier Status Report Location Report Type                  | Type of Study           | Study Design and Type of Control   | Objective(s) of the Study                                                                                                                                                                                                                                              | Product,Route,Dose and Duration of Treatment                                                                                                                                                                                                                                                                                                                      | Subject Population Mean age (range)                                                                |
|-----------------------------------------------------------------------|-------------------------|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| AAML1421 Efficacy complete; Follow-up ongoing Module 5.3.5.2 Full CSR | Safety, Efficacy and PK | Phase 1/2 OL, MC                   | To determine a RP2D and the toxicities associated with CPX- 351 in pediatric and young adult subjects with relapsed / refractory AML To estimate the response rate (CR + CRp) after CPX-351 (Cycle 1) followed by FLAG (Cycle 2) in children with AML in first relapse | Cycle 1 2 doses IT cytarabine (age-based dosing) CPX-351 135 units/m² by CVC over90 minutes onDays1,3 and 5 Cycle 2 fludarabine 30 mg/m² IV over 30 minutes on Days 1-5. High dose cytarabine 2000 mg/m² IV over 1 to 3 hours on Days 1-5 5 μg/kg filgrastim IV or SC on Days 1-5. Dosing was restarted on Day 15 and continued until the post-nadir ANC ≥ 500/μL | 18 male subjects and 20 female subjects with pathologically confirmed relapsed AML; 10.6 (1 to 21) |

## 1.5.2. Pharmacokinetics

## Pharmacokinetics in adults

Non-liposomal cytarabine and daunorubicin have markedly different PK parameters from one another. In contrast, when administered as components of daunorubicin and cytarabine powder for concentrate for solution for infusion (referred to thereafter also as CPX-351 in this report), the PK parameters for cytarabine and daunorubicin are similar ( Table 1 ).  The  convergence of PK parameters suggests that most of the cytarabine  and  daunorubicin  in  the  circulation  remains  trapped  within  the  liposomes  that  are  slowly eliminated. Therefore, the measured PK parameters for cytarabine and daunorubicin following CPX-351 administration mostly reflect the PK of the liposomes. Small volume of distribution (~7 litres in adults) indicates that the liposomes are highly confined in the vascular space. The accumulation ratio is 1.3 and 1.4 for daunorubicin and cytarabine, respectively, following IV administration at days 1, 3, and 5, consistent with the elimination half-lives.

Table 1. Mean plasma PK parameters for cytarabine and daunorubicin when administered as CPX-351 or as non-liposomal formulations in adult patients.

| PKParameter'   | CPX-351    | CPX-351      | Non-liposomal   | Non-liposomal   |
|----------------|------------|--------------|-----------------|-----------------|
|                | Cytarabine | Daunorubicin | Cytarabine      | Daunorubicin    |
| V(L)           | 7.11       | 6.64         | 138?            | 1364?           |
| CL (L/h)       | 0.131      | 0.163        | 272a            | 129a            |
| t12(h)         | 40.4       | 31.5         | 1-3             | 18.5c           |

Abbreviations:CL=clearance;ti/2=terminalhalf-life;V=volume ofdistribution.

Dose adjustment is not required in elderly patients or in patients with mild or moderate renal impairment. There is no experience in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) or endstage renal disease. Dose adjustment is not required in patients with a bilirubin level less than or equal to 50 µmol/L. There is no experience in patients with hepatic impairment resulting in a bilirubin level greater than 50 µmol/L.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics in the paediatric population

Pharmacokinetics of Vyxeos in the paediatric and young adult population (age 1 to 21 years old, inclusive) were investigated in two clinical trials (CPX-MA-1201 and AAML1421). For both studies, the MAH was not involved in study conduct, but has received the data from the Sponsors and summarized the results of the study for the purposes of regulatory submission. The studies are described in detail in section 5.4 Clinical efficacy of this AR. The PK results are summarised below.

## Pharmacokinetic data analysis in individual paediatric studies

In study 1201, the PK Analysis Set included all subjects who received at least 1 infusion of CPX-351 and had at least 1 evaluable PK concentration. This analysis set was used for all descriptive PK summaries. In study 1421, the PK population includes all patients who received at least one dose of the study drug treatment and provided enough PK samples to estimate at least one PK parameter. The PK analysis was performed using the PK population.

Plasma concentration data used in the PK analyses corresponded to 'total' concentrations of cytarabine or daunorubicin, where 'total' corresponds to the sum of encapsulated drug (ie, drug retained within the liposomes) plus free drug (i., drug released from the liposomes). Given that &gt;99% of the cytarabine and daunorubicin in the circulation remains encapsulated within the CPX-351 liposomes (see initial marketing authorisation application assessment report), PK analyses based on total plasma concentrations basically describe the plasma kinetics of the encapsulated drugs. The MAH considers PK based on encapsulated drugs relevant  to  clinical  benefits,  because  uptake  of  intact  liposomes  by  leukemia  cells  is  central  to  the mechanism of action for CPX-351 in antileukemic effects.

Plasma concentration-time profiles were generated for cytarabine and daunorubicin for each subject. All plasma PK parameter calculations were performed using actual or nominal times (when actual time was not  available),  calculated  relative  to  the  start  of  study  drug  infusion  in  hours.  Concentration  values  of plasma cytarabine and daunorubicin that were reported as below the limit of quantitation (BLQ) were set to zero for PK parameter calculation and concentration summary statistics.

PK parameters were determined using non-compartmental (NCA) methods based on individual plasma concentration-time  data  for  cytarabine  and  daunorubicin  following  Day  5  CPX-351  administration.  PK parameters were estimated from the plasma concentration-time profile of all evaluable subjects using noncompartmental methods in Phoenix WinNonlin 7.0 (Pharsight, St. Louis, MO, USA).

## Study CPX-MA-1201

Study CPX-MA-1201 was a phase 1 pilot study to assess the PK, toxicity and tolerability of CPX-351 in paediatric and young adult patients (age 1 to 21 years old, inclusive) with relapsed / refractory hematologic malignancies. This study was conducted in two phases: Dose Exploration Phase and Expanded Phase (Table 2).

Table 2. Study design and posology for study CPX-MA-1201

| Phase       | Treatment               | Dose/Regimen                                                      | Patients (n)   |
|-------------|-------------------------|-------------------------------------------------------------------|----------------|
| Exploration | Induction 1 Induction 1 | 100 units/m 2 , Days 1, 3, and 5 134 units/m 2 , Days 1, 3, and 5 | 4 5            |
| Expanded    | Induction 1             | 100 units/m 2 , Days 1, 3, and 5                                  | 18             |

Note: 1 unit CPX-351 = 1 mg cytarabine and 0.44 mg daunorubicin

<div style=\"page-break-after: always\"></div>

Blood samples for the determination of the concentrations of plasma cytarabine and daunorubicin were collected following Day 5 infusion, as follows: at predose (0), 45 min, 90 min (end of infusion), 2, 5, 8, 12, 24, 72 and 120 h post start of CPX-351 infusion.

A total of 27 patients were enrolled and included in the PK analysis. No doses were missed on Day 1, Day 3 and Day 5.

At Day 5, peak plasma concentrations of cytarabine and daunorubicin were observed at the end of or soon after the end of infusion. Measurable concentrations were observed until the end of PK follow-up (120 hours after dosing) for both analytes ( Figure 1 ). The PK parameters for cytarabine and daunorubicin (calculated using noncompartmental analyses) are summarized in Table 3 .

Figure 1: Mean (+SD) Plasma Concentrations of Cytarabine and Daunorubicin vs. Time Following a 90 Minute IV Infusion of CPX-351 - Dose Exploration and Expanded Phase (Study CPX-MA-1201)

<!-- image -->

Notes: Open squares represent mean plasma concentrations for subjects who received 100 units/m2 CPX-351 during the Dose Exploration Phase. Open triangles represent mean plasma concentrations for subjects who received 134 units/m² CPX-351 during the Dose Exploration Phase. Open circles represent mean plasma concentrations for subjects who received 100 units/m² CPX-351 during the Expanded Phase.

<div style=\"page-break-after: always\"></div>

Table 3. Geometric Mean (CV%) Plasma PK Parameters of Cytarabine and Daunorubicin Following a 90 Minute IV Infusion of CPX-351 (Study CPX-MA-1201)

| Plasma PK Parameters     | Dose Exploration Phase   | Dose Exploration Phase   | Expanded Phase         |
|--------------------------|--------------------------|--------------------------|------------------------|
| Plasma PK Parameters     | 100 Units/m 2 N = 4      | 134 Units/m 2 N = 5      | 100 Units/m 2 N = 18   |
| Cytarabine               | Cytarabine               | Cytarabine               | Cytarabine             |
| Actual Dose (mg)         | 106 (113, 46.0-151)      | 155 (115, 77.7-279)      | 87.6 (65.5, 44.0-209)  |
| AUC 48h (ng × h/mL)      | 2237575 (43.4)           | 3127565 (32.7)           | 2178534 (39.0)         |
| AUC 0-48 /D (h*ng/mL/mg) | 23134.0 (102.8)          | 23234.2 (80.1)           | 27828.1 (58.7)         |
| AUC last (ng × h/mL)     | 3049826 (48.5)           | 4225148 (41.5)           | 3049429 (47.7)         |
| AUC last /D (h*ng/mL/mg) | 31531.8 (106.0)          | 31388.0 (79.7)           | 38952.7 (59.4)         |
| AUC ∞ (ng × h/mL)        | 3272299 (52.7)           | 4510790 (44.6)           | 3278296 (51.1)         |
| AUC ∞ /D (h*ng/mL/mg)    | 33831.9 (107.3)          | 33510.0 (79.0)           | 41876.2 (59.4)         |
| C max (ng/mL)            | 91607 (31.7)             | 117609 (19.7)            | 82803 (20.4)           |
| C max /D (ng/mL/mg)      | 947.1 (94.3)             | 873.7 (77.3)             | 1057.7 (60.0)          |
| t max (h)                | 1.73 (1.68, 2.08)        | 1.97 (1.50, 5.17)        | 2.00 (1.50, 12.02)     |
| t ½ (h)                  | 28.5 (28.5)              | 28.6 (19.2)              | 29.4 (27.9)            |
| CL (mL/h)                | 43.2 (102.8)             | 43.0 (80.1)              | 35.9 (58.7)            |
| V ss (mL)                | 1736 (105.1)             | 1679 (89.5)              | 1501 (69.3)            |
| Molar Ratio C:D AUC 48h  | 7.95 (37.2)              | 7.03 (23.3)              | 5.96 (10.7)            |
| Molar Ratio C:D AUC last | 8.57 (37.1)              | 7.59 (27.5)              | 6.36 (12.5)            |
| Molar Ratio C:D AUC ∞    | 7.26 (3.2)               | 7.81 (29.8)              | 6.50 (13.7)            |
| Daunorubicin             | Daunorubicin             | Daunorubicin             | Daunorubicin           |
| Actual Dose (mg)         | 46.4 (49.5, 20.2-66.4)   | 68.4 (50.7, 34.2-123)    | 38.5 (28.8, 19.4-92.0) |
| AUC 48h (ng × h/mL)      | 610702 (41.5)            | 965409 (30.1)            | 792767 (38.6)          |
| AUC 0-48 /D (h*ng/mL/mg) | 14350.0 (107.0)          | 16299.7 (71.6)           | 23015.1 (60.3)         |
| AUC last (ng × h/mL)     | 771934 (41.6)            | 1206643 (38.1)           | 1040673 (44.6)         |
| AUC last /D (h*ng/mL/mg) | 18138.5 (109.0)          | 20372.7 (72.1)           | 30212.1 (60.4)         |
| AUC ∞ (ng × h/mL)        | 847450 (49.2)            | 1252827 (38.8)           | 1093606 (46.7)         |
| AUC ∞ /D (h*ng/mL/mg)    | 21397.0 (138.4)          | 21152.4 (71.8)           | 31748.8 (60.8)         |
| C max (ng/mL)            | 39086 (29.1)             | 47891 (12.7)             | 36420 (23.1)           |
| C max /D (ng/mL/mg)      | 918.4 (93.6)             | 808.6 (71.4)             | 1057.3 (62.5)          |
| tmax (h)                 | 1.69 (1.58, 1.75)        | 1.60 (1.50, 2.00)        | 1.83 (1.50, 2.05)      |
| t½ (h)                   | 21.1 (13.2)c             | 25.8 (8.6)               | 26.3 (22.2)            |
| CL (mL/h)                | 69.7 (107.0)             | 61.4 (71.6)              | 43.4 (60.3)            |
| Vss (mL)                 | 1594 (102.4)c            | 1806 (78.5)              | 1504 (66.7)            |

During the Dose Exploration Phase after the day 5 infusion, the geometric mean (geomean) molar ratio of cytarabine:daunorubicin (C:D) AUC0-48 for the 100 units/m 2  dose was 7.95 (CV 37.2%). A similar value was observed for the 134 units/m 2  dose (7.03; CV 23.3%). GeoMean molar ratios for AUC0-48 were slightly lower, and closer to the expected 5:1 C:D ratio, during the Expanded Phase for the 100 units/m 2  dose (5.96; CV 10.7%).

<div style=\"page-break-after: always\"></div>

## Study AAML1421

This study comprised 2 phases: Dose-finding Phase (n=6) and an Efficacy Phase (total n=32). All patients received a dose of 135 units/m 2  CPX-351.

Frequent plasma PK samples were collected in the Dose-finding Phase at the following times: Day 5: predose, and 45 minutes, 90 minutes, 2, 5, 8, 12, 24, 72 and 120 hours after the start of the infusion. For one subject (#861842, the dose record was not consistent with treatment plan and other treatment record and the data were excluded from PK summary statistics.

Sparse plasma PK samples were collected in the Efficacy Phase in 22 patients at the following times: Cycle 1, Day 1: 2 hours after the start of the infusion; Day 5: pre-dose, 2 and 6 hours and 72 hours (± 24 hours) after the start of the Day 5 infusion.

The observed PK data are summarized in Figure 2 and Table 4 .

Figure 2. Mean (+SD) Plasma Concentrations of Cytarabine and Daunorubicin vs. Time Following a 90 Minute IV Infusion of 135 units/m2 CPX-351 - Day 5 of Dose-finding Phase and Efficacy Phase (Study AAML1421)

<!-- image -->

Notes: Open triangles represent mean plasma concentrations for cytarabine. Open circles represent mean plasma concentrations for daunorubicin.

<div style=\"page-break-after: always\"></div>

Table  4. Geometric  Mean  (Geo  Mean  CV%)  Plasma  PK  Parameters  of  Cytarabine  and  Daunorubicin Following a 90-Minute IV Infusion of 135 units/m 2  CPX-351 (Study AAML1421, Dose-finding Phase)

| PK Parameter               | Cytarabine (N = 5)   | Daunorubicin (N = 5)    |
|----------------------------|----------------------|-------------------------|
| Actual Dose (units/m 2 ) a | 135 (135, 134 - 137) | 135 (135, 134 - 137)    |
| Actual Dose (mg) a         | 220 (218, 122 - 370) | 96.9 (95.9, 53.7 - 163) |
| AUC0-48 (ng*h/mL)          | 2848294 (24.1)       | 949730 (22.7)           |
| AUClast (ng*h/mL)          | 4418582 (34.8)       | 1288010 (35.3)          |
| Cmax (ng/mL)               | 94598 (18.3)         | 38890 (12.9)            |
| tmax (h) b                 | 5.00 (1.92 - 5.07)   | 2.00 (1.42 - 2.07)      |
| t1/2 (h)                   | 41.1 (28.7)          | 28.8 (27.6)             |
| CL (mL/h)                  | 71.8 (65.2)          | 94.7 (65.2)             |
| Vss (mL)                   | 4158 (41.5)          | 3828 (45.9)             |

AUC0-48 = AUC from time 0 to 48 hours; AUClast = AUC from time 0 to the last measurable non-zero concentration; Cmax = maximum plasma concentration; CL = clearance; Max = maximum; Min = minimum; t 1/2 = terminal half-life; t max = time to maximum plasma concentration; Vss = volume of distribution at steady state.

a   Mean (Median, Min - Max).

b   Median (Min - Max),.

Note : 1 unit = 1 mg cytarabine and 0.44 mg daunorubicin.

## 1.5.3. Pharmacodynamics

The applicant did not submit any new data on pharmacodynamics.

## 1.5.4. PK/PD modelling

## · Population pharmacokinetic analysis

Report  JAZP-PMX-CPX351-1032\\_PPK: Population  PK  Analysis  of  CPX-351  (Liposomal  Cytarabine  and Daunorubicin)  in  Children,  Adolescents  and  Young  Adults  with  Recurrent  or  Refractory  Hematologic Malignancies (2020-Jul-14)

## Objectives

The  objective  was  to  perform  a  population  PK  analysis  of  cytarabine  and  daunorubicin  in  children, adolescents  and  young  adults  with  AML  in  study  AAML1421  and  CPX-MA-1201  and  assess  sources  of variability in exposure. The analysis was performed to support dosing in paediatric patients with AML.

The final population PK models were subsequently used for exposure response modelling.

## Methods

The  dataset  included  information  from  paediatric  studies  AAML1421  and  CPX-MA-1201  and  previously conducted  adult  studies  101,  206  and  301.  Individual  concentration  values  were  excluded  from  the population PK analysis if the actual collection time was not available or was evidently inaccurate, if the value corresponded to measurable drug in a Day 1 pre-dose sample, or (in rare cases) if inclusion of the value prohibited the PK model from providing a covariance matrix. Plasma concentrations below the limit of quantification (BLQ) of the assay were flagged and set to missing. All concentrations excluded from the

<div style=\"page-break-after: always\"></div>

PK analysis were retained in the dataset and reasons for the exclusions were documented. Concentration data were log-transformed before the population PK analysis.

Prior  cytarabine  and  daunorubicin  population  PK  models  developed  for  adult  patients  with  hematologic malignancies were used as initial models; the models were developed using data from studies 101, 206 and 301.

The prior model for cytarabine was a 2-compartment model, with an OMEGA block on CL and central volume of distribution (Vc), a residual error model (log additive with ETA), and an allometric model of BSA on CL, Vc, peripheral clearance (Q), and peripheral volume of distribution (Vp). The CL, Vc, and Vp were mainly dependent upon BSA. The effect of bilirubin on CL was statistically significant, but the relationship was shallow,  with  an  exponent  of  0.197.  Dose,  formulation,  and  other  intrinsic  covariates  did  not  exert  a significant effect on the PK parameters.

The prior model for daunorubicin was a 2-compartment model, with an OMEGA block on PK parameters (CL, Vc, Q, and Vp), a residual error model (log additive with ETA); and an allometric model of BSA on CL, Vc, Q, and Vp was previously used to assess the concentration-time profiles of daunorubicin in adult patients with hematologic malignancies. The CL, Vc, and Vp of daunorubicin were mainly dependent upon BSA. The model also included an effect of bilirubin on CL and formulation (frozen) effect on all PK parameters (CL, Vc, Q, and Vp).

In the first step, data from the paediatric studies (CPX-MA-1201 and AAML142) were included in the dataset and population PK parameters were re-estimated using the prior models. In the second step, residual effects of age were explored (after taking into account differences in BSA by including BSA as a covariate for clearance and volume parameters) and the effect of age was formally evaluated within the models.

Modelling was performed using (FOCE and/or the mu-referencing method (SAEM/IMP methods with ITS pre-estimation  if  possible)  in  NONMEM  (Version  VII  [Level  7.4];  ICON  plc,  Dublin,  Ireland).  Data  set preparation, exploration, and visualization of the data will be performed using the statistical package in R (Version 3.5.2). Perl-Speak-NONMEM (PsN, Version 4.4.8) was used for modeling, stepwise analysis of covariates, and visual predictive checks (VPC).

## Results

A total of 250 patients with AML were included in the analysis. The population included a total of 46 (18.4%) paediatric patients (1-17 years) and 204 (81.6%) adults ( ≥ 18 years). Overall, 22 (8.8%), 10 (4.0%) and 14 (5.6%) patients were in age category 1-5 years, 6-11 years and 12-17 years, respectively. The median age (range) in study CPX-MA-1201 and AAML1421 were 5.0 years (1 to 19 years) and 13.0 years (1 to 21 years), respectively. The median (range) BSA in study CPX-MA-1201 and AAML1421 were 0.74 m 2  (0.44 to 2.09 m 2 ) and 1.55 m 2  (0.45 to 2.75 m 2 ), respectively. Overall, the PK population included 148 (59.2%) male and 102 (40.8%) female patients, mainly of white origin (82.4%). All paediatric patients received the lyophilized formulation of CPX-351.

## Cytarabine

Of 2614 samples assayed for cytarabine, a total of 2490 (95.3%) were included in the PK analysis. Most of the excluded samples (64; 2.4%) were BLQ first predose; only 19 (0.7%) were BLQ post dose.

The concentration-time profile of cytarabine declined in a bi-exponential manner. Using the previously developed model (run001), the PK parameters were robustly estimated with RSE values less than 20%. However, the goodness-of-fit (GOF) plots suggested that the population predictions (PRED) over-estimated the  observed  concentrations  in  children  and  young  adults  (CPX-MA-1201  and  AAML1421)  and  underestimated the observed concentrations in adults.

<div style=\"page-break-after: always\"></div>

A covariate analysis was performed to assess the potential effects of age as categorical and continuous covariates. In addition, populations defined as children, adolescents and young adults (CPX-MA-1201 and AAML1421) vs adults were evaluated with and without age effects. Results of the covariate analysis are presented  in Table  5 .  A  model  integrating  the  effect  of  populations  (run003)  defined  as  children, adolescents and young adults (CPX-MA-1201 and AAML1421) vs. adults (study 101, 206, and 301) resulted in the lowest reduction in objective function (ΔOFV = -21.3).

Table 5. Cytarabine - Covariate runs for age

| Model   | Covariate Effect                                                |      OFV | Δ OFV   | Comment                               |
|---------|-----------------------------------------------------------------|----------|---------|---------------------------------------|
| run001  | Original Model (Reference)                                      | -4284.79 |         |                                       |
| run002  | Age on CL (power)                                               | -4295.43 | -10.6   |                                       |
| run003  | Studies (CPX-MA-1201 and AAML1421) on CL and Vc                 | -4306.12 | -21.3   | Best Model                            |
| run004  | Studies (CPX-MA-1201and AAML1421)on CL and Vc; Age on CL(power) | -4307.74 | -22.9   | 95%CI for Age Effect includes 0       |
| run005  | Age Group (1-5, 6-11, 12-17 years) on CL                        | -4291.02 | -6.2    |                                       |
| run006  | Pediatric (1-17 years) on CLand Vc                              | -4293.63 | -8.8    | 95%CI for Age Effect on CL includes 0 |

Typical population PK parameters of cytarabine derived with the final model are presented in Table 6 . The population estimates of CL and Vc for cytarabine in adults were 0.101 L/h and 4.76 L, respectively. The population estimates of CL and Vc for cytarabine in children, adolescents and young adults were 0.0731 L/h and 3.91 L, respectively.

The population PK model included an allometric component that accounted for differences in BSA. The exponent for the effect of BSA on CL was 0.948 suggesting faster clearance in patients with higher BSA. For example, typical patients with BSA values of 0.44 and 2.8 m 2  (corresponding to the minimum and maximum in the population) would be expected to have CL values 75% lower and 44% higher, respectively (0.0252 and 0.146 L/h, respectively) relative to a typical subject with a BSA of 1.9 m 2  (0.101 L/h). These differences in CL are expected to be offset by the BSA-based dosing of CPX-351. For example, relative to the dose administered in a typical subject with a BSA of 1.9 m 2 , doses administered to patients with BSA values of  0.44  and  2.8  m 2   would  be  77%  lower  and  47%  higher,  respectively.  As  expected,  BSA  was identified as statistically significant covariates describing the variability of Vc.

<div style=\"page-break-after: always\"></div>

Table 6. Final Population PK Parameters of Cytarabine (run003)

| Parameter         | Estimate                   | SE                   | RSE%            | 10 %56                               | Shrinkage   | Erquation                                                               |
|-------------------|----------------------------|----------------------|-----------------|--------------------------------------|-------------|-------------------------------------------------------------------------|
| OFV               | -4306.6935                 |                      |                 |                                      |             |                                                                         |
| CL                | 0.101                      | 0.00380              | 3.7%            | 0.0939 -0.109                        |             | CL =tvCL · exp(mCL)                                                     |
| BSA_CL            | 0.948                      | 0.0418               | 4.4%            | 0.866 - 1.03 0.195 -0.295            |             | × (BSA/1.9)BSA_CL × (Bilinubin/0.6Bii_CL                                |
| Vc BSA_Vc Stud_Vc | 4.76 1.26 -0.196           | 0.0943 0.0460 0.0456 | 2.0% 3.6% 23.3% | 4.58 - 4.95 1.17 -1.36 -0.285--0.106 |             | Vc =tvVc · exp(mVc) x (BSA/1.9)BSA_vc x exp(Stud_Ve)ifStudy 1201 or1421 |
| Q BSA_Q           | 0.00176                    | 0.000594 pexy        | 33.7%           | 0.000600 -0.00293                    |             | Q=tvQ: exp(nQ) × (BSA/1.9)BSA_Q                                         |
| Vp                | 1.00                       |                      | 26.2%           |                                      |             |                                                                         |
|                   | 0.133 1.00                 | 0.0349 pexy          |                 | 0.0650 -0.202                        |             | Vp = tvVp · exp(mVp) x (BSA/1.9)BSA_Vp                                  |
| BSA_Vp            |                            |                      |                 |                                      | 12.5%       |                                                                         |
| LogErr BSV_CL     | 0.161                      | 0.00674 0.0542       | 4.2%            | 0.147 - 0.174 0.163 - 0.376          | 3.3%        | In(Cobs)=ln(Cpred)+ LogEr : exp(mLogEmr) ∞²CL                           |
| BSV_Vc            | 0.270(55.6%) 0.0528(23.3%) | 0.0115               | 20.1% 21.7%     | 0.0303 -0.0753                       | 9.5%        | @²Vc                                                                    |
| BSV_Q             | 0.00                       | pexy                 |                 |                                      |             | @Q                                                                      |
|                   | 0.00                       | pexy                 |                 |                                      |             | @²Vp                                                                    |
| BSV_Vp            |                            |                      |                 |                                      |             |                                                                         |
| BSV_LogErr        | 0.416(71.8%)               | 0.0703               | 16.9%           | 0.278-0.553                          | 13.6%       | ∞²LogErr                                                                |

CL =clearance;BSA\\_CL=BSA effecton CL;Bili\\_CL =bilirubin effecton CL; Stud\\_CL=studyeffectonCL

Vc = centralvolume ofdistribution; BSA\\_Vc =BSA effect on Vc; Stud\\_Vc =studyeffecton Vc

Q=penipheralclearance; BSA\\_Q=BSA effect on Q

Vp = peripheralvolume ofdistribution;BSA\\_Vp =BSA effect on Vp

OFV=objective functionvalue; BSV=between-subjects variability;CI=confidence intervals; RSE=relative standarderror; SE= standarderror NOTE: BSV% were calculated as (exp(@²)-1).5

GOF plots for the whole population indicated that the model structure of run003 was appropriate ( Figure 3 ).    A  visual predictive check (VPC) of predicted vs. observed concentrations of cytarabine in children, adolescents and young adults (CPX-MA-1201 and AAML1421) and in adults are presented in Figure 4 . Observed median and upper/lower 95 th  percentiles of cytarabine concentrations were contained within the model-predicted ranges, indicating that the model could reproduce the observed data.

<div style=\"page-break-after: always\"></div>

Figure 3. Goodness-of-Fit plots for cytarabine (all studies; Final model (run003))

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4. VPC for Final Model of Cytarabine (run003): Children, Adolescents and Young Adults (Top) and Adults (Bottom).

<!-- image -->

## Daunorubicin

Of 2613 samples assayed for daunorubicin, a total of 2469 (94.5%) were included in the PK analysis. Most of the excluded samples (63; 2.4%) were BLQ first predose; only 39 (1.5%) were BLQ post dose.

The concentration-time profile of daunorubicin declined in a bi-exponential manner. The population PK model previously developed in adults (run001) was used in a first step to assess the concentration-time profiles in this expanded dataset. Population PK parameters were robustly estimated with RSE values less than 20%. However, the GOF plots suggested that the population predictions (PRED) over-estimated the observed concentrations in children, adolescents and young adults (CPX-MA-1201 and AAML1421) and under-estimated the observed concentrations in adults.

A covariate analysis was performed to assess the potential effects of age as categorical and continuous covariates. In addition, populations defined as children, adolescents and young adults (CPX-MA-1201 and

<div style=\"page-break-after: always\"></div>

AAML1421) vs adults were evaluated with and without age effects. Results of the covariate analysis are presented  in Table  7 .  A  model  integrating  the  effect  of  populations  (run003)  defined  as  children, adolescents and young adults (CPX-MA-1201 and AAML1421) vs. adults (study 101, 206, and 301) resulted in the lowest reduction in objective function (ΔOFV = -11.2).

Table 7. Daunorubicin - Covariate runs for age

| Model   | Covariate Effect                                                |      OFV | Δ OFV   | Comment                                |
|---------|-----------------------------------------------------------------|----------|---------|----------------------------------------|
| run001  | Original Model (Reference)                                      | -4423.56 |         |                                        |
| run002  | Age on CL (power)                                               | -4420.49 | 3.1     | 95% CI for Age Effect includes 0       |
| run003  | Studies (CPX-MA-1201 and AAML1421) on CL and Vc                 | -4434.81 | -11.2   | Best Model                             |
| run004  | Studies (CPX-MA-1201and AAML1421)on CL and Vc; Age on CL(power) | -4436.77 | -13.2   | 95% CI for Age Effect includes 0       |
| run005  | Age Group (1-5, 6-11, 12-17 years) on CL                        | -4419.23 | 4.3     | 95% CI for Age Effect includes 0       |
| run006  | Pediatric (1-17 years) on CLand Vc                              | -4424.01 | -0.4    | 95% CI for Age Effect on CL includes 0 |

Typical population PK parameters of daunorubicin derived with the final model are presented in Table 8 . The population estimates of CL and Vc for daunorubicin in adults were 0.140 L/h and 4.04 L, respectively. The population estimates of CL and Vc for daunorubicin in children, adolescents and young adults were 0.0932 L/h and 3.28 L, respectively.

The population PK model included an allometric component that accounted for differences in BSA. The exponent for the effect of BSA was 0.876 suggesting faster clearance in patients with higher BSA. For example, CL values in typical patients with BSA values of 0.44 and 2.8 m 2  (corresponding to the minimum and maximum in the population) would be expected to have CL values 72% lower and 40% higher (0.0389 and 0.197 L/h, respectively) than a typical subject with a BSA of 1.90 m 2  (0.140 L/h). These differences in CL are expected to be largely offset by BSA-based dosing of CPX-351. For example, relative to the dose administered to a typical subject with a BSA of 1.9 m 2 , doses administered to patients with BSA values of 0.44 and 2.8 m 2  would be expected to be 77% lower and 47% higher, respectively. In addition, bilirubin and  formulation  (frozen  vs  lyophilized)  remained  statistically  significant  covariates  on  the  CL  of daunorubicin. Patients treated with the frozen formulation that was used in early studies would be expected to display a 18% lower CL relative to the current lyophilized formulation that was used in the pediatric studies. BSA was identified as statistically significant covariate describing the variability of Vc, as expected.

<div style=\"page-break-after: always\"></div>

Table 8. Final Population PK Parameters of Daunorubicin (run003)

| Parameter   | Units   | Estimate      | SE      | RSE%   | 10 %≤6           | Shrinkage   | Erquation                                        |
|-------------|---------|---------------|---------|--------|------------------|-------------|--------------------------------------------------|
| OFV         |         | -4433.8649    |         |        |                  |             |                                                  |
| CL          | Lh      | 0.140         | 0.00559 | 4.0%   | 0.129 -0.151     |             | CL =tvCL · exp(mCL)                              |
| BSA_CL      |         | 0.876         | 0.103   | 11.7%  | 0.675 - 1.08     |             | × (BSA/1.9)BSA_CL                                |
| Bili_CL     |         | 0.155         | 0.0513  | 33.0%  | 0.0548 -0.256    |             | × (Bilirubin/0.6)Bi-CL ifbilirubin is available* |
| Form_CL     |         | -0.199        | 0.0829  | 41.7%  | -0.361 - -0.0364 |             | Xexp(Form_CL) if Frozen Fommlation               |
| Stud_CL     |         | -0.406        | 0.0901  | 22.2%  | -0.583 - -0.23   |             | xexp(Stud_CL)if Study 1201or 1421                |
| Vc          | L       | 4.04          | 0.0845  | 2.1%   | 3.88 -4.21       |             | Vc =tvVc · exp(mVc)                              |
| BSA_Vc      |         | 1.23          | 0.0584  | 4.7%   | 1.12 -1.35       |             | × (BSA/1.9)BSA_vc                                |
| Form_Vc     |         | -0.167        | 0.0388  | 23.2%  | -0.243 --0.0912  |             | xexp(Form_Ve) ifFrozenFommlation                 |
| Stud_Vc     |         | -0.209        | 0.0508  | 24.3%  | -0.308 - -0.109  |             | x exp(Stud_Ve)if Study 1201 or 1421              |
| Q           | Lh      | 0.0375        | 0.00843 | 22.5%  | 0.0210 -0.0540   |             | Q=tvQ: exp(mQ)                                   |
| BSA_Q       |         | 1.00          | pex     |        |                  |             | × (BSA/1.9)BSA_Q                                 |
| Form_Q      |         | -1.21         | 0.586   | 48.3%  | -2.36 - -0.0650  |             | xexp(Form_Q)if FrozenFomlation                   |
| Vp          | L       | 0.788         | 0.173   | 22.0%  | 0.449 - 1.13     |             | Vp = tvVp : exp(mVp)                             |
| BSA_Vp      |         | 1.00          | pex     |        |                  |             | × (BSA/1.9)BSA_Vp                                |
| Form_ Vp    |         | -1.49         | 0.376   | 25.2%  | -2.23 --0.756    |             | Xexp(Form_Vp)ifFrozenFomlation                   |
| LogErr      |         | 0.141         | 0.00799 | 5.7%   | 0.125 - 0.157    | 13.2%       | In(Cobs)=ln(Cpred)+ LogEr · exp(nLogEm)          |
| BSV_CL      |         | 0.200(47.1%)  | 0.0208  | 10.4%  | 0.159 - 0.241    | 3.2%        | 0²CL                                             |
| BSV_Vc      |         | 0.0372(19.5%) | 0.00440 | 11.8%  | 0.0286 -0.0458   | 10.3%       | @²Vc                                             |
| BSV_Q       |         | 1.80(224.7%)  | 0.298   | 16.5%  | 1.22 -2.38       | 30.2%       | ²Q                                               |
| BSV_Vp      |         | 1.62(201.8%)  | 0.367   | 22.6%  | 0.903 - 2.34     | 28.8%       | @²Vp                                             |
| BSV_LogErr  |         | 0.392(69.3%)  | 0.0501  | 12.8%  | 0.294 - 0.491    | 17.9%       | ∞²LogEr                                          |

CL = clearance,BSA\\_CL; BSA effecton CL; Fomm\\_CL= fommlation effect(Frozen)on CL; Stud\\_CL=studyeffecton CL

Vc = centralvolume ofdistribution;BSA\\_Vc =BSA effect on Vc; Fom\\_Vc = formlation effect (Frozen)on Vc; Stud\\_Vc =study effecton Vc

Q=peripheralclearance; BSA\\_Q=BSA effect on Q: Fom\\_Q=fomlationeffect (Frozen)on Q

Vp =peripheralvolume ofdistribution; BSA\\_Vp=BSA effectonVp;Fom\\_Vp =fommlation effect(Frozen)on Vp

OFV = objective functionvalue; BSV=between-subjects variability, CI= confidence intervals, RSE= relative standarderror, SE = standarderror.

NOTE: BSV% were calculated as (exp(@²)-1).5

GOF plots for the whole population indicated that the model structure of run003 was appropriate (Figure 5 ).    A  visual predictive check (VPC) of predicted vs. observed concentrations of cytarabine in children, adolescents and young adults (CPX-MA-1201 and AAML1421) and in adults are presented in Figure 6 . Observed median and upper/lower 95 th  percentiles of cytarabine concentrations were contained within the model-predicted ranges, indicating that the model could reproduce the observed data.

<div style=\"page-break-after: always\"></div>

Figure 5. Goodness-of-Fit plots for daunorubicin (all studies; Final model (run003))

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 6: VPC for Final Model of Daunorubicin (run003): Children, Adolescents and Young Adults (Top) and Adults (Bottom).

<!-- image -->

## Predicted exposures

The final population PK models were used to derive post hoc estimates for PK parameters, simulated dense concentration-time profiles and exposure parameters for cytarabine ( Table 9 ) and daunorubicin ( Table 10 ).

The predicted exposure parameters (Cmax; AUC over 48 hours (AUC0-48); concentration at 48 hours after the  dose  (C48))  were  highly  correlated,  especially  AUC0-48  and  C48  but  also  Cmax  and  the  other  two parameters.

<div style=\"page-break-after: always\"></div>

Table 9. Cytarabine Predicted PK and Exposure Parameters by Age Group

<!-- image -->

| Age Group      | Statistic     | PK Parameters    | PK Parameters   | PK Parameters        | PK Parameters    | PK Parameters   | Day 5 Exposure    | Day 5 Exposure   | Day 5 Exposure   |
|----------------|---------------|------------------|-----------------|----------------------|------------------|-----------------|-------------------|------------------|------------------|
| Age Group      | Statistic     | CL (L/h)         | Vc(L)           | Q (L/h)              | Vp(L)            | Vss(L)          | AUC4sh (μg ×h/mL) | Cmar (μg/mL)     | C48 (g/mL)       |
|                | N             | 22               | 22              | 22                   | 22               | 22              | 22                | 22               | 22               |
|                | Mean (CV%)    | 0.0275 (51.6%)   | 0.946 (38.6%)   | 0.000557 (20.4%)     | 0.0421 (20.4%)   | 0.988 (37.7%)   | 2767 (33.5%)      | 102 (28.6%)      | 29.0 (42.4%)     |
|                | SD            | 0.0142           | 0.365           | 0.000113             | 0.00858          | 0.373           | 928               | 29.1             | 12.3             |
|                | GeoMean (CV%) | 0.0247 (47.5%)   | 0.888 (36.6%)   | 0.000547 (19.4%)     | 0.0413 (19.4%)   | 0.930 (35.7%)   | 2601 (39.3%)      | 97.6 (30.3%)     | 25.6 (63.9%)     |
| (135 Units/m2) | Median        | 0.0248           | 0.848           | 0.000539             | 0.0407           | 0.888           | 2686              | 98.9             | 28.9             |
| (135 Units/m2) | Range         | 0.0145 to 0.0658 | 0.503 to 1.98   | 0.000409 to 0.000836 | 0.0309 to 0.0632 | 0.535 to 2.04   | 940 to 4516       | 52.2 to 161      | 4.04 to 51.6     |
| (135 Units/m2) | ID %S6        | 0.0215 to 0.0334 | 0.794 to 1.10   | 0.000509 to 0.000604 | 0.0385 to 0.0457 | 0.832 to 1.14   | 2379 to 3154      | 89.5 to 114      | 23.9 to 34.2     |
|                | N             | 10               | 10              | 10                   | 10               | 10              | 10                | 10               | 10               |
|                | Mean (CV%)    | 0.0447 (22.3%)   | 2.09 (33.9%)    | 0.00100 (16.0%)      | 0.0757 (16.0%)   | 2.17 (33.2%)    | 2783 (17.1%)      | 93.1 (15.7%)     | 33.5 (27.5%)     |
|                | SD            | 0.00995          | 0.709           | 0.000160             | 0.0121           | 0.719           | 475               | 14.6             | 9.19             |
|                | GeoMean (CV%) | 0.0438 (20.5%)   | 2.01 (30.2%)    | 0.000990 (15.4%)     | 0.0749 (15.4%)   | 2.08 (29.5%)    | 2740 (19.6%)      | 92.0 (17.3%)     | 32.3 (30.3%)     |
|                | Median        | 0.0420           | 1.99            | 0.000980             | 0.0741           | 2.05            | 2856              | 97.8             | 32.4             |
|                | Range         | 0.0322 to 0.0688 | 1.36 to 3.86    | 0.000817 to 0.00136  | 0.0618 to 0.102  | 1.43 to 3.96    | 1701 to 3325      | 62.5 to 109      | 17.6 to 47.7     |
|                | D %S6         | 0.0385 to 0.0509 | 1.65 to 2.53    | 0.000902 to 0.00110  | 0.0682 to 0.0832 | 1.72 to 2.61    | 2489 to 3078      | 84.1 to 102      | 27.8 to 39.2     |

<!-- image -->

| Age Group      | Statistic     | PK Parameters    | PK Parameters   | PK Parameters      | PK Parameters   | PK Parameters   | Day 5 Exposure   | Day 5 Exposure   | Day 5 Exposure   |
|----------------|---------------|------------------|-----------------|--------------------|-----------------|-----------------|------------------|------------------|------------------|
| Age Group      | Statistic     | CL (L/h)         | Vc(L)           | Q (L/h)            | Vp(L)           | Vss (L)         | AUC48h (g ×h/mL) | Cmar (g/mL)      | C4s (μg/mL)      |
|                | N             | 14               | 14              | 14                 | 14              | 14              | 14               | 14               | 14               |
|                | Mean (CV%)    | 0.0815 (46.0%)   | 3.36 (26.2%)    | 0.00158 (14.5%)    | 0.119 (14.5%)   | 3.48 (25.7%)    | 2806 (34.9%)     | 94.3 (26.4%)     | 33.8 (50.2%)     |
|                | SD            | 0.0375           | 0.879           | 0.000229           | 0.0173          | 0.892           | 979              | 24.9             | 17.0             |
|                | GeoMean (CV%) | 0.0741 (47.7%)   | 3.24 (28.4%)    | 0.00156 (14.7%)    | 0.118 (14.7%)   | 3.36 (27.8%)    | 2644 (37.8%)     | 91.1 (28.5%)     | 29.7 (59.2%)     |
| (135 Units/m)  | Median        | 0.0727           | 3.52            | 0.00156            | 0.118           | 3.65            | 2610             | 94.1             | 31.3             |
| (135 Units/m)  | Range         | 0.0338 to 0.162  | 1.85 to 4.91    | 0.00123 to 0.00193 | 0.0927 to 0.146 | 1.94 to 5.04    | 1309 to 4428     | 51.1 to 140      | 11.6 to 65.3     |
| (135 Units/m)  | ID %S6        | 0.0619 to 0.101  | 2.90 to 3.82    | 0.00146 to 0.00170 | 0.110 to 0.128  | 3.01 to 3.94    | 2293 to 3319     | 81.3 to 107      | 24.9 to 42.7     |
|                | N             | 9                | 9               | 9                  | 9               | 6               | 9                | 9                | 9                |
|                | Mean (CV%)    | 0.0707 (46.3%)   | 4.07 (28.2%)    | 0.00187 (17.6%)    | 0.141 (17.6%)   | 4.21 (27.7%)    | 3654 (29.9%)     | 109 (25.1%)      | 51.2 (37.3%)     |
|                | SD            | 0.0327           | 1.15            | 0.000329           | 0.0249          | 1.17            | 1093             | 27.3             | 19.1             |
|                | GeoMean (CV%) | 0.0653 (42.0%)   | 3.94 (27.2%)    | 0.00184 (17.0%)    | 0.139 (17.0%)   | 4.08 (26.7%)    | 3502 (32.3%)     | 106 (25.2%)      | 47.6 (44.0%)     |
| (135 Units/m²) | Median        | 0.0591           | 3.99            | 0.00192            | 0.145           | 4.13            | 3742             | 106              | 55.6             |
| (135 Units/m²) | Range         | 0.0404 to 0.140  | 2.61 to 6.47    | 0.00148 to 0.00255 | 0.112 to 0.193  | 2.74 to 6.67    | 2156 to 5185     | 76.8 to 152      | 23.4 to 73.9     |
| (135 Units/m²) | ID %S6        | 0.0493 to 0.0920 | 3.32 to 4.82    | 0.00165 to 0.00208 | 0.125 to 0.157  | 3.45 to 4.97    | 2940 to 4368     | 91.2 to 127      | 38.7 to 63.6     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Age Group                        | Statistic     | PKParameter's   | PKParameter's   | PKParameter's      | PKParameter's   | PKParameter's   | Day 5 Exposure   | Day 5 Exposure   | Day 5 Exposure   |
|----------------------------------|---------------|-----------------|-----------------|--------------------|-----------------|-----------------|------------------|------------------|------------------|
| Age Group                        | Statistic     | CL (L/h)        | Vc(L)           | Q(L/h)             | Vp(L)           | Vss (L)         | AUC48h (g ×h/mL) | Cmar (μg/mL)     | C48 (μg/mL)      |
| Adults (Study 206,and Study 301) | N             | 156             | 156             | 156                | 156             | 156             | 156              | 156              | 156              |
| Adults (Study 206,and Study 301) | Mean (CV%)    | 0.123 (66.0%)   | 5.07 (27.2%)    | 0.00181 (12.7%)    | 0.137 (12.7%)   | 5.20 (26.7%)    | 1928 (45.9%)     | 61.3 (31.6%)     | 25.5 (64.2%)     |
| Adults (Study 206,and Study 301) | SD            | 0.0810          | 1.38            | 0.000230           | 0.0174          | 1.39            | 884              | 19.4             | 16.3             |
|                                  | GeoMean (CV%) | 0.103 (64.3%)   | 4.89 (27.5%)    | 0.00180 (12.8%)    | 0.136 (12.8%)   | 5.02 (26.9%)    | 1720 (53.6%)     | 58.3 (32.9%)     | 19.3 (105.0%)    |
| (100 Units/m²)                   | Median        | 0.104           | 4.82            | 0.00181            | 0.137           | 4.96            | 1764             | 59.0             | 22.0             |
| (100 Units/m²)                   | Range         | 0.0282 to 0.436 | 2.36 to 9.19    | 0.00123 to 0.00248 | 0.0927 to 0.187 | 2.46 to 9.36    | 410 to 4974      | 26.2to 126       | 0.569 to 84.5    |
| (100 Units/m²)                   | ID %S6        | 0.110 to 0.135  | 4.85 to 5.28    | 0.00178 to 0.00185 | 0.134 to 0.140  | 4.98 to 5.42    | 1789 to2067      | 58.3 to 64.4     | 22.9 to 28.0     |

CI = confidence interval; CL = clearance; Cmax = maximum concentration on Day; CV% = coefficient of variation; GeoMean = geometric mean; Q = peripheral clearance; PK = Pharmacokinetic(s); SD = standard deviation; Ve = central volume of distribution; Vp = peripheral volume of distribution, Vss = total volume of distribution.

Abbreviations: AUC4sh = area under the concentration-time curve from time 0 to 48 on Day 5; C4s = concentration 48 hours after dosing on Day 5;

Note: In the \"Adult\" group, 1 subject from Study 310-301 did not have dose on Day 5 and was excluded from the PK parameter calculations.

Table 10. Daunorubicin Predicted PK and Exposure Parameters by Age Group

|                |               | PK Parameter's   | PK Parameter's   | PK Parameter's    | PK Parameter's   | PK Parameter's   | Day 5 Exposure    | Day 5 Exposure   | Day 5 Exposure   |
|----------------|---------------|------------------|------------------|-------------------|------------------|------------------|-------------------|------------------|------------------|
|                | Statistic     | CL (L/h)         | Vc(L) Q (L/h)    | Vc(L) Q (L/h)     | Vp(L)            | Vs(L)            | AUC4sh (μg ×h/mL) | Cmar (μg/mL)     | C48 (ug/mL)      |
|                | N             | 22               | 22               | 22                | 22               | 22               | 22                | 22               | 22               |
|                | Mean (CV%)    | 0.0364 (58.3%)   | 0.786 (32.1%)    | 0.0125 (59.7%)    | 0.277 (82.9%)    | 1.06 (42.1%)     | 967 (36.7%)       | 45.6 (26.2%)     | 8.17 (48.0%)     |
|                | SD            | 0.0212           | 0.252            | 0.00747           | 0.230            | 0.447            | 355               | 11.9             | 3.93             |
|                | GeoMean (CV%) | 0.0318 (53.5%)   | 0.750 (32.2%)    | 0.0103 (76.7%)    | 0.203 (102.0%)   | 0.985 (40.8%)    | 898 (43.5%)       | 44.1 (27.3%)     | 6.93 (74.3%)     |
| (135 Units/m2) | Median        | 0.0288           | 0.720            | 0.0127            | 0.225            | 0.968            | 991               | 44.9             | 8.44             |
| (135 Units/m2) | Range         | 0.0181 to 0.0821 | 0.420 to 1.39    | 0.00246 to 0.0302 | 0.0323 to 0.982  | 0.543 to 2.16    | 352 to 1706       | 25.8 to 71.1     | 1.35 to 15.0     |
| (135 Units/m2) | ID %S6        | 0.0275 to 0.0452 | 0.680 to 0.891   | 0.00939 to 0.0156 | 0.181 to 0.373   | 0.876 to 1.25    | 819 to 1116       | 40.6 to 50.6     | 6.53 to 9.81     |
|                | N             | 10               | 10               | 10                | 10               | 10               | 10                | 10               | 10               |
|                | Mean (CV%)    | 0.0645 (30.9%)   | 1.73 (29.1%)     | 0.0526 (88.5%)    | 0.963 (99.4%)    | 2.69 (48.9%)     | 896 (26.0%)       | 40.2 (19.2%)     | 8.67 (27.8%)     |
|                | SD            | 0.0200           | 0.504            | 0.0465            | 0.957            | 1.32             | 233               | 7.72             | 2.41             |
|                | GeoMean (CV%) | 0.0621 (28.4%)   | 1.68 (25.5%)     | 0.0377 (104.0%)   | 0.655 (116.0%)   | 2.46 (44.1%)     | 864 (30.6%)       | 39.4 (20.9%)     | 8.3 (31.4%)      |
|                | Median        | 0.0580           | 1.49             | 0.0362            | 0.673            | 2.36             | 986               | 41.9             | 9.02             |
|                | Range         | 0.0449 to 0.107  | 1.35 to 2.97     | 0.0127 to 0.147   | 0.164 to 3.34    | 1.62 to 5.46     | 508 to 1146       | 27.6 to 48.7     | 4.75 to 11.9     |
|                | ID %S6        | 0.0521 to 0.0769 | 1.42 to 2.04     | 0.0238 to 0.0815  | 0.369 to 1.56    | 1.88 to 3.51     | 752 to 1041       | 35.4 to 44.9     | 7.18 to 10.2     |

<div style=\"page-break-after: always\"></div>

|                |               | PK Parameters   | PK Parameters   | PK Parameters     | PK Parameters   | PK Parameters   | Day 5 Exposure    | Day 5 Exposure   | Day 5 Exposure   |
|----------------|---------------|-----------------|-----------------|-------------------|-----------------|-----------------|-------------------|------------------|------------------|
|                | Statistic     | CL (L/h)        | Vc(L) Q (L/h)   | Vc(L) Q (L/h)     | Vp(L)           | Vs(L)           | AUC4sh (μg ×h/mL) | Cmar (μg/mL)     | C48 (ug/mL)      |
|                | N             | 14              | 14              | 14                | 14              | 14              | 14                | 14               | 14               |
|                | Mean (CV%)    | 0.103 (36.9%)   | 2.96 (26.0%)    | 0.0356 (64.3%)    | 0.472 (49.2%)   | 3.43 (24.5%)    | 982 (32.5%)       | 40.3 (22.9%)     | 9.70 (48.6%)     |
|                | SD            | 0.0378          | 0.769           | 0.0229            | 0.232           | 0.840           | 319               | 9.23             | 4.71             |
|                | GeoMean (CV%) | 0.0960 (39.4%)  | 2.87 (26.9%)    | 0.0290 (83.4%)    | 0.414 (61.3%)   | 3.33 (26.2%)    | 930 (36.5%)       | 39.2 (25.3%)     | 8.53 (61.1%)     |
| (135 Units/m2) | Median        | 0.0955          | 2.97            | 0.0337            | 0.449           | 3.57            | 950               | 42.4             | 8.17             |
| (135 Units/m2) | Range         | 0.0477 to 0.167 | 1.83 to 4.45    | 0.00433 to 0.0983 | 0.112 to 0.930  | 1.94 to 5.10    | 406 to 1586       | 24.0 to 58.9     | 2.23 to 18.7     |
| (135 Units/m2) | ID%S6         | 0.0827 to 0.122 | 2.56 to 3.36    | 0.0236 to 0.0476  | 0.350 to 0.594  | 2.99 to 3.87    | 815 to 1149       | 35.4 to 45.1     | 7.23 to 12.2     |
|                | N             | 9               | 9               | 9                 | 9               | 9               | 9                 | 9                | 9                |
|                | Mean (CV%)    | 0.0939 (48.9%)  | 3.34 (28.8%)    | 0.0603 (119.0%)   | 1.04 (94.7%)    | 4.38 (33.3%)    | 1275 (32.6%)      | 47.2 (24.9%)     | 14.8 (41.8%)     |
|                | SD            | 0.0459          | 0.961           | 0.0718            | 0.981           | 1.46            | 415               | 11.7             | 6.18             |
|                | GeoMean (CV%) | 0.0864 (42.5%)  | 3.24 (25.5%)    | 0.0388 (116.0%)   | 0.741 (99.2%)   | 4.17 (33.8%)    | 1214 (35.0%)      | 46.0 (24.8%)     | 13.5 (51.9%)     |
|                | Median        | 0.0784          | 3.30            | 0.0306            | 0.652           | 3.95            | 1225              | 45.7             | 13.3             |
|                | Range         | 0.0568 to 0.193 | 2.45 to 5.65    | 0.0140 to 0.238   | 0.284 to 2.84   | 2.74 to 6.63    | 700 to 1923       | 33.9to 67.6      | 5.60 to 22.4     |
|                | ID%S6         | 0.0639 to 0.124 | 2.71 to 3.97    | 0.0134 to 0.107   | 0.395 to 1.68   | 3.42 to 5.33    | 1004 to 1547      | 39.5 to 54.9     | 10.8 to 18.8     |

|                                                       |               | PK Parameters   | PK Parameters   | PK Parameters   | PK Parameters   | PK Parameters   | Day 5 Exposure    | Day 5 Exposure   | Day 5 Exposure   |
|-------------------------------------------------------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|-------------------|------------------|------------------|
|                                                       | Statistic     | CL (L/h)        | Vc(L) Q(L/h)    | Vc(L) Q(L/h)    | Vp(L)           | Vss(L)          | AUC4sh (ug ×h/mL) | Cmar (g/mL)      | C4s (μg/mL)      |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | N             | 156             | 156             | 156             | 156             | 156             | 156               | 156              | 156              |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | Mean (CV%)    | 0.164 (60.3%)   | 4.22 (25.2%)    | 0.130 (218.0%)  | 2.27 (180.0%)   | 6.49 (70.6%)    | 615 (41.8%)       | 25.8 (25.5%)     | 6.37 (59.2%)     |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | SD            | 0.0988          | 1.06            | 0.285           | 4.09            | 4.58            | 257               | 6.58             | 3.77             |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | GeoMean (CV%) | 0.143 (54.2%)   | 4.09 (25.4%)    | 0.0543 (182.0%) | 1.08 (151.0%)   | 5.65 (49.9%)    | 558 (49.5%)       | 24.9 (27.7%)     | 5.09 (86.6%)     |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | Median        | 0.142           | 4.11            | 0.0405          | 0.820           | 5.17            | 580               | 25.1             | 5.64             |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | Range         | 0.0590 to 0.557 | 2.07 to 7.94    | 0.00192 to 2.83 | 0.100 to 25.8   | 2.39 to 30.9    | 140 to 1213       | 11.8 to 41.4     | 0.278 to 16.1    |
| Adults (CLTR0310-206, andCLTR0310-301) (100 Units/m²) | ID %S6        | 0.148 to 0.179  | 4.05 to 4.38    | 0.0858 to 0.175 | 1.63 to 2.92    | 5.77 to 7.21    | 575 to 655        | 24.7 to 26.8     | 5.78 to 6.96     |

Abbreviations:AUC4sh=areaunderthe curvefromt=0 to48hourspostdose;C4s=concentrationat48hourspostdose;CI=confidenceinterval;CL=total body clearance of drug following vascular administration; Cmax = maximum concentration; CV% = coefficient of variation for the arithmetic mean, expressed as a percentage; GeoMean = geometric mean; h = hour, N = number, or sample size; PK = pharmacokinetic(s); Q = distributional clearance; SD = standard deviation; Vc = central volume of distribution; Vp = peripheral volume of distribution; Vss = steady-state volume of distribution. Note: In the \"Adult\"' group, 1 subject from Study 310-301 did not have dose on Day 5 and was excluded from the PK parameter calculations.

|                                    |                                           | PK Parameters                                                       | PK Parameters                                   | PK Parameters                                                           | PK Parameters                                                 | PK Parameters                                   | Day5 Erposure                              | Day5 Erposure                                   | Day5 Erposure                                    |
|------------------------------------|-------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|--------------------------------------------|-------------------------------------------------|--------------------------------------------------|
| Age Group                          | Statistic                                 | CL(L/h)                                                             | Vc (L)                                          | Q(L/b)                                                                  | Vp (L)                                                        | Vss (L)                                         | AUC04shr (ug·h/mL)                         | Cmx (ug/mL)                                     | C48hr (ug/mL)                                    |
| Adults ≥18 years* (100 or 135 U/m) | N Mean(CV%6) SD GeoMean(CV%) Median Range | 166 0.160(61.0%) 0.0976 0.139(54.9%) 0.139 0.0568-0.557 0.145-0.175 | 166 4.17(25.6%) 1.07 4.04(25.8%) 4.04 2.07-7.94 | 166 0.126(220.0%) 0.277 0.0531(177.0%) 0.0396 0.00192-2.83 0.0839-0.168 | 166 2.20(181.0%) 3.98 1.06(147.0%) 0.817 0.100-25.8 1.59-2.80 | 166 6.37(70.4%) 4.48 5.55(49.5%) 5.13 2.39-30.9 | 166 636(42.6%) 271 575(50.1%) 592 138-1466 | 166 26.4(26.7%) 7.06 25.4(28.5%) 25.5 11.9-51.5 | 166 6.64(59.6%) 3.96 5.31(86.7%) 6.04 0.275-17.1 |
| Adults ≥18 years* (100 or 135 U/m) |                                           |                                                                     |                                                 |                                                                         |                                                               | 5.68-7.05                                       | 594-677                                    | 25.3-27.5                                       | 6.04-7.24                                        |
| Adults ≥18 years* (100 or 135 U/m) | 9596CI                                    |                                                                     | 4.01-4.33                                       |                                                                         |                                                               |                                                 |                                            |                                                 |                                                  |
| Adults ≥18 years* (100 or 135 U/m) |                                           |                                                                     |                                                 |                                                                         |                                                               |                                                 |                                            |                                                 |                                                  |
| Adults ≥18 years* (100 or 135 U/m) |                                           |                                                                     |                                                 |                                                                         |                                                               |                                                 |                                            |                                                 |                                                  |
| Adults ≥18 years* (100 or 135 U/m) |                                           |                                                                     |                                                 |                                                                         |                                                               |                                                 |                                            |                                                 |                                                  |
| Adults ≥18 years* (100 or 135 U/m) |                                           |                                                                     |                                                 |                                                                         |                                                               |                                                 |                                            |                                                 |                                                  |

CL = clearance; Vc = central volume of distribution; Q = peripheral clearance; Vp = peripheralvolume of distribution, Vss =total volume of distribution; AUCo-4s =area umder the concentration-time cuve from time 0to 48 on Day 5; Cmax =maximum concentation on Day;C4g = concentation48-h after dosingon Day 5; GeoMean = geometric mean, CV% = coefficientof variation.

NOTE: Inthe\"Adilt\" goup, one subject from Sudy 310-301 did not have dose on Day 5 and was excluded from the PK parametercalculations.

* Adilts in study 310-206 (n=26) and310-301(n=131)received100 U/m*while youmg adilts in stwty CPX-MA-1201 (n=1) andAAML1421 (n=8)received135 U/m*.

<div style=\"page-break-after: always\"></div>

## · Exposure-response analyses

Pharmacometrics report: Exposure-Response Analysis of CPX-351 (Liposomal Cytarabine and Daunorubicin)  in  Children,  Adolescents  and  Young  Adults  with  Recurrent  or  Refractory  Hematologic Malignancies (JAZP-PMX-CPX351-1032\\_ER; 14-Jul-2020)

The objective was to perform exposure-response (ER) analysis of key efficacy and safety endpoints in paediatric and young adult patients with AML treated with CPX-351.

## Exposure-Response Analysis of Efficacy

## Methods

The dataset was constructed by combining data from children, adolescents and young adults (Studies CPXMA-1201 and AAML1421) and adult patients with relapsed and refractory AML (Studies 101 and 206). For Study 101, only therapeutic doses (i.e., approximately 100 and 134/135 units/m 2 ) were included in the analysis.  The  following  exposure  parameters  of  cytarabine  and  daunorubicin  were  derived  based  on  a population PK model:

- Area under the curve up to 48 hours post dose on Day 5 Cycle 1 (AUC0-48)
- Maximum concentration on Day 5 Cycle 1 (Cmax)
- Concentration at 48 hours post dose on Day 5 Cycle 1 (C48)

In addition, the observed predose concentration on Day 5, Cycle 1 (Cpredose) was also considered in the ER analysis.

Exposure parameters were merged with the following response endpoints (see Table 5.3.4.5):

- Complete response (CR)
- CR + CRp (complete response with partial recovery of platelet count)
- CR + CRp + CRi (complete response with partial recovery of platelet count and incomplete blood count recovery)

The following covariates were tested in efficacy analyses.

- Age, as
- o continuous parameter (years)
- o categorical (pediatric vs. adults): 1-17 vs. ≥ 18 years
- o categorical (pediatric vs. young adults, adults and elderly): 18 to 29, 30 to &lt; 60, and ≥ 60 years
- Sex (categorical, male, female)
- Bone marrow blast count (%) (categorical, &lt;5% vs. 5-25% vs. &gt; 25% blast count)
- White blood cell (WBC) count (x 10 9 /L)
- Platelet count (x 10 9 /L)

<div style=\"page-break-after: always\"></div>

Table 11. Definition of efficacy response criteria in each study

| Definition                                                      | Study                                                                             | Study                                                                | Study                                                  | Study                                                  |
|-----------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Definition                                                      | 305-101                                                                           | 310-206                                                              | CPX-MA-1201                                            | AAML1421                                               |
| Complete Response (CR)                                          | - BMC <5%, - ANC ≥ 1000/µL, - Platelet ≥ 100,000/µL; - No Auer rods               | - BMC <5%, - ANC ≥ 1000/µL, - Platelet ≥ 100,000/µL, - No Auer rods. | - BMC <5%, - ANC ≥ 1000/µL, - Platelet ≥ 100,000/µL;   | - BMC <5%, - ANC ≥ 1000/µL, - Platelet ≥ 100,000/µL;   |
| Complete Response with Partial Recovery of Platelet Count (CRp) | Not Monitored                                                                     | Not Monitored                                                        | - BMC <5%, - ANC ≥ 1000/µL, - No platelet transfusions | - BMC <5%, - ANC ≥ 1000/µL, - No platelet transfusions |
| Complete Response with Incomplete Blood Count Recovery (CRi)    | Not Monitored                                                                     | - BMC <5%, - ANC < 1000/µL, - Platelet < 100,000/µL, - No Auer rods  | - BMC <5%, - ANC < 1000/µL, - Platelet < 100,000/µL;   | - BMC <5%, - ANC < 1000/µL, - Platelet < 100,000/µL;   |
| Partial Response (PR)                                           | - Presence of Auer rods and BMC <5%, OR - Presence of Auer rods and BMC 5% to 25% | Not Monitored                                                        | - BMC 5% to 25%                                        | - BMC 5% to 25%                                        |

BMC = bone marrow blasts count; ANC = absolute neutrophil count

A logistic regression model was developed to link cytarabine and/or daunorubicin exposures to response criteria. The model tested the effect of cytarabine and daunorubicin separately and for the combined effect assuming additive properties. Finally, the logistic regression model tested the combined effect of cytarabine and daunorubicin with an interaction term to potentially capture a less than or more than additive effect. The best fitting model according to Akaike information criterion (AIC) was selected.

The statistical significance of covariates was tested in the logistic regression models with a p-value of 0.05.

Data set preparation, exploration, visualization of the data and exposure-response analyses were performed using R (Version 3.5.2) with comprehensive R archive network (CRAN) and Certara Strategic Consulting (CSC) package.

## Results

Dataset: Exposure-response analysis of efficacy was performed based on response criteria in children, adolescents and young adults (study CPX-MA-1201 and AAML1421) and adult patients with relapsed and refractory AML (study 101 and 206). A total of 81 patients were included in the analysis. The population included a total of 43 (53.1%) pediatric patients (1-17 years) and 38 (46.9%) adults ( ≥ 18 years). Baseline characteristics are summarized in Table 12 and Table 13 ). Of the 81 patients included in the analysis, a total  of  28  (30.9%)  patients  presented CR, 16 (24.6%) patients presented CRi and 1 (1.92%) patient presented CRp, while 39 (48.1%) presented a negative response ( Table 14 ).

<div style=\"page-break-after: always\"></div>

Table 12. Baseline Characteristics in the Exposure-Efficacy Population - Categorical Data

| Covariate                   | Sub-Population              | Study ID   | Study ID   | Study ID   | Study ID   | Overall   |
|-----------------------------|-----------------------------|------------|------------|------------|------------|-----------|
| Covariate                   | Sub-Population              | 305-101    | 310-206    | 1201       | 1421       | Overall   |
| Age Categories              | 1-5 years                   | -          | -          | 16(64.0%)  | 6(22.2%)   | 22(27.2%) |
| Age Categories              | 6-11 years                  | -          | -          | 3(12.0%)   | 6(22.2%)   | 9(11.1%)  |
| Age Categories              | 12-17 years                 | -          | -          | 5(20.0%)   | 7(25.9%)   | 12(14.8%) |
| Age Categories              | ≥18 years                   | 16(100.0%) | 13(100.0%) | 1(4.0%)    | 8(29.6%)   | 38(46.9%) |
| Age Groups                  | Pediatric (1-17 years)      | -          | -          | 24(96.0%)  | 19(70.4%)  | 43(53.1%) |
| Age Groups                  | Adults (≥18 years)          | 16(100.0%) | 13(100.0%) | 1(4.0%)    | 8(29.6%)   | 38(46.9%) |
| Per Protocol Age Population | Children and Younger Adults | -          | -          | 25(100.0%) | 27(100.0%) | 52(64.2%) |
| Per Protocol Age Population | Adults                      | 16(100.0%) | 13(100.0%) | -          | -          | 29(35.8%) |
| Total Bilirubin Categories  | Not Recorded                | -          | -          | 25(100.0%) | 27(100.0%) | 52(64.2%) |
| Total Bilirubin Categories  | <1.2 mg/dL                  | 15(93.8%)  | 12(92.3%)  | -          | -          | 27(33.3%) |
| Total Bilirubin Categories  | 1.2 - 3 mg/dL               | 1(6.3%)    | 1(7.7%)    | -          | -          | 2(2.5%)   |
| Formulation                 | Frozen                      | 16(100.0%) | -          | -          | -          | 16(19.8%) |
| Formulation                 | Lyophilized                 | -          | 13(100.0%) | 25(100.0%) | 27(100.0%) | 65(80.2%) |
| Race                        | White                       | 12(75.0%)  | 13(100.0%) | 19(76.0%)  | 19(70.4%)  | 63(77.8%) |
| Race                        | Black                       | 1(6.3%)    | -          | 2(8.0%)    | 3(11.1%)   | 6(7.4%)   |
| Race                        | Asian                       | 3(18.8%)   | -          | -          | 1(3.7%)    | 4(4.9%)   |
| Race                        | Other                       | -          | -          | -          | 2(7.4%)    | 2(2.5%)   |
| Race                        | Unknown                     | -          | -          | 4(16.0%)   | 2(7.4%)    | 6(7.4%)   |
| Renal Function              | Not Recorded                | -          | -          | -          | 27(100.0%) | 27(33.3%) |
| Renal Function              | CRCL ≥90 mL/min             | 5(31.3%)   | 6(46.2%)   | 18(72.0%)  | -          | 29(35.8%) |
| Renal Function              | CRCL 60 to 89 mL/min        | 10(62.5%)  | 3(23.1%)   | 7(28.0%)   | -          | 20(24.7%) |
| Renal Function              | CRCL 30 to 56 mL/min        | 1(6.3%)    | 4(30.8%)   | -          | -          | 5(6.2%)   |
| Renal Function              | CRCL 15 to 29 mL/min        | -          | -          | -          | -          | -         |
| Sex                         | Male                        | 11(68.8%)  | 7(53.8%)   | 13(52.0%)  | 15(55.6%)  | 46(56.8%) |
| Sex                         | Female                      | 5(31.3%)   | 6(46.2%)   | 12(48.0%)  | 12(44.4%)  | 35(43.2%) |

CRCL= creatinine clearance

<div style=\"page-break-after: always\"></div>

Table 13. Baseline Characteristics in the Exposure-Efficacy Population - Continuous Data

| Covariate                     | Statistic                     | Study ID                      | Study ID                           | Study ID                       | Study ID                       | Overall                        |
|-------------------------------|-------------------------------|-------------------------------|------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Covariate                     | Statistic                     | 305-101                       | 310-206                            | CPX-MA-1201                    | AAML1421                       | Overall                        |
| Age (years)                   | n Mean (CV%) Median (Min-Max) | 16 59.8(20.4%) 61.5(36-76)    | 13 63.8(17.2%) 63.0(37-80)         | 25 6.3(93.7%) 4.0(1-19)        | 27 11.6(56.6%) 13.0(1-21)      | 81 27.9(96.2%) 16.0(1-80)      |
| BSA (m²)                      | n Mean (CV%) Median (Min-Max) | 16 1.98(19.4%) 1.90(1.44-2.8) | 13 1.94(16.5%) 1.88(1.32-2.67)     | 25 0.93(55.8%) 0.69(0.44-2.09) | 27 1.41(43.4%) 1.51(0.45-2.75) | 81 1.46(44.7%) 1.64(0.44-2.8)  |
| Body Weight (kg)              | n Mean (CV%) Median (Min-Max) | 16 83.6(34.9%) 75.1(49-156.5) | 13 81.0(27.1%) 79.7(41.9-          | 25 28.8(83.1%) 16.8(9.1-90.4)  | 27 52.8(64.2%) 50.2(9.4-145.3) | 81 56.0(63.5%) 59.4(9.1-156.5) |
| ALP (U/L)                     | n Mean (CV%) Median (Min-Max) | 16 111.3(59.7%) 89.5(47-319)  | 133.3) 13 91.6(43.8%) 72.0(54-164) | - - -                          | - - -                          | 29 102.5(54.8%) 86.0(47-319)   |
| ALT (U/L)                     | n Mean (CV%) Median (Min-Max) | 16 31.7(55.1%)                | 13 38(105.2%) 22.0(9-153)          | 25 53.4(90%) 40.0(22-219)      | - - -                          | 54 43.2(92.1%)                 |
| AST (U/L)                     | n Mean (CV%) Median (Min-Max) | 24.0(15-77) 16 27.7(57.2%)    | 13 24.8(41.8%) 23.0(9-40)          | - - -                          | - - -                          | 30.5(9-219) 29 26.4(51.2%)     |
| Total Bilirubin (mg/dL)       | n Mean (CV%)                  | 22.5(12-73) 16 0.70(50.8%)    | 13 0.56(53.7%)                     | - -                            | - -                            | 23.0(9-73) 29 0.64(52.4%)      |
| Direct Bilirubin              | Median (Min-Max)              | 0.60(0.3-1.8) -               | 0.50(0.2-1.2) - -                  | - 25                           | - -                            | 0.60(0.2-1.8) 25               |
| (mg/dL)                       | n Mean (CV%) Median (Min-Max) | - - 16                        | - 13                               | 0.1(60.8%) 0.1(0.1-0.4) 25     | - -                            | 0.1(60.8%) 0.1(0.1-0.4) 54     |
| Creatinine Clearance (mL/min) | n Mean (CV%) Median (Min-Max) | 86.0(33%) 79.9(53.3-165.6)    | 101.5(56.1%) 88.0(42.3-            | 120.7(34.8%) 110.0(62.2-       | - - -                          | 105.8(42.2%) 93.2(42.3-229.6)  |
| WBC                           | n Mean (CV%)                  | 16                            | 211.7) 13                          | 229.6) 25                      | 26                             | 80 9.8(192.1%)                 |
|                               |                               | 7.0(168.5%)                   |                                    |                                |                                |                                |
| (10^9/L)                      | Median (Min-Max)              | 2.4(0.4-44.8)                 | 12.8(233.4%) 3.8(0.7-110.9)        | 10.7(191.9%) 2.0(0.2-73.9)     | 9.1(150.5%) 3.8(1-62.4)        | 3.4(0.2-110.9)                 |

ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BSA = body surface area, CV = coefficient of variation, Max = maximum, Min = minimum, WBC = white blood cells.

Note : The WBC value for ID AAML1421-AL013-852842 (750 10^9/L) was excluded from descriptive statistics.

<div style=\"page-break-after: always\"></div>

Table 14. Number and Percentage of Patients with Response

|                            | Number Subject with Response / Total Subject Number (%) 95% CI (%)   | Number Subject with Response / Total Subject Number (%) 95% CI (%)   | Number Subject with Response / Total Subject Number (%) 95% CI (%)   | Number Subject with Response / Total Subject Number (%) 95% CI (%)   |
|----------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Study                      | Complete Response (CR)                                               | Complete Response with Incomplete Blood Count Recovery (CRi)         | Complete Response with Partial Recovery of Platelet Count (CRp)      | Negative Response                                                    |
| 8/16 (50.0%) (28.0, 72.0)  | Not Monitored                                                        | Not Monitored                                                        | 8/16 (50.0%) (46.4, 84.3)                                            | 305-101                                                              |
| 2/13 (15.4%) (2.71, 46.3)  | 3/13 (23.1%) (6.16, 54.0)                                            | Not Monitored                                                        | 8/13 (61.5%) (32.3, 84.9)                                            | 310-206                                                              |
| 5/25 (20.0%) (7.61, 41.3)  | 3/25 (12.0%) (3.15, 32.3)                                            | 0/25 (0%)                                                            | 17/25 (68.0%) (46.4, 84.3)                                           | CPX-MA-1201                                                          |
| 10/27 (37.0%) (20.1, 57.5) | 10/27 (37.0%) (20.1, 57.5)                                           | 1/27 (3.70%) (0.194, 20.9)                                           | 6/27 (22.2%) (9.38, 42.7)                                            | AAML1421                                                             |
| 28/81 (30.9%) (21.3, 42.2) | 16/65 (24.6%) (15.1, 37.1)                                           | 1/52 (1.92%) (0.100, 11.6)                                           | 39/81 (48.1%) (37.0, 59.5)                                           | Overall                                                              |

Probability of (CR, CRi or CRp): CR, CRi and CRp were assessed in CPX-MA-1201 and AAML1421 (i.e., children, adolescents and young adults). In all, 29 of 52 patients were classified as responders (CR, CRi or CRp).  Various  exposure-response  models  were  developed  to  assess  the  effect  of  cytarabine  and/or daunorubicin exposures on the probability of response ( Table 15 ). Cytarabine C48 was associated with the best  statistical  goodness-of-fit  (AIC  =  67.750)  in  the  logistic  regression  model;  the  AIC  value  for daunorubicin C48 was similar (AIC = 67.950).

Table 15. Univariate Exposure-Response Analysis of Efficacy (Probability of CR, CRi or CRp)

| Model                                                            |   Degrees of Freedom |     AIC |     BIC | Statistical Significance of Exposure (p<0.05)   |
|------------------------------------------------------------------|----------------------|---------|---------|-------------------------------------------------|
| Model 1: Daunorubicin AUC0-48                                    |                    2 | 70.1693 | 74.0718 | Yes                                             |
| Model 2: Daunorubicin Cmax                                       |                    2 | 72.6043 | 76.5068 | No                                              |
| Model 3: Daunorubicin C48                                        |                    2 | 67.95   | 71.8524 | Yes                                             |
| Model 4: Cytarabine AUC0-48                                      |                    2 | 70.304  | 74.2064 | Yes                                             |
| Model 5: Cytarabine Cmax                                         |                    2 | 73.6204 | 77.5228 | No                                              |
| Model 6: Cytarabine C48                                          |                    2 | 67.7499 | 71.6524 | Yes                                             |
| Model 7: Daunorubicin C48 + Cytarabine C48                       |                    3 | 69.4637 | 75.3174 | No                                              |
| Model 8: Interaction between Daunorubicin C48 and Cytarabine C48 |                    4 | 70.1924 | 77.9973 | No                                              |

Note : Studies CPX-MA-1201 and AAML1421 were included in the analysis.

All exposure parameters were derived using the population PK model.

AIC = Akaike information criterion; AUC0-48 = area under the concentration-time curve from time zero to 48 h post-dose on Day 5 (Cycle 1); BIC = Bayesian information criterion; C48 = Concentration 48-h after dosing on Day 5 (Cycle 1); Cmax = maximum concentration on Day 5 (Cycle 1).

The probability of response (CR, CRi or CRp) as a function of the C48 of cytarabine on Day 5 is presented in Figure 7 . The effect of cytarabine exposure (C48) on the probability of response was statistically significant (p=0.0144) with an odds ratio of 1.057. These results suggest that the odds of response increased by approximately 5.7% for each 1 unit increment of cytarabine C48 (i.e., 1 μg/mL).

<div style=\"page-break-after: always\"></div>

Figure 7. Probability of Response (CR, CRi or CRp) as a Function of Cytarabine C48

25.2

32.2

45.4

<!-- image -->

Subsequently, multivariate regression analyses were performed to identify potential factors affecting the probability of response (in addition to cytarabine C48). None of the tested covariates (age, sex, bone marrow blast count, WBC count, platelet count, haemoglobin) explained the variability in response. Parameters derived with the final exposure-response model of cytarabine C48 on the probability of response (CR, CRi or CRp) are presented in Table 16 .

Table 16. Exposure-Response Parameters: Impact of Cytarabine C48 on the Probability of Response (CR, CRi or CRp)

| Term                                                     | Parameter Estimates (95% CI)                             | (P-Value)                                                |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Intercept                                                | -1.653 (-3.367, -0.178)                                  | 0.0388                                                   |
| Slope of Drug Effect (cytarabine C48)                    | 0.0555 (0.0151, 0.106)                                   | 0.0144                                                   |
| C48 = concentration 48-h after dosing on Day 5 (Cycle 1) | C48 = concentration 48-h after dosing on Day 5 (Cycle 1) | C48 = concentration 48-h after dosing on Day 5 (Cycle 1) |

The impact of cytarabine C48 (after converting from the logit scale) on the probability of response (CR, CRi or CRp) are presented below:

- The estimated odds of response without cytarabine (C48 = 0 μg/mL) was 0.191 (i.e., exp[ - 1.653]), suggesting a 16.1% probability of response (odds/1+odds).
- The estimated odds of response for a 20 μg/mL increment in C48 (0.0555 x 20 = 1.11) was 3.03 (i.e., exp[1.11]). The odds for the combined intercept and drug effect (C48 = 20 μg/mL) is 0.581 (i.e., exp[-1.653 + 1.11]) which corresponds to a 36.7% probability of response.
- The estimated odds of response for a 40 μg/mL in crement in C48 (0.05550 x 40 = 2.22) was 9.21 (i.e., exp[2.22]). The odds for the combined intercept and drug effect (C48 = 40 μg/mL) is 1.76 (i.e., exp[-1.653 + 2.22]) which corresponds to a 63.8% probability of response.

<div style=\"page-break-after: always\"></div>

For both cytarabine and daunorubicin, model-predicted C48 and AUC0-48 were highly correlated with each other and both predicted parameters were highly correlated with the observed Day 5 predose concentration (Cpredose) as well (r=0.88 to r=0.95 for each comparison). Daunorubicin C48 and cytarabine and daunorubicin AUC0-48 and Cpredose were statistically significant predictors of response (CR, CRi or CRp).

Probability of (CR or CRp): CR and CRp were assessed in Studies CPX-MA-1201 and AAML1421. In all, 16 of  52  patients  were  classified  as  responders  (CR  or  CRp).  Various  exposure-response  models  were developed to assess the effect of cytarabine and/or daunorubicin exposures on the probability of response (CR or CRp) obtained in pediatric studies (Studies CPX-MA-1201 and AAML1421). None of the exposure parameters of cytarabine or daunorubicin were statistically significantly associated with the probability of response (CR or CRp).

Probability of (CR or Cri): CR and CRi were assessed in Studies CPX-MA-1201, AAML1421 and 310-206. In all, 33 of 65 patients were classified as responders (CR or Cri). Various exposure-response models were developed to assess the effect of cytarabine and/or daunorubicin exposures on the probability of response ( Table 17 ).

Table 17. Univariate Exposure-Response Analysis of Efficacy (Probability of CR or Cri)

| Model                                                            |   Degrees of Freedom |     AIC |     BIC | Statistical Significance of Exposure (p<0.05)   |
|------------------------------------------------------------------|----------------------|---------|---------|-------------------------------------------------|
| Model 1: Daunorubicin AUC0-48                                    |                    2 | 85.0676 | 89.4164 | Yes                                             |
| Model 2: Daunorubicin Cmax                                       |                    2 | 89.0884 | 93.4372 | Yes                                             |
| Model 3: Daunorubicin C48                                        |                    2 | 81.8967 | 86.2455 | Yes                                             |
| Model 4: Cytarabine AUC0-48                                      |                    2 | 86.573  | 90.9218 | Yes                                             |
| Model 5: Cytarabine Cmax                                         |                    2 | 89.9564 | 94.3051 | No                                              |
| Model 6: Cytarabine C48                                          |                    2 | 84.7299 | 89.0787 | Yes                                             |
| Model 7: Daunorubicin C48 + Cytarabine C48                       |                    3 | 83.7828 | 90.306  | No                                              |
| Model 8: Interaction between Daunorubicin C48 and Cytarabine C48 |                    4 | 84.3642 | 93.0618 | No                                              |

Note : Studies CPX-MA-1201, AAML1421 and 310-206 were included in the analysis.

All exposure parameters were derived using the population PK model.

AIC = Akaike information criterion; AUC0-48 = area under the concentration-time curve from time zero to 48 h post-dose on Day 5 (Cycle 1); BIC = Bayesian information criterion; C48 = Concentration 48-h after dosing on Day 5 (Cycle 1); Cmax = maximum concentration on Day 5 (Cycle 1).

The C48 of cytarabine and daunorubicin were associated with the best statistical goodness-of-fit (AIC of 69.544 and 68.681, respectively). Cytarabine C48 was selected for subsequent analyses for consistency with other analyses. The probability of response (CR or CRi) as a function of cytarabine C48 on Day 5 is presented in Figure 8 . The effect of cytarabine exposure (C48) on the probability of response (CR or CRi) was statistically significant (p=0.00631) with an odds ratio of 1.056. These results suggest that the odds of response increased by approximately 5.6% for each 1 unit increment of cytarabine C48 (i.e., 1 μg/mL).

<div style=\"page-break-after: always\"></div>

Figure 8. Probability of Response (CR or CRi) as a Function of Cytarabine C48

24.6

31.8

40.4

<!-- image -->

Subsequently, multivariate regression analyses were performed to identify potential factors affecting the probability of response (in addition to cytarabine C48). None of the tested covariates (age, sex, bone marrow blast count, WBC count, platelet count, haemoglobin) explained the variability in response. Parameters derived with the final exposure-response model of cytarabine C48 on the probability of response (CR, CRi or CRp) are presented in Table 18 .

Table 18. Exposure-Response Parameters: Impact of Cytarabine C48 on the Probability of Response (CR or CRi)

| Term                                                     | Parameter Estimates (95% CI)                             | (P-Value)                                                |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Intercept                                                | -1.749 (-3.218, -0.475)                                  | 0.0113                                                   |
| Slope of Drug Effect (cytarabine C48)                    | 0.0540 (0.0183, 0.0971)                                  | 0.00631                                                  |
| C48 = concentration 48-h after dosing on Day 5 (Cycle 1) | C48 = concentration 48-h after dosing on Day 5 (Cycle 1) | C48 = concentration 48-h after dosing on Day 5 (Cycle 1) |

The impact of cytarabine C48 (after converting from the logit scale) on the probability of response (CR or CRi) are presented below.

- The estimated odds of response without cytarabine exposure (C48 = 0 μg/mL) was 0.174 (i.e., exp[ -1.7494]), suggesting a 14.8% probability of response (odds/1+odds).
- The estimated odds of response for a 20 μg/mL increment in C48 (0.0540x 20 = 1.08) was 2.94 (i.e., exp[1.08]). The odds for the combined intercept and drug effect (C48 = 20 μg/mL) is therefore 0.512 (i.e., exp[-1.174 + 1.08]) which corresponds to a 33.9% probability of response.
- The estimated odds of response for a 40 μg/mL increment in C48 (0.00540 x 40 = 2.16) was 8.67 (i.e., exp[2.16]). The odds for the combined intercept and drug effect (C48 = 40 μg/mL) is 1.51 (i.e., exp[-1.174+ 2.16]) and a 60.1% probability of response.

<div style=\"page-break-after: always\"></div>

Probability of (CR): Various exposure-response models were developed to assess the effect of cytarabine and/or daunorubicin exposures on the probability of response (CR) obtained in in all studies (Studies CPXMA-1201, AAML1421, 310-206 and 310-101). In all, 28 of 81 patients were classified as responders (CR). None of the exposure parameters of cytarabine or daunorubicin were statistically significantly associated with the probability of response (CR).

## Exposure-response analyses for safety

## Methods

Exposure-response analysis of safety was performed based on data collected in all studies (0305-101, 310206, 310-301, CPX-MA-1201 and AAML1421). The exposure-safety population included patients with at least 1 measurable concentration of cytarabine and daunorubicin on Day 5, Cycle 1.

In a first step, treatment emergent adverse events (TEAE) were merged with Cmax and classified according to the quartile of exposure for the overall safety population and for only pediatric patients in the safety population. Descriptive statistics were derived according to the following toxicity grade and severity.

- Adverse events grades (grades 1, 2, 3, 4 and 5 according to NCI-CTC toxicity grade)
- Adverse events grade ≥ 3 (according to NCI-CTC toxicity grade)
- Serious treatment-emergent adverse events (SAE)

Then, descriptive statistics were derived for adverse events (AEs) according to the 'body system or organ class' (AEBODSYS, e.g., blood and lymphatic system disorders) and 'dictionary derived' terms (AEDECOD, e.g., febrile neutropenia). Only AEs associated with a 'definite' or ' possible' causality with CPX-351 were included in the analysis. Based on the descriptive statistics results, key AEs were selected for a formal exposure-response analysis. Predicted exposure parameters of cytarabine and daunorubicin (AUC0-48, Cmax or C48 on Day 5, Cycle 1) were merged with AEs of interest.

Logistic regression models were developed to link cytarabine and/or daunorubicin exposures to the above probability of AEs.

## Results

The exposure-safety population included a total of 46 (18.5%) pediatric patients (1-17 years) and 204 (81.5%) adults ( ≥ 18 years). The population included 147 (59.3%) male and 101 (40.7%) female patients, mainly of white origin (82.3%). The Phase III study (310-301) contributed the largest number of patients in the exposure-safety population (130 patients; 52.4%).

Of a total of 178 patients who presented an adverse event associated with the 'blood and lymphatic system disorders' preferred term, 141 (79.2%) presented neutropenia. Of a total of 203 patients who presented an adverse event associated with the 'skin and subcutaneous tissue disorders' preferred term, 79 (38.9%) presented  a  rash.  Based  on  the  above,  exposure-response  analyses  were  performed  to  determine  the impact of drug exposure on the probability of neutropenia or rash.

## Neutropenia

Various ER models were developed to assess the effect of cytarabine and/or daunorubicin exposures on the probability  of  neutropenia.  Of  all  models  tested,  the  Cmax  of  cytarabine  and  AUC  of  daunorubicin  were associated with the best statistical goodness-of-fit (AIC = 332.057 and 332.522, respectively). The Cmax of cytarabine  was  used  in  subsequent  analyses  for  consistency  with  analyses  for  rash  (see  below).  The probability of neutropenia as a function of the Cmax of cytarabine on Day 5 is presented in Figure 9 .

<div style=\"page-break-after: always\"></div>

Figure 9 . Probability of Neutropenia as a Function of Cytarabine Cmax on Day 5

<!-- image -->

The effect of cytarabine Cmax on the probability of neutropenia was statistically significant (p=0.0011) with an odds ratio of 1.015. These results suggest that the odds of response increased by approximately 1.5% for each 1 unit increment of cytarabine Cmax (i.e., 1 μg/mL).

A covariate analysis was performed to identify potential risk factors for the probability of neutropenia. After taking into account drug exposure in the logistic regression model, no tested covariate (age, sex, bone marrow blast count, WBC count, platelet count) explained the probability of neutropenia.

Parameters  derived  with  the  final  exposure-response  model  of  cytarabine  Cmax  on  the  probability  of neutropenia are presented in Table 19 .

Table 19 . ER Parameters: Impact of Cytarabine Cmax on the Probability of Neutropenia

| Term                                      | Parameter Estimates (95% CI)   | (P-Value)   |
|-------------------------------------------|--------------------------------|-------------|
| Intercept                                 | -0.730 (-1.415, -0.0696)       | 0.0327      |
| Slope of Drug Effect (Cmax of cytarabine) | 0.0152 (0.00592, 0.0250)       | <0.01       |

The magnitude of effects of cytarabine Cmax (after converting from the logit scale) are presented below.

- The estimated odds of neutropenia without cytarabine exposure (Cmax = 0 μ g/mL) was 0.482 (i.e., exp[-0.730]), suggesting a 32.5% probability of neutropenia (odds/1+odds).
- The odds for a 50 μg/mL increment in Cmax (0.0152 x 50 = 0.760) was 2.14 (i.e., exp[0.760]). The odds for the combined intercept and drug effect (Cmax = 50 μ g/mL) is 1.03 (i.e., exp[-0.730 + 0.759]) which corresponds to a 50.7% probability of neutropenia
- The odds for a 100 μg/mL increment in Cmax (0.0152 x 100 = 1.52) was 4.57 (i.e., exp[1.52]). The odds for the combined intercept and drug effect (Cmax = 100 μ g/mL) is 2.20 (i.e., exp[-0.730 + 1.52]) which corresponds to a 68.8% probability of neutropenia

<div style=\"page-break-after: always\"></div>

## Rash

Various ER models were developed to assess the effect of cytarabine and/or daunorubicin exposures on the probability  of  a  rash  event.  Of  all  models  tested,  the  Cmax  of  cytarabine  was  associated  with  the  best statistical goodness-of-fit based on the AIC values. The probability of rash as a function of the Cmax of cytarabine on Day 5 is presented in Figure 10 .

Figure 10 . Probability of rash as a function of cytarabine Cmax

46.9

63.9

85.2

<!-- image -->

The effect of cytarabine Cmax on the probability of rash was statistically significant (p=0.0092) with an odds ratio of 1.012. These results suggest that the odds of a rash increased by approximately 1.2% for each 1 unit increment of Cmax (i.e., 1 μg/mL).

A covariate analysis was performed to identify potential risk factors for the probability of rash. After taking into account drug exposure in the logistic regression model, no tested covariate (age, sex, bone marrow blast count, WBC count, platelet count) explained the probability of rash. Parameters derived with the final exposure-response model of cytarabine Cmax for the probability of rash are presented in Table 20 .

Table 20. ER Parameters: Impact of Cytarabine Cmax on the Probability of Rash

| Term                           | Parameter Estimates (95% CI)   | (P-Value)   |
|--------------------------------|--------------------------------|-------------|
| Intercept                      | -1.11 (-1.797, -0.453)         | <0.01       |
| Slope: Cytarabine Cmax (µg/mL) | 0.0118 (0.00289, 0.0211)       | 0.0106      |

The impact of cytarabine Cmax (after converting from the logit scale) on the probability of rash are presented below.

- The estimated odds of rash without cytarabine exposure (Cmax = 0 ng/mL) was 0.330 (i.e., exp[1.11]), suggesting a 24.8% probability of rash (odds/1+odds).

<div style=\"page-break-after: always\"></div>

- The odds for a 50 μ g/mL increment in Cmax (0.0118 x 50 = 0.590) was 1.80 (i.e., exp[0.590]). The odds for the combined intercept and drug effect (Cmax = 50 μ g/mL) is 0.595 (i.e., exp[-0.845 + 0.590]) which corresponds to a 37.3% probability of rash
- The odds for a 100 μ g/mL increment in Cmax (0.0118 x 100 = 1.18) was 3.25 (i.e., exp[1.18]). The odds for the combined intercept and drug effect (Cmax = 100 μ g/mL) is 1.07 (i.e., exp[-1.11 + 1.18]) which corresponds to a 51.7% probability of rash

## Time to neutrophil recovery and platelet recovery

Longitudinal measures of absolute neutrophil count (ANC) and platelet count were available in study CPXMA-1201 and AAML1421 (total N=51). No statistically significant effect of cytarabine Cmax was observed on the time to recovery of ANC or platelet count. Results should be interpreted with caution due to the low number of patients.

## Distribution of TEAEs by exposure

The distribution of TEAEs across quartiles of cytarabine Cmax for all studies are presented in Table 21 . A gradual increase in frequency of Grade 3 to 5 TEAEs was observed across quartiles of cytarabine Cmax. The probabilities of Grade 3 to 5 TEAEs for the 1st, 2nd, 3rd, and 4th quartiles of cytarabine Cmax were 11.3%, 13.1%, 18.0% and 53.2%, respectively. The frequency of severe adverse events was low (n=11) with apparent gradual increases in frequencies across quartiles of exposure. Similar results were observed for daunorubicin Cmax.

Table 21. Overall Summary of Treatment Emergent Adverse Events by Quartiles of Cytarabine Cmax (All Studies)

|                                | Cytarabine Quartiles of Cmax (μg/mL)                                      | Cytarabine Quartiles of Cmax (μg/mL)                                      | Cytarabine Quartiles of Cmax (μg/mL)                                      | Cytarabine Quartiles of Cmax (μg/mL)                                      | Overall (N=246)                |
|--------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------|
|                                | Q1 = [2.21,46.9) (N=62) Q2 = [46.9,63.4) Q3 = [63.4,84.9) Q4 = [84.9,161] | Q1 = [2.21,46.9) (N=62) Q2 = [46.9,63.4) Q3 = [63.4,84.9) Q4 = [84.9,161] | Q1 = [2.21,46.9) (N=62) Q2 = [46.9,63.4) Q3 = [63.4,84.9) Q4 = [84.9,161] | Q1 = [2.21,46.9) (N=62) Q2 = [46.9,63.4) Q3 = [63.4,84.9) Q4 = [84.9,161] |                                |
| Any TEAEs                      | 62 (100%)                                                                 | (N=61) 61 (100%)                                                          | (N=61) 61 (100%)                                                          | (N=62) 62 (100%)                                                          | 246 (100%)                     |
| TEAEs by Maximum NCI-CTC Grade | TEAEs by Maximum NCI-CTC Grade                                            | TEAEs by Maximum NCI-CTC Grade                                            | TEAEs by Maximum NCI-CTC Grade                                            | TEAEs by Maximum NCI-CTC Grade                                            | TEAEs by Maximum NCI-CTC Grade |
| 1                              | 41 (66.1%)                                                                | 34 (55.7%)                                                                | 30 (49.2%)                                                                | 18 (29.0%)                                                                | 123 (50.0%)                    |
| 2                              | 14 (22.6%)                                                                | 19 (31.1%)                                                                | 20 (32.8%)                                                                | 11 (17.7%)                                                                | 64 (26.0%)                     |
| 3                              | 6 (9.7%)                                                                  | 7 (11.5%)                                                                 | 10 (16.4%)                                                                | 28 (45.2%)                                                                | 51 (20.7%)                     |
| 4                              | 1 (1.6%)                                                                  | 1 (1.6%)                                                                  | 1 (1.6%)                                                                  | 4 (6.5%)                                                                  | 7 (2.8%)                       |
| 5                              | 0 (0%)                                                                    | 0 (0%)                                                                    | 0 (0%)                                                                    | 1 (1.6%)                                                                  | 1 (0.4%)                       |
| 3-5                            | 7 (11.3%)                                                                 | 8 (13.1%)                                                                 | 11 (18.0%)                                                                | 33 (53.2%)                                                                | 59 (24.0%)                     |
| TEAEs by Closest Relationship  | TEAEs by Closest Relationship                                             | TEAEs by Closest Relationship                                             | TEAEs by Closest Relationship                                             | TEAEs by Closest Relationship                                             | TEAEs by Closest Relationship  |
| Not related                    | 37 (59.7%)                                                                | 32 (52.5%)                                                                | 28 (45.9%)                                                                | 34 (54.8%)                                                                | 131 (53.3%)                    |
| Related                        | 25 (40.3%)                                                                | 29 (47.5%)                                                                | 33 (54.1%)                                                                | 28 (45.2%)                                                                | 115 (46.7%)                    |
| Not severe                     | 62 (100%)                                                                 | 60 (98.4%)                                                                | 58 (95.1%)                                                                | 55 (88.7%)                                                                | 235 (95.5%)                    |
| Severe                         | 0 (0%)                                                                    | 1 (1.6%)                                                                  | 3 (4.9%)                                                                  | 7 (11.3%)                                                                 | 11 (4.5%)                      |

In studies CPX-MA-1201 and AAML1421 (total N=53), probabilities of Grade 3 to 5 TEAEs for the 1 st , 2 nd , 3 rd , and 4 th  quartiles of cytarabine Cmax were 76.9%, 84.6%, 84.6% and 71.4%, respectively ( Table 22 ). Similar results were observed daunorubicin Cmax. Overall no apparent ER relationship of TEAEs was observed in study CPX-MA-1201 and AAML1421.

<div style=\"page-break-after: always\"></div>

Table  22. Overall  Summary  of  Treatment  Emergent  Adverse  Events  by  Quartiles  of  Cytarabine  Cmax (Studies CPX-MA-1201 and AAML1421)

|                                | Cytarabine Quartiles of Cmax (μg/mL)   | Cytarabine Quartiles of Cmax (μg/mL)   | Cytarabine Quartiles of Cmax (μg/mL)   | Cytarabine Quartiles of Cmax (μg/mL)   |                                |
|--------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|--------------------------------|
|                                | Q1 = [51.1, 82.8) (N=13)               | Q2 = [82.8, 98.6) (N=13)               | Q3 = [98.6, 111) (N=13) Q4             | = [111,161] (N=14)                     | Overall (N=53)                 |
| Any TEAEs                      | 13 (100%)                              | 13 (100%)                              | 13 (100%)                              | 14 (100%)                              | 53 (100%)                      |
| TEAEs by Maximum NCI-CTC Grade | TEAEs by Maximum NCI-CTC Grade         | TEAEs by Maximum NCI-CTC Grade         | TEAEs by Maximum NCI-CTC Grade         | TEAEs by Maximum NCI-CTC Grade         | TEAEs by Maximum NCI-CTC Grade |
| 1                              | 0 (0%)                                 | 0 (0%)                                 | 1 (7.7%)                               | 4 (28.6%)                              | 5 (9.4%)                       |
| 2                              | 3 (23.1%)                              | 2 (15.4%)                              | 1 (7.7%)                               | 0 (0%)                                 | 6 (11.3%)                      |
| 3                              | 8 (61.5%)                              | 9 (69.2%)                              | 9 (69.2%)                              | 9 (64.3%)                              | 35 (66.0%)                     |
| 4                              | 2 (15.4%)                              | 2 (15.4%)                              | 1 (7.7%)                               | 1 (7.1%)                               | 6 (11.3%)                      |
| 5                              | 0 (0%)                                 | 0 (0%)                                 | 1 (7.7%)                               | 0 (0%)                                 | 1 (1.9%)                       |
| 3-5                            | 10 (76.9%)                             | 11 (84.6%)                             | 11 (84.6%)                             | 10 (71.4%)                             | 42 (79.2%)                     |
| TEAEs by Closest Relationship  | TEAEs by Closest Relationship          | TEAEs by Closest Relationship          | TEAEs by Closest Relationship          | TEAEs by Closest Relationship          | TEAEs by Closest Relationship  |
| Not related                    | 3 (23.1%)                              | 2 (15.4%)                              | 7 (53.8%)                              | 7 (50.0%)                              | 19 (35.8%)                     |
| Related                        | 10 (76.9%)                             | 11 (84.6%)                             | 6 (46.2%)                              | 7 (50.0%)                              | 34 (64.2%)                     |
| Not severe                     | 12 (92.3%)                             | 9 (69.2%)                              | 11 (84.6%)                             | 12 (85.7%)                             | 44 (83.0%)                     |
| Severe                         | 1 (7.7%)                               | 4 (30.8%)                              | 2 (15.4%)                              | 2 (14.3%)                              | 9 (17.0%)                      |

## 1.5.5. Discussion on clinical pharmacology

Two  investigator-sponsored  paediatric  studies  (CPX-MA-1201  and  AAML1421)  have  been  conducted  in paediatric and young adult patients from 1 to 21 years of age with r/r AML. The studies were conducted independently and without input on design of the MAH.

## Observed PK

Frequent plasma PK samples following the Day 5 dose were collected in 27 and in 5 paediatric and young adult patients in studies CPX-MA-1201 and AAML1421, respectively. In addition, sparse PK samples were available for 22 subjects in study AAML1421. The observed exposure (AUC over 48 hours following the Day 5  dose)  in  paediatric  patients  following  intravenous  doses  100  and  135  units/m 2   was  approximately comparable to the exposure observed previously in adult patients at similar dose levels. This is expected, because the dose is  adjusted  by  body  surface  area.  Moreover,  when  cytarabine  and  daunorubicin  are administered  as  components  of  Vyxeos  liposomal,  the  liposomes  govern  their  disposition  kinetics:  the volume of distribution is close to the blood volume and the rate of drug release from the liposomes becomes the factor that determines the rate of elimination.

No major deviations from dose proportionality were observed over the dose range 100 to 135 units/m 2  in the paediatric studies, which is in line with previous data in adult patients.

## Population PK analyses

Population PK (PPK) analyses were conducted in accordance with pre-specified pharmacometric analysis plan. The analysis plan was included in the dossier, which is appreciated.

PPK analyses were conducted using previously developed adult PPK models for cytarabine and daunorubicin as the starting point. The proportion of paediatric subjects in the updated dataset was moderate (46/250 subjects; 18.4%). After the PPK parameters were re-estimated, the effects of age on PK parameters were further investigated. At this point, the PPK models over-estimated concentrations for paediatric studies (CPX-MA-1201 and AAML1421) population and under-estimated the concentrations in adult studies (101, 206 and 301) population.  For  both  cytarabine  and  daunorubicin  models,  'paediatric  study'  categorical covariate  effect  on  CL  and  Vc  parameters  improved  the  fits  more  than  age-based  covariates.  The introduction of a study effect on paediatric studies led to lower estimates for CL and Vc. This effect appeared

<div style=\"page-break-after: always\"></div>

to be only driven by the unexpectedly high exposure observed in young adults (18-21 years old) in studies CPX-MA-1201 and AAML1421.

One weakness of the PPK analysis is that serum bilirubin level data were not available for studies CPX-MA1201 and AAML1421; bilirubin was a covariate for clearance for both cytarabine and daunorubicin in adult PPK models. It is acknowledged that the MAH does not have the data and the issue is not pursued; it is unlikely that the overall conclusions regarding the current variation application are affected by this lack of data given that the effect of bilirubin level on clearance was modest.

The MAH withdrew the application for the paediatric indication during the procedure. The responses to questions  on  PPK  analyses  were  deemed  sufficient  for  the  final  scope  of  the  variation  application. Simulations  using  the  PPK  models  indicated  that  the  predicted  exposures  following  the  Day  5  dose  in patients  1-5,  6-11,  and  12-17  years  of  age  following  the  135  units/m 2   dose  were  very  similar,  and approximately 40% higher than the exposure in adults (≥ 18 years of age) following the 100 units/m 2  dose, i.e. exposure increased by 40% for a 35% dose increase. However, the predicted exposures for young adults  (18-21  years)  from  studies  CPX-MA-1201  and  AAML1421  were  markedly  higher  compared  with paediatric patients. As expected, the predicted exposure parameters (Cmax; AUC over 48 hours (AUC0-48); concentration at 48 hours after the dose (C48)) were highly correlated, especially AUC0-48 and C48 but also Cmax and the other two parameters.

The MAH is reminded that because the final population PK models for cytarabine and daunorubicin have empirical  covariate  'paediatric  study  effect'  on  clearance  and  central  volume  parameters,  use  of  the presented population PK models to predict PK in other populations is not recommended. The MAH should consider  to  re-develop  the  PPK  models  in  future  as  more  data  become  available;  re-evaluation  of  the 'formulation effect' on the PK of daunorubicin at that time is also recommended.

## Exposure-response analyses

Exposure-response (ER) analyses for efficacy and safety were conducted in accordance with pre-specified pharmacometric analysis plan. The analysis plan was included in the dossier, which is appreciated.

ER analyses for efficacy were conducted for paediatric and adult patients with relapsed and refractory AML from studies CPX-MA-1201, AAML1421, 101 and 206. Various efficacy endpoints were tested. Because some endpoints were not monitored in the adult studies (101 and 206), the number of subjects in the efficacy ER analyses was variable.

For the strict [complete response (CR)] endpoint, no statistically significant association between predicted exposure and efficacy  was  observed;  CR  was  observed  in  28  of  81  (30.9%)  patients.  The  least  strict endpoint [CR, or response with incomplete blood count recovery (CRi), or response with partial recovery of platelet count (CRp)] was monitored only in the paediatric and young adult studies (CPX-MA-1201 and AAML1421). This joint endpoint was observed in 29 of 52 (55.8%) patients, and exposure to cytarabine or daunorubicin was a statistically significant predictor of response.

Of note, only dose levels 100-101 and 134-135 units/m 2  were investigated in the ER analyses for efficacy, and  data  for  the  higher  dose  are  mainly  from  studies  CPX-MA-1201  and  AAML1421.  Therefore,  the sensitivity to detect exposure-efficacy relationships may be decreased when data from studies 101 and 206 are  included in the  analyses.  On  the other hand, the number of patients in studies  CPX-MA-1201 and AAML1421 was relatively low (N=52), and the results should, therefore, be interpreted with caution.

A total of 250 patients, mostly (204/250) adults, were included in the ER analyses for safety. Treatment emergent adverse events (TEAEs) 'neutropenia' and 'rash' were frequently reported (in 79.2% and in 38.9% of patients, respectively) and were selected for ER analyses.

Probability  of  neutropenia  increased  approximately  linearly  with  increasing  predicted  cytarabine  (or daunorubicin) Cmax and the association was statistically significant. The result is expected, because both

<div style=\"page-break-after: always\"></div>

cytarabine and daunorubicin are known to cause bone marrow depression. Probability of rash also increased statistically significantly with increasing predicted cytarabine (or daunorubicin) Cmax.

The probability of any TEAE of grade 3-5 increased with increasing predicted cytarabine (or daunorubicin) Cmax in the overall safety population, whereas in the paediatric and young adult population (studies CPXMA-1201 and AAML1421; N=53) this association was not observed. Because the number of paediatric and young adult patients was low, results for this subset should be interpreted with caution.

## 1.5.6. Conclusions on clinical pharmacology

A question on pharmacokinetics and exposure in young adult patients, which was initially raised as part of the MO on the proposed indication, as well as several other concerns on clinical pharmacology were not further pursued since MAH withdrew the application for the paediatric indication.

Information on paediatric PK will be added to section 5.2 of the SmPC within the current variation. See the annexed product information document for details.

## 1.6. Clinical efficacy

## 1.6.1. Dose response studies

## Dose response in study CPX-MA-1201

## Study Design

Study CPX-MA-1201 was a phase 1, single-center pilot study to assess the PK, toxicity and tolerability of CPX-351 in paediatric and young adult patients with relapsed / refractory hematologic malignancies. The primary efficacy objectives included determination of a safe and tolerable dose of CPX-351 (defined as maximum tolerated dose, MTD) that could be given to patients with advanced hematologic malignancies, recommended a dose of CPX-351 for future studies in young patients with previously untreated AML, and PK after CPX-351 administration to young patients with recurrent or refractory hematologic malignancies

The secondary efficacy objective of this study was to estimate the overall response rate (ORR) to a single course of CPX-351 to young patients with recurrent or refractory hematologic malignancies.

This study comprised 2 phases: a Dose Exploration Phase and an Expanded Phase.

The Dose Exploration Phase was used to determine a safe and tolerable dose of CPX-351 in patients between 1 and 21 years of age with hematologic malignancies in first or greater relapse or with disease refractory to  standard  induction  chemotherapy.  Two  dose  levels  of  CPX-351  were  explored:  100  units/m2 administered intravenously (IV) once daily on Days 1, 3 and 5 (dose level 1), and 134 units/m2 IV once daily on Days 1, 3 and 5 (dose level 2). After completion of the Dose Exploration Phase, the Expanded Phase enrolled 3 to 18 patients between 1 and 30 years of age to collect additional toxicity / tolerability information and to estimate the ORR of CPX-351 using the dose determined during the Dose Exploration Phase.

At specific time points during the treatment course, all patients underwent PK assessments. Consenting patients also participated in a cardiotoxicity biomarker study.

<div style=\"page-break-after: always\"></div>

Throughout the study, patients were monitored for safety and adverse events (AEs); documentation began from day 1 of study treatment and continued through the 30-day follow-up period after treatment was discontinued. Patients continued to be followed for 6 months after completing their treatment course.

## Results

A total of 27 patients were enrolled in the study, received at least 1 dose of study drug, and comprised the safety population. A total of 9 patients were included in the Dose Exploration Phase. Of these, 5 patients received a dose of 134 units/m2 CPX-351 and 4 patients received a dose of 100 units/m2 CPX-351. All 9 patients (100.0%) completed course 1 of therapy and entered the follow-up period.

Among patients who received 134 units/m2 CPX-351, 4/5 (80.0%) patients completed the 6-month followup period, and 1/5 (20.0%) subject died during follow-up. Among patients who received 100 units/m2 CPX351, 2/4 (50.0%) patients completed the 6-month follow-up period, and 2/4 (50.0%) patients died during follow-up.

A total of 18 patients were included in the Expanded Phase, and all received a dose of 100 units/m2 CPX351. A total of 17/18 patients (94.4%) completed course 1 therapy and entered the follow-up period. One subject went off protocol therapy because of disease progression and pursuit of other therapy. A total of 11/18 (61.1%) patients completed the 6-month follow-up period, and 7/18 (38.9%) patients died during follow-up.

The majority of patients were white (77.8%) and there were slightly more female (51.9%) than male (48.1%) patients . Patients had a mean (SD) age of 6.7 (5.90) years, ranging from 1 to 19 years, with most patients (59.3%) in the age group 2 to &lt; 12 years. No patients aged &lt; 1 year were enrolled. The majority of patients enrolled had AML (23/27 patients, 85.2%) and 4/27 patients (14.8%) had ALL.

## Maximum tolerated dose (MTD)

A minimum of 2 evaluable patients was entered at each dose level for determination of MTD. Once the MTD was defined, up to 3 to 18 additional patients were enrolled. The minimum number of patients required to determine a MTD was 5 patients; the maximum was 12.

During  the  Dose  Exploration  Phase,  a  rolling  6  trial  design  was  employed.  Two  to  6  patients  were concurrently enrolled onto a dose level, dependent upon 1) the number of patients enrolled at the current dose level, 2) the number of patients who experienced a dose-limiting toxicity (DLT) at the current dose level, and 3) the number of patients with tolerability data pending at the current dose level. Accrual was suspended when a cohort of 6 had enrolled or when the study endpoints were met.

Dose level assignment was based on the number of patients enrolled in the cohort at the time, the number of DLTs observed, and the number of patients at risk for developing a DLT.

The MTD of CPX-351 observed in adults with AML was 100 units/m2, and it was projected to be tolerable in children based upon previous experience with liposomal anthracycline preparations in pediatric patients. If the 100 units/m2 dose was tolerable, then patients were entered into the study at 134 units/m2. This dose was chosen since it would deliver a total daunorubicin dose of 177 mg/m2, which is comparable to the dose of liposomal daunorubicin administered with fludarabine and high-dose cytarabine by the AMLBerlin / Frankfurt/ Muenster (BFM) study group during re-induction therapy for children with relapsed AML (Sander 2010).

The 134 unit/m2 dose resulted in DLTs in 2 patients; therefore, the 100 unit/m2 dose was administered to all patients in the Expansion Phase.

<div style=\"page-break-after: always\"></div>

## D ose response in study AAML1421

Study AAML1421 was a phase 1/2, multicenter study of CPX-351 for children with AML in first relapse, conducted and sponsored by Children's Oncology Group (COG). The primary objectives of this study were to determine a recommended phase 2 dose (RP2D) and the toxicities associated with CPX-351 in pediatric and  young  adult  patients  with  relapsed/refractory  AML  and  to  estimate  the  response  rate  (complete remission [CR] + complete remission with partial platelet recovery [CRp]) after CPX-351 (Cycle 1) followed by fludarabine/cytarabine/G-CSF (FLAG; Cycle 2) in children with AML in first relapse.

This  study  comprised  2  phases:  a  Dose-finding  Phase  and  an  Efficacy  Phase.  The  Dose-finding  Phase employed a modified rolling 6 design. Patients were assigned a dose of CPX-351 at the time of enrollment. The starting dose was 135 units/m 2 /dose on Days 1, 3 and 5. If 135 units/m 2 /dose was not tolerated, a single dose de-escalation to 100 units/m 2 /dose was allowed. After completion of the Dose-finding Phase, the Efficacy Phase employed a single arm 2-stage design with patients enrolled at the RP2D determined in the Dose-finding Phase. The number of patients enrolled was dependent on the number of responses. In both phases of the trial, CPX-351 was administered intravenously (IV) over 90 minutes on Days 1, 3, and 5 in Cycle 1 and FLAG was administered in Cycle 2.

Pharmacokinetic sampling during the first cycle of treatment was required for patients enrolled in the Dosefinding Phase, and optional for patients enrolled in the Efficacy Phase of this study.

Optional studies of biomarkers of cardiac injury, novel biochemical and imaging markers of cardiotoxicity, and rare coding variants as risk factors for anthracycline-induced cardiomyopathy were also included in the study design.

Throughout the study, patients were monitored for safety and adverse events (AEs); documentation began from day 1 of study treatment and continued through the 30-day follow-up period after treatment was discontinued.

## Results

A total of 38 patients provided informed consent and were enrolled in this study. All patients received a dose of 135 units/m2 CPX-351 and were included in the Safety Analysis Set.

A total of 6 patients were included in the Dose-finding Phase; of these, 4 patients (66.7%) completed planned therapy and entered the follow-up period. One subject (16.7%) experienced treatment failure, and 1 subject (16.7%) did not complete the planned therapy because the physician determined it was in the subject's best interest.

Thirty-two patients were included in the Efficacy Phase; of these, 21 patients (65.6%) completed planned therapy  and  entered  the  follow-up  period.  Two  patients  (6.3%)  experienced  treatment  failure,  and  9 patients (28.1%) did not complete the planned therapy because the physician determined it was in the subject's best interest. Overall, most patients (25/38 patients, 65.8%) completed the study.

In the Safety Analysis Set (N = 38), the majority of patients were white (68.4%) and there were slightly more female (52.6%) than male (47.4%) patients. Patients had a mean (SD) age of 10.6 (6.42) years, ranging from 1 to 21 years, with most patients (44.7%) between the ages of 2 and 12 years.

## Maximum tolerated dose (MTD)

Dose limiting toxicities were defined as any of the following events that occurred after the first dose of CPX351 during the first cycle of therapy. DLT assessment occurred during the Dose Finding Phase.

<div style=\"page-break-after: always\"></div>

## Non-hematologic DLT

Non-hematolog ic DLTs were defined as any ≥ Grade 3 non -hematologic toxicity that occurred after the first dose of CPX-351 that was possibly, probably or definitely related to CPX-351, and with the specific exclusion of:

- a) Alopecia
- b) Grade 3 fatigue, anorexia, nausea, vomiting, or diarrhea
- c) Grade 3 or 4 aspartate aminotransferase (AST) or ALT elevation that improved to ≤ Grade 2 within 14 days
- d) Grade 3 or 4 isolated electrolyte abnormalities that resolved, with or without intervention, to ≤ Grade 2 within 72 hours
- e) Tumor lysis syndrome
- f) Grade 3 or 4 fever, febrile neutropenia, or infection with or without hospitalization
- g) Grade 3 rash
- h) Grade 3 mucositis that resolves (with or without supportive care) to ≤ Grade 2 elevation within 14 days
- i) Early  nutritional  intervention  with  total  parenteral  nutrition  or  enteral  tube  feeding  for  anorexia, nausea, or concern for poor nutritional status will not be considered a DLT
- j) Grade 3 troponin elevations without EKG or other evidence of myocardial ischemia
- k) Grade 3 or greater pain due to leukemia, mucositis, typhlitis, infection, or obvious injury.

## Hematologic Dose-Limiting Toxicity

Hematologic DLTs were defined as failure to recover a peripheral ANC &gt; 500/μL and non - transfusion dependent platelet count &gt; 20,000/μL due to documented bone marrow aplasia/hypoplasia (i.e., not due to malignant infiltration) for ≥ 50 days from the start of the therapeutic cycle. Failure to recover peripheral counts due to disease involvement of the bone were not considered dose-limiting.

A pediatric phase 1 trial of CPX-351 at Cincinnati Children's Hospital (Study CPX-MA-1201) completed the initial dose level of 100 units/m2/dose on Days 1, 3, 5 with no DLTs. However, enrollment on AAML1421 began at 135 units/m2/dose on Days 1, 3, 5.

The rationale for studying this dose level included:

1. No DLTs observed with CPX-351 at 100 units/m2/dose on Days 1, 3, 5 in the Study CPX-MA-1201.

2. The DLTs in the adult Study 101 that were observed at 134 units/m2 were persistent cytopenia &gt; 56 days (1 subject), congestive heart failure (1 subject), and hypertensive crisis (1 subject). One episode of congestive heart failure occurred during a period of sepsis and was transient. Hypertensive crises are very rare in the pediatric / adolescent and young adult population; therefore, this toxicity was not considered to be relevant to the eligible patients in this study. The FDA agreed to a starting dose of 134 units/m2/dose (this study rounds the dose to 135 units/m2) upon review of the phase 1 protocol for Study CPX-MA-1201.

3. CPX-351 at a dose of 135 units/m2/dose delivers a total daunorubicin dose of approximately 180 mg/m2, which is comparable to the liposomal daunorubicin delivered in studies with daunoxome (Kaspers 2013). Also,  this  dose  is  comparable  to  the  150  mg/m2 cumulative dose of daunorubicin administered during Induction I of COG studies AAML0531 and AAML1031, thus providing a dose that is comparable to published literature and potentially translatable to a randomized phase 3 study.

<div style=\"page-break-after: always\"></div>

4. If 135 units/m2/dose is not tolerated, a single dose de-escalation to 100 units/m2/dose was allowed.

The Dose-finding Phase of Study AAML1421 demonstrated that CPX-351 at 135 units/m2/dose given on Days 1, 3, and 5 was identified as the RP2D. This dose was used in the Efficacy Phase.

## 1.6.2. Main study

Study AAML1421: A Phase 1/2 Study of CPX 351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML).

## Methods

## Study participants

The eligibility criteria were selected to enrol patients representative of relapsed, pediatric (and young adults) AML population.

The key inclusion criteria were the following:

1. Age: Patients must be ≥ 1 year and ≤ 21 years of age at the time of enrollment.
2. Diagnosis: Patients must have had histologic verification of AML at original diagnosis, with one of the following:
- Recurrent disease with ≥ 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary disease.
- Recurrent disease with an absolute blast count &gt; 1,000 per microliter in the peripheral blood with or without extramedullary disease.
- l) Disease Status for Dose-finding Phase:
- Relapse patients: Patients must be in first relapse, and must not have received prior re-induction therapy.
- Refractory patients: Patients must not have received more than 1 attempt at remission induction, which may consist of up to 2 different therapy courses. (COG AAML1031 de novo therapy including Induction I and Induction II is an example.)
- Treatment-related AML: Patients must be previously untreated for secondary AML.
- m) Disease Status for Phase 2 Efficacy Phase:
- Relapse patients: Patients must be in first marrow relapse, and must not have received prior reinduction therapy. Donor lymphocyte infusion is considered a reinduction attempt.
5. Central nervous system (CNS) Disease: Patients must have the status of CNS1 or CNS2 only, and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy.
6. Performance status: Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Karnofsky for patients &gt; 16 years of age and Lansky for patients ≤ 16 years of age.

<div style=\"page-break-after: always\"></div>

7. Prior Therapy - patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant  (SCT)  or  radiotherapy  prior  to  entering  this  study.  All  prior treatmentrelated toxicities must have resolved to ≤ Grade 2 prior to enrollment.
- Myelosuppressive chemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study (excluding hydroxyurea).
- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent such as steroids, retinoids.
- Radiation therapy (RT): ≥ 2 weeks for local palliative RT (small port); ≥ 6 months must have elapsed if pri or craniospinal RT or if ≥ 50% radiation of pelvis; ≥ 6 weeks must have elapsed if other substantial BM radiation.
- SCT: No evidence of active graft vs. host disease for at least 4 weeks. For allogeneic SCT patients, ≥ 3 months must have elapsed since trans plant.
6. -Must have received no more than 1 prior autologous or allogeneic SCT.
7. -Patients must be off all systemic immunosuppressive therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacement.
8. -At least 14 days must have elapsed since receiving liposomal cytarabine (DepoCyte) by IT injection.
- Growth factors:
- Patients must not have received growth factors for 7 days prior to CPX-351.
- Patients must not have received pegfilgrastim for 14 days prior to CPX-351.
8. Concomitant medication restrictions:
- No other cancer chemotherapy or immunomodulating agents may be given while the subject is on study.
- Corticosteroid  therapy  is  not  permitted  unless  administered  to  treat  anaphylactic  reactions, symptoms of Ara-C syndrome, rash possibly related to CPX-351, suspected adrenal insufficiency, or pain management (in short courses ≤ 3 days).
- Filgrastim should only be used during Cycle 1 with the discretion of the treating physician; the pegylated formulation (pegfilgrastim) should not be used.
- Dexrazoxane use is not permitted during the study.

## The key exclusion criteria were the following:

1. Patients who have received &gt; 450 mg/m 2  daunorubicin equivalents.

NOTE: For the purposes of determining eligibility for this study, the following cardiotoxicity multipliers were used to determine daunorubicin equivalents: Doxorubicin: 1, Mitoxantrone: 3, Idarubicin: 3 and Epirubicin: 0.5.

2. Patients who are currently receiving another investigational drug.
3. Patients receiving medications for treatment of left ventricular systolic dysfunction.
4. Patients with any of the following diagnoses:

<div style=\"page-break-after: always\"></div>

- Acute promyelocytic leukemia
- Down syndrome
- Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
- Wilson's disease and any other disorder of copper metabolism
- Juvenile myelomonocytic leukemia
5. Patients with documented active, uncontrolled infection at the time of study entry.
6. Patients with known active hepatitis B virus and hepatitis C virus infections.
7. Patients with prior allergy to daunorubicin and / or cytarabine.

## · Treatments

Patients received up to 2 cycles of therapy as follows:

## Cycle 1:

All patients received 2 doses of IT cytarabine based on age:

- At the time of diagnostic lumbar puncture, or on Day 0 of Cycle 1. Patients may have received IT cytarabine up to 1 week prior to Day 1, but at least 24 hours prior to the start of CPX-351 on Day 1.
- At the time of the Day 28-30 bone marrow biopsy (or up to 1 week prior to Day 1 of Cycle 2).

Age-based dosing was as follows: patients aged 1 to 1.99 years received 30 mg; patients aged 2 to 2.99 years received 50 mg; and patients aged ≥ 3 years received 70 mg.

CPX-351 was administered at a dose of 135 units/m 2  by central venous catheter over 90 minutes on Days 1, 3, and 5.

## Cycle 2: (FLAG)

Patients received 5 mcg/kg Filgrastim (G-CSF) administered IV or subcutaneously on Days 1-5 one hour prior to each dose of fludarabine. Dosing was restarted on Day 15 and continued until the post-nadir ANC ≥ 500/μ L.

Fludarabine was given at a dose of 30 mg/m 2  IV over 30 minutes on Days 1-5.

High dose cytarabine at a dose of 2000 mg/m 2  was administered by IV infusion over 1 to 3 hours on Days 1-5 (4 hours after the start of fludarabine).

## Primary Objective

The primary objectives of this study were to:

- Determine  a  recommended  phase  2  dose  (RP2D)  and  the  toxicities  associated  with  CPX-351  in pediatric and young adult patients with relapsed / refractory AML.
- Estimate the response rate (CR + complete remission with partial platelet recovery [CRp]) after CPX351 (Cycle 1) followed by FLAG (Cycle 2) in children with AML in first relapse.

## Secondary Objectives

The secondary objectives of this study were to:

<div style=\"page-break-after: always\"></div>

- Estimate the response rate (CR + CRp + complete remission with incomplete blood count recovery [CRi]) after 1 cycle of CPX-351.
- Describe the pharmacokinetics (PK) of plasma cytarabine and daunorubicin after  CPX-351 administration to pediatric and young adult patients with relapsed / refractory AML.

## Exploratory Objectives

## Exploratory objectives of this study were to:

- Describe the response in biomarkers of cardiac injury to a single cycle of CPX-351.
- Explore the effect of CPX-351 on novel biochemical and imaging markers of cardiotoxicity, including plasma microRNAs and myocardial deformation.
- Explore the role of rare coding variants as risk factors for anthracycline-induced cardiomyopathy.

## Outcomes/endpoints

## Efficacy Variables

## Primary efficacy endpoint

The primary efficacy  endpoint  was  the  proportion  of  patients  with  CR  or  CRp  after  CPX-351  (cycle  1) followed  by  FLAG  (cycle  2).  The  summary  was  done  by  dose  level  (100  units/m2/dose  and  135 units/m2/dose).

Response criteria employed revised AML International Working Group criteria (Cheson 2003) and included:

Overall Response (OR): OR rate is defined as the sum of the number of patients with CR plus those with CRp divided by the total number of evaluable enrolled patients.

Complete Remission (CR): Attainment of an M1 bone marrow (&lt; 5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral blood counts (ANC ≥ 1000/μ L and platelet count  ≥  100,000/μ L).  Flow  cytometry  may  also  be  useful  to  distinguish  between  leukemia  and  a regenerating bone marrow. There is no requirement for bone marrow cellularity.

CR with Partial Recovery of Platelet Count (CRp): Attainment of an M1 bone marrow (&lt; 5% blasts) and no evidence of circulating blasts or extramedullary disease and with recovery of ANC ≥ 1000/μ L and platelet transfusion independence (defined as: no platelet transfusions x 1 week).

Complete Remission with Incomplete Blood Count Recovery (CRi): Attainment of an M1 bone marrow (&lt; 5% blasts) and no evidence of circulating blasts or extramedullary disease and with ANC &lt; 1000/ μ L or platelet count &lt; 100,000/ μ L without platelet transfusion independence (defined as: no platelet transfusions x 1 week).

Partial Response (PR): M2 bone marrow (5% to 25% blasts) and at least a 50% decrease in bone marrow blast  percent  from  baseline.  Bone  marrow  must  have  adequate  cellularity  (eg,  ≥  10%,  if  a  biopsy  is performed) to determine response. PR status will not be included in calculation of response to the regimen. A repeat bone marrow aspiration within 14 days may be required to distinguish between a PR and increased blasts caused by bone marrow regeneration nd is left to the discretion of the investigator.

Treatment Failure (TF): In the Efficacy Phase, if after Cycle 1 (CPX-351) a subject has a hypoplastic bone marrow for ≥ 60 days and failure to recover a peripheral ANC &gt; 500/μ L and a non-transfusion dependent

<div style=\"page-break-after: always\"></div>

platelet count &gt; 20,000/ μ L not due to malignant infiltration or severe inf ection (defined as ≥ Grade 3), they will be considered a treatment failure and will go off protocol therapy.

The definition of treatment failure includes:

- a) An increase in the extent of bone marrow infiltration by leukemic cells (absolute increase of ≥ 20% blasts), OR
- b) Development of extramedullary disease, OR
- c) M2 marrow that does not qualify for PR status, OR
- d) An M1 marrow with circulating blasts, OR
- e) &gt; 25% blasts in the bone marrow after Cycle 1 of therapy.

Relapse: Morphologic  relapse  after  CR/CRp/CRi  is  defined  as  a  reappearance  of  leukemic  blasts  in  the peripheral blood or ≥ 5% blasts in the bone marrow not attributable to any other cause (eg, bone marrow regeneration after therapy). In the setting of recent treatment, if there are no circulating blasts and the bone marrow contains 5% to 20% blasts, a repeat bone marrow performed at least a week later is necessary to  distinguish  relapse  from  bone  marrow  regeneration.  Should  flow  cytometric  or  molecular  analyses suggest relapse (by the reappearance of a similar immunophenotype or mutation to the original leukemia) in the presence of &lt; 5% blasts, or ≥ 5% blasts in a regenerating marrow, a repeat bone marrow(s) performed at least a week later is necessary to confirm relapse by morphologic methods. In such instances the date of recurrence is defined as the first date that more than 5% blasts were observed in the marrow. The reappearance or development of cytologically proven extramedullary disease also indicates relapse. Molecular  and/or  genetic  relapse  is  characterized  by  reappearance  of  a  cytogenetics  or  molecular abnormality.

## Bone Marrow Classification:

## M1 is &lt; 5% blasts M2 is 5 to 25% blasts M3 is &gt; 25% blasts

## Evaluability for Response

A subject was considered evaluable for response if:

2. The subject met the eligibility criteria for the Efficacy Phase;
3. The subject received at least 1 dose of CPX-351 at the RP2D; and
4. The subject was under follow-up for a sufficient period to evaluate the disease at the end of Cycle 1 or met the definition of Treatment Failure.

Patients  who  demonstrated  a  CR  or  CRp  were  considered  to  have  experienced  a  response.  All  other evaluable patients were considered non-responders. A subject who died as a result of toxicity during Cycle 1 after receiving all or part of protocol therapy were considered as non-responders.

## Secondary Efficacy Endpoint

The secondary efficacy endpoint was the proportion of patients with CR or CRp after CPX-351 (cycle 1).

## Sample size

Up to 50 evaluable patients (12 for the Dose-finding Phase, 38 for the Efficacy  Phase) were planned. Allowing for 10% of patients being inevaluable, enrollment of up to 56 patients was planned.

Study AAML1421 was designed to evaluate a minimum of 6 patients and a maximum of 12 potential patients in the Dose-finding Phase of the study. During the course of the study, the Dose-finding Phase only needed

<div style=\"page-break-after: always\"></div>

6 patients at Dose Level 1 and the RP2D was deemed to be 135 units/m 2 /dose on Days 1, 3, 5. There was no need to further expand this portion of the study and the final 6 patients were not accrued.

In the Efficacy Phase of the study, a total of 38 evaluable patients were required. All 6 patients entering the Dose-finding Phase of the study met the criteria to be considered evaluable for response in the Efficacy Phase and were therefore included in the efficacy analysis. The study organizers and the COG statistician considered the Dose-finding Phase of the study to be complete. Similarly, the Efficacy Phase evaluation was also considered complete, with a total of 38 evaluable patients (6 patients form the Dose-finding Phase plus 32 additional patients from the Efficacy Phase). As a consequence, the final 6 patients were not accrued because they were not necessary for the evaluation of efficacy.

## Randomisation and Blinding (masking)

This was an open-label, single-arm study.

## Statistical methods

## Efficacy Phase

The Efficacy Phase is a single arm two-stage design. The following optimal Simon two-stage design was used to test the null hypothesis that the overall response rate is ≤ 40% versus the alternative hypothesis that the response rate is ≥ 60%.

|                                      | CumulativeNumber ofResponses   | Decision                                                                                                               |
|--------------------------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Stage 1: Enter 12 patients           | 5orfewer                       | Terminate the trial because the therapy is ineffective                                                                 |
| Stage 2: Enter 26 additionalpatients | 6-12 18orfewer 19-38           | Inconclusive result, continue trial (proceed to Stage 2) Conclude therapy is ineffective Conclude therapy is effective |

If the therapy is associated with a 40% response rate (CR+CRp) after up to 2 cycles of therapy, the therapy will be identified as effective with probability 0.10. If the therapy is associated with a 60% response rate, the therapy will be identified as effective with probability 0.80.

All efficacy endpoints will be presented at a 0.05 level of significant without multiplicity adjustment.

## Primary Efficacy Endpoint and Analysis

## Definition

The primary efficacy endpoint is the proportion of patients with CR or CRp after CPX-351 (cycle 1) followed by FLAG (cycle 2). The summary will be done by Dose-Finding Phase and Efficacy Phase.

## Primary Analysis

The proportion of patients with CR or CRp will be estimated using the Jung and Kim's method (Jung and Kim, 2004).

The 90% confidence intervals were calculated using the approach of Koyama and Chen (Koyama and Chen 2008).

<div style=\"page-break-after: always\"></div>

For example, if m = 2 and s = 20, then the p-value = 0.0607 and the 90% CI is (0.3923, 0, 6923). No sensitivity analyses or subgroup analyses were planned.

## Secondary Efficacy Endpoint

The proportion of patients with CR or CRp or CRi was estimated after 1 cycle of CPX-351 similar to the primary efficacy endpoint using Jung and Kim's method.

## Results

## Participant flow

The participant flow is presented in Figure 11 .

Figure 11. Disposition of patients, Safety population

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Recruitment

Between 26 April 2016 and June 2018, a total of 38 patients were randomized at 9 study centres in the USA.

## Conduct of the study

The original study protocol was issued on 02 March 2016. It was subsequently amended twice: Amendment 1 was finalized on 23 February 2017, and Amendment 2 was finalized on 22 February 2018 (Version 3).

## Protocol Amendment 1 (23 February 2017)

- a) Results of Study 301 in adults with de novo high risk AML / MDS were added to the background.
- b) The  Dose-finding  Phase  of  the  study  had  completed  as  of  12  December  2016,  and  results  were summarized and added, including:
- One DLT was experienced among the 6 patients who received 135 units/m 2  CPX-351 (and no pain related DLTs were observed).
- The RP2D was determined to be 135 units/m 2  CPX-351 and this dose was recommended for further study in the Efficacy Phase.
- Updated information in the background regarding early results from the cardiac biomarker data collected in the CPX-MA-1201 study, and added a justification to modify the serial time points collected for patients on AAML1421.
- Updated the time points for the blood samples to be drawn for the optional biomarker studies, including optional miRNA studies. (A justification for longer monitoring of miRNA was also added.)
- Added information regarding the optional PK that is included in the Efficacy Phase of the trial, including information about updated time points and the analysis of the PK samples to be drawn.
- Clarified diagnosis / disease status required for study eligibility and removed the exclusion of prior allergy to liposomal lipids.
- In eligibility criteria for the Efficacy Phase, clarified that patients must be in first marrow relapse and that donor lymphocyte infusion was considered a re-induction attempt.
- Updated schedule of required observations for the first cycle of treatment to clarify timing of CBC and  differential  with  platelets,  timing  for  ECHO  and  optional  biomarker  specimens  (including cardiotoxicity), and timing of the optional PK blood draws.
- Added guidance to have both ejection fraction and shortening fraction calculated from the ECHO, and added a timeline for submitting CDs with ECHOs exams.

## Protocol Amendment 2 (22 February 2018)

- Clarified that yearly echocardiograms should be repeated annually from the start of therapy.
- Clarified the time points for the echocardiograms and EKG.
- Updated criterion for removal from protocol therapy for the Efficacy phase from 50 to 60 days for hypoplastic marrow so that it matched the definition of Treatment Failure in Section 10.2.
- Updated the warning about concomitant use of cardiotoxic and hepatotoxic agents with CPX-351, and reformatted and updated toxicity table to match side effects outlined in the most current investigator brochure.

<div style=\"page-break-after: always\"></div>

- Added definition of treatment failure in the Efficacy Phase of the study.
- Clarified that specimens for cytogenetic analysis were required and must have been obtained prior to initiating therapy.
- The following information regarding PK was updated: blood samples during the Efficacy phase of the study and for ordering PK kits; the Jazz contact for PKs; the blood draw volume was updated to to 2 mL since the tubes provided in the kits were 2 mL; and shipping information for PK samples.
- Added a ± of 1 hour for the Day 5, hour 6 specimen time point.
- Clarified oversight for the biomarkers of cardiotoxicity and the miRNA studies.
- Clarified time points for echocardiograms and blood biomarkers.

## Baseline data

In the Safety Analysis Set (N = 38), the majority of patients were White (68.4%) and there were slightly more female (52.6%) than male (47.4%) patients ( Table 23 ). Patients had a mean (SD) age of 10.6 (6.42) years, ranging from 1 to 21 years, with most patients (44.7%) between the ages of 2 and 12 years.

Most  patients  enrolled  in  the  study  had  ECOG  performance  score  of  0  (78.9%),  and  CNS  status  of  1 (86.8%). At enrollment, patients had AML WHO Disease Classifications in a number of categories, but the the category 'AML, other or unclassifiable' included the highest proportion of patients (36.8%). Mean (SD) cumulative  prior  anthracycline  exposure  was  344.51  (96.461)  mg/m 2 ,  which  is  as  expected  given  the heavily pretreated relapsed AML population. Baseline bone marrow and hematology results were consistent with  what  would  be  expected  for  patients  with  AML.  Two  patients  (5.3%)  presented  with  non-CNS extramedullary disease ( Table 24 ).

Table 23. Demographics

|                                        | NumberofSubjects,n(%)   | NumberofSubjects,n(%)   | NumberofSubjects,n(%)   |
|----------------------------------------|-------------------------|-------------------------|-------------------------|
|                                        | DoseFindingPhase N=6    | Efficacy Phase N=32     | Total N=38              |
| Gender                                 |                         |                         |                         |
| Male                                   | 3 (50.0)                | 15 (46.9)               | 18 (47.4)               |
| Female                                 | 3 (50.0)                | 17 (53.1)               | 20 (52.6)               |
| Age (years)                            |                         |                         |                         |
| n                                      | 6                       | 32                      | 38                      |
| Mean (SD)                              | 13.8 (5.91)             | 10.0 (6.41)             | 10.6 (6.42)             |
| Median                                 | 14.5                    | 10.5                    | 11.0                    |
| Min, Max                               | 7,21                    | 1,21                    | 1, 21                   |
| AgeGroup(year's)                       |                         |                         |                         |
| ≥1to<2                                 | 0                       | 3 (9.4)                 | 3 (7.9)                 |
| ≥2 to<12                               | 3 (50.0)                | 14 (43.8)               | 17 (44.7)               |
| ≥ 12 to < 18                           | 0                       | 10 (31.3)               | 10 (26.3)               |
| ≥ 18 to ≤ 21                           | 3 (50.0)                | 5 (15.6)                | 8 (21.1)                |
| Race                                   |                         |                         |                         |
| Asian                                  | 0                       | 2 (6.3)                 | 2 (5.3)                 |
| Black/AfricanAmerican                  | 2 (33.3)                | 2 (6.3)                 | 4 (10.5)                |
| NativeHawaiian or OtherPacificIslander | 0                       | 1 (3.1)                 | 1 (2.6)                 |
| White                                  | 4 (66.7)                | 22 (68.8)               | 26 (68.4)               |
| Other                                  | 0                       | 1 (3.1)                 | 1 (2.6)                 |
| Unknown                                | 0                       | 4 (12.5)                | 4 (10.5)                |
| Ethnicity                              |                         |                         |                         |
| Hispanic or Latino                     | 1 (16.7)                | 6 (18.8)                | 7 (18.4)                |
| Not Hispanic or Latino                 | 5 (83.3)                | 24 (75.0)               | 29 (76.3)               |
| Unknown                                | 0                       | 2 (6.3)                 | 2 (5.3)                 |

Abbreviations:Max=maximum;Min=minimum.

Note:Percentages arebased on N.

<div style=\"page-break-after: always\"></div>

Table 24. Baseline Disease Characteristics

|                                                                                | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|--------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                                                | Dose Finding Phase N=6      | Efficacy Phase N=32         | Total N=38                  |
| Weight (kg)a                                                                   |                             |                             |                             |
| n                                                                              | 6                           | 32                          | 38                          |
| Mean (SD)                                                                      | 62.17 (43.195)              | 47.63 (36.884)              | 49.93 (37.694)              |
| Median                                                                         | 53.30                       | 33.25                       | 41.85                       |
| Min, Max                                                                       | 23.6, 145.3                 | 9.4, 169.0                  | 9.4, 169.0                  |
| BSA (m²)a                                                                      |                             |                             |                             |
| n                                                                              | 6                           | 32                          | 38                          |
| Mean (SD)                                                                      | 1.602 (0.648)               | 1.234 (0.574)               | 1.292 (0.592)               |
| Median                                                                         | 1.525                       | 1.125                       | 1.150                       |
| Min, Max                                                                       | 0.90, 2.75                  | 0.45, 2.23                  | 0.45, 2.75                  |
| ECOG Performance Status                                                        |                             |                             |                             |
| 0                                                                              | 3 (50.0)                    | 27 (84.4)                   | 30 (78.9)                   |
| 1                                                                              | 3 (50.0)                    | 4 (12.5)                    | 7 (18.4)                    |
| 2                                                                              | 0                           | 1 (3.1)                     | 1 (2.6)                     |
| CNS Status                                                                     |                             |                             |                             |
| 1                                                                              | 4 (66.7)                    | 29 (90.6)                   | 33 (86.8)                   |
| 2a                                                                             | 1 (16.7)                    | 1 (3.1)                     | 2 (5.3)                     |
| 2b                                                                             | 1 (16.7)                    | 2 (6.3)                     | 3 (7.9)                     |
| Radiographic Evidence of Intracranial Mass Consistent with CNS Myeloid Sarcoma |                             |                             |                             |
| Yes                                                                            | 0                           | 0                           | 0                           |
| No                                                                             | 2 (33.3)                    | 8 (25.0)                    | 10 (26.3)                   |
| Not evaluated                                                                  | 4 (66.7)                    | 24 (75.0)                   | 28 (73.7)                   |
| AML WHO Disease Classification                                                 |                             |                             |                             |
| AML with t(8;21) (q22;q22); RUNX1- RUNX1T1                                     | 1 (16.7)                    | 4 (12.5)                    | 5 (13.2)                    |
| AML with inv(16) (p13.1q22) or t(16;16) (p13.1;q22); CBFB-MYH11                | 0                           | 1 (3.1)                     | 1 (2.6)                     |
| AML with t(9;11) (p22;q23); MLLT3-MLL                                          | 0                           | 1 (3.1)                     | 1 (2.6)                     |
| Provisional entity: AML with mutated NPM1                                      | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Provisional entity: AML with mutated CEBPA                                     | 2 (33.3)                    | 0                           | 2 (5.3)                     |
| AML with myelodysplasia-related changes                                        | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| AML with maturation                                                            | 0                           | 1 (3.1)                     | 1 (2.6)                     |

<div style=\"page-break-after: always\"></div>

|                                              | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|----------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                              | DoseFindingPhase N=6        | Efficacy Phase N=32         | Total N=38                  |
| Acutemyelomonocyticleukemia                  | 0                           | 4 (12.5)                    | 4 (10.5)                    |
| Acutemonoblastic/monocyticleukemia           | 1 (16.7)                    | 4 (12.5)                    | 5 (13.2)                    |
| Erythroleukemia,erythroid/myeloid            | 0                           | 1 (3.1)                     | 1 (2.6)                     |
| AML,other orunclassifiable                   | 2 (33.3)                    | 12 (37.5)                   | 14 (36.8)                   |
| PrimaryMorphologyoftheSubject'sAML           |                             |                             |                             |
| FAB MO                                       | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| FAB M1                                       | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| FAB M2                                       | 0                           | 5 (15.6)                    | 5 (13.2)                    |
| FAB M3                                       | 0                           | 0                           | 0                           |
| FAB M4                                       | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| FAB M5                                       | 0                           | 6 (18.8)                    | 6 (15.8)                    |
| FAB M6                                       | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| FAB M7                                       | 0                           | 1 (3.1)                     | 1 (2.6)                     |
| AMLnotfurthersubclassified                   | 4 (66.7)                    | 16 (50.0)                   | 20 (52.6)                   |
| CumulativePriorAnthracyclineExposure (mg/m²) |                             |                             |                             |
| n                                            | 6                           | 32                          | 38                          |
| Mean (SD)                                    | 345.00 (120.524)            | 344.42 (93.610)             | 344.51 (96.461)             |
| Median                                       | 369.00                      | 325.75                      | 325.75                      |
| Min, Max                                     | 150.0, 444.0                | 105.0, 444.0                | 105.0, 444.0                |
| Bone MarrowBlastPercentage (%)               |                             |                             |                             |
| n                                            | 6                           | 32                          | 38                          |
| Mean (SD)                                    | 57.253 (28.176)             | 55.119 (27.198)             | 55.456 (26.976)             |
| Median                                       | 58.760                      | 60.500                      | 60.500                      |
| Min, Max                                     | 19.00, 91.00                | 5.00,98.00                  | 5.00, 98.00                 |
| Peripheral WBC (10*/L)                       |                             |                             |                             |
| n                                            | 6                           | 32                          | 38                          |
| Mean (SD)                                    | 4.17 (1.300)                | 33.98 (131.351)             | 29.27 (120.735)             |
| Median                                       | 3.75                        | 4.05                        | 4.00                        |
| Min, Max                                     | 2.6, 6.2                    | 1.0, 750.0                  | 1.0, 750.0                  |
| Peripheral Blasts (%)                        |                             |                             |                             |
| n                                            | 6                           | 31                          | 37                          |
| Mean (SD)                                    | 42.97 (32.754)              | 22.43 (29.406)              | 25.76 (30.471)              |
| Median                                       | 52.50                       | 7.00                        | 7.00                        |
| Min, Max                                     | 2.8, 88.0                   | 0.0, 89.5                   | 0.0, 89.5                   |

|                                            | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|--------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                            | DoseFindingPhase N=6        | Efficacy Phase N=32         | Total N=38                  |
| PeripheralPlateletCount (10°/L)            |                             |                             |                             |
| n                                          | 6                           | 32                          | 38                          |
| Mean (SD)                                  | 48.0 (35.77)                | 89.1 (47.73)                | 82.6 (48.09)                |
| Median                                     | 39.0                        | 75.5                        | 71.5                        |
| Min, Max                                   | 16,117                      | 39,295                      | 16,295                      |
| Non-CNSExtramedullaryDisease at Enrollment |                             |                             |                             |
| Yes                                        | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| No                                         | 6 (100)                     | 30 (93.8)                   | 36 (94.7)                   |

a During development of the CSR, it was noted that 1 subject in the Efficacy Phase had 2 records included in the database for weight, height and BSA.

Abbreviations: AML = acute myeloid leukemia; BSA = body surface area; CNS = central nervous system; ECOG = Eastern Cooperative Oncology Group; Max = maximum; Min = minimum; WBC = white blood cells; WHO = World Health Organization.

Note: Percentages are based on N.

Note: Weight, height and BSA measurements were taken at the beginning of Cycle 1.

<div style=\"page-break-after: always\"></div>

The MAH states that 'Data on prior and concomitant medications were noted in the subject records but were not collected on the CRF. Therefore, for the purposes of this CSR, no data on prior and concomitant medications are available in the datasets'.

## Numbers analysed

A total of 38 patients provided informed consent and were enrolled in this study. All patients received CPX351 and were included in the Safety Analysis Set.

The Efficacy Evaluable Analysis Set included all patients who 1) met the eligibility criteria for the Efficacy Phase;2) received at least 1 dose of CPX-351 at the RP2D; and 3) were under follow-up for a sufficient period to evaluate the disease at the end of Cycle 1 or met the definition of treatment failure (TF).

A total of 37 patients were included in the Efficacy Evaluable Analysis Set.

## Outcomes and estimation

Primary efficacy endpoint: Overall Response Rate (ORR) After CPX-351 (Cycle 1) followed by FLAG (Cycle 2).

The ORR (CR + CRp) after CPX-351 (Cycle 1) followed by FLAG (Cycle 2) was 68% using Jung and Kim's method (90% CI: 53% to 78%; p-value: &lt; 0.001, using the approach of Koyama and Chen; Table 25 ).

When examining best response (defined as CR or CRp or CRi) after CPX-351 (Cycle 1) followed by FLAG (Cycle 2), the best response rate was 81% using Jung and Kim's method (90% CI: 67% to 89%; p-value: &lt; 0.001, using the approach of Koyama and Chen). Best response was achieved by 21/37 patients (56.8%) after Cycle 1 and by 9/37 patients (24.3%) after Cycle 2.

Table 25. Summary of Best Response for Patients with CR, CRp or CRi over 2 Cycles

|                                | Overall N=37 (%) uI   | p^ (90%CI)'       | p-value'   | p^ (80%CI)        |
|--------------------------------|-----------------------|-------------------|------------|-------------------|
| Best Response Rate (CR)        | 20 (54.1)             | 0.59 (0.40,0.70)  | 0.047      | 0.59 (0.43, 0.66) |
| Best Response Rate (CRp)       | 5 (13.5)              |                   |            |                   |
| Best Response Rate (CRi)       | 5 (13.5)              |                   |            |                   |
| OverallResponseRate (CR + CRp) | 25 (67.6)             | 0.68 (0.53, 0.78) | <0.001     | 0.68 (0.56, 0.76) |
| Stage 1                        | 10 (27.0)             |                   |            |                   |
| Stage 2                        | 15 (40.5)             |                   |            |                   |

<div style=\"page-break-after: always\"></div>

| SubjectswithBestResponseof CR or CRp or CRi   | 30 (81.1)   | 0.81 (0.67, 0.89)   | <0.001   | 0.81 (0.70, 0.87)   |
|-----------------------------------------------|-------------|---------------------|----------|---------------------|
| Tiningof Best Response (CR, CRp, CRi)         |             |                     |          |                     |
| Cycle 1                                       | 21 (56.8)   |                     |          |                     |
| Cycle 2                                       | 9 (24.3)    |                     |          |                     |

Abbreviations: CI = confidence interval; CR = complete remission; CRi = complete remission with incomplete PR = partial response; TF = treatment failure.

Estimated using the method of Jung and Kim.

Calculated using the approach of Koyama and Chen.

Percentages are based on N.

Note: Subject's best response over 2 cycles during reporting period was determined by the following order of responses (CR &gt; CRp &gt; CRi &gt; PR &gt; TF).

## Secondary efficacy endpoint: Response Rate After CPX-351 (Cycle 1)

As a secondary objective of Study AAML1421, the response rate (CR + CRp + CRi) after 1 cycle of CPX351 was 76% using Jung and Kim's method (90% CI: 61% to 85%; p-value: &lt; 0.001, using the approach of Koyama and Chen) (5.4.2.3). A total of 7/37 patients (18.9%) had a partial response (PR) and 2/37 patients (5.4%) were diagnosed with treatment failure (TF).

During  Cycle  2,  13/27  patients  (48.1%)  achieved  CR,  7/27  patients  (25.9%)  achieved  CRp,  and  2/27 patients (7.4%) achieved CRi. No patients had a PR and 5/27 patients (18.5%) were diagnosed with TF ( Table 26 ).

Table 26. Summary of Best Response

| Response                                                                   | Cycle 1 N=37   | Cycle 2 N=27   |
|----------------------------------------------------------------------------|----------------|----------------|
| CR, n (%)                                                                  | 14 (37.8)      | 13 (48.1)      |
| CRp, n (%)                                                                 | 2 (5.4)        | (25.9)         |
| CRi, n (%)                                                                 | 12 (32.4)      | 2 (7.4)        |
| PR, n (%)                                                                  | 7 (18.9)       | 0              |
| TF, n (%)                                                                  | 2 (5.4)        | 5 (18.5)       |
| Relapse, n (%)                                                             | 0              | 0              |
| Unevaluable, n (%)                                                         | 0              | 0              |
| Subjects with CR or CRp or CRi, n (%)                                      | 28 (75.7)      | NC             |
| Proportion of Subjects with CR or CRp or CRi After 1 Cycle of CPX-351, p b | 0.76           | NC             |
| JID %06                                                                    | 0.61, 0.85     | NC             |
| p-valuec                                                                   | <0.001         | NC             |

Abbreviations:CI=confidence interval;CR=complete remission;CRi=complete remission with incomplete blood count recovery; CRp = complete remission with partial recovery of platelet count; NC = not calculated; PR = partial response; TF = treatment failure.

b Estimated using the method of Jung and Kim.

a This includes all responses.

Calculated using the approach of Koyama and Chen.

Note:Cycle 1 treatment was135unit/m'CPX-351 andCycle 2treatment wasFLAG. Percentages are based on N.

Of the patients classified as responders (i.e., those whose best response over 2 cycles was CR or CRp or CRi), 10/30 patients (33.3%) had cytogenetics classified as other, 6/30 patients (20.0%) had inv(16); t(8;21), and 6/30 patients (20.0%) had unknown cytogenetics.

## Exploratory Analysis: Overall Survival

<div style=\"page-break-after: always\"></div>

The median OS was estimated as 32.5 months for all 37 efficacy evaluable patients using the Kaplan-Meier method  (26/37  patients  [70.3%]  survived  at  the  time  of  analysis; Figure  12 ).  The  median  OS  was estimated as 32.5 months for the 30 responders (ie, patients with best response of CR or CRp or CRi over 2 cycles; 23/37 patients [62.2%] survived at the time of analysis). The median OS was estimated as 10.1 months for the 7 non-responders (i.e., patients who had a PR or were diagnosed with TF; 3/37 [8.1%] survived at the time of analysis).

Figure   12. Summary of Overall Survival (Efficacy Evaluable Analysis Set)

<!-- image -->

Abbreviations: CR = complete remission; CRi = complete remission with incomplete blood count recovery; CRp = complete remission with partial recovery of platelet count.

Note: Responders are defined as patients whose best response was CR or CRp or CRi and non-responders if otherwise.

## Ancillary analyses

No formal subgroup analyses were planned or conducted.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 27. Summary of Efficacy for AAML1421

Title: A Phase 1/2 Study of CPX-351 (NSC# 775341 ) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)ag

<div style=\"page-break-after: always\"></div>

| Study identifier                                | AAML1421 (NCT02642965)                                                                                                                                                           | AAML1421 (NCT02642965)                                                                                                                                                           | AAML1421 (NCT02642965)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | AAML1421 (NCT02642965)                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                                          | Single-arm, open-label, multi-institutional                                                                                                                                      | Single-arm, open-label, multi-institutional                                                                                                                                      | Single-arm, open-label, multi-institutional                                                                                                                                                                                                                                                                                                                                                                                                                               | Single-arm, open-label, multi-institutional                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                          | Duration of main phase:                                                                                                                                                          | Duration of main phase:                                                                                                                                                          | 29 April 2016 (first subject screened) 30 June 2019 (primary database cut-off)                                                                                                                                                                                                                                                                                                                                                                                            | 29 April 2016 (first subject screened) 30 June 2019 (primary database cut-off)                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                          | Duration of Run-in phase:                                                                                                                                                        | Duration of Run-in phase:                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                          | Duration of Extension phase                                                                                                                                                      | Duration of Extension phase                                                                                                                                                      | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hypothesis                                      | The null hypothesis that the overall response rate with the study treatment is ≤ 40% versus the alternative hypothesis that the response rate with the study treatment is ≥ 60%. | The null hypothesis that the overall response rate with the study treatment is ≤ 40% versus the alternative hypothesis that the response rate with the study treatment is ≥ 60%. | The null hypothesis that the overall response rate with the study treatment is ≤ 40% versus the alternative hypothesis that the response rate with the study treatment is ≥ 60%.                                                                                                                                                                                                                                                                                          | The null hypothesis that the overall response rate with the study treatment is ≤ 40% versus the alternative hypothesis that the response rate with the study treatment is ≥ 60%.                                                                                                                                                                                                                                                                                          |
| Treatments groups                               | Single arm                                                                                                                                                                       | Single arm                                                                                                                                                                       | Cycle 1: CPX-351 was administered at a dose of 135 units/m 2* by central venous catheter over 90 minutes on Days 1, 3, and 5. *1 unit of Vyxeos contains 0.44 mg daunorubicin and 1 mg cytarabine. Cycle 2: Subjects received 5 µg/kg Filgrastim (G-CSF) administered IV or subcutaneously on Days 1-5 one hour prior to each dose of fludarabine. Dosing was restarted on Day 15 and continued until the post- nadir ANC ≥ 500/μL. Fludarabine was given at a dose of 30 | Cycle 1: CPX-351 was administered at a dose of 135 units/m 2* by central venous catheter over 90 minutes on Days 1, 3, and 5. *1 unit of Vyxeos contains 0.44 mg daunorubicin and 1 mg cytarabine. Cycle 2: Subjects received 5 µg/kg Filgrastim (G-CSF) administered IV or subcutaneously on Days 1-5 one hour prior to each dose of fludarabine. Dosing was restarted on Day 15 and continued until the post- nadir ANC ≥ 500/μL. Fludarabine was given at a dose of 30 |
| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                 | Safety                                                                                                                                                                           | The recommended phase 2 dose (RP2D) determined by toxicities associated with CPX- 351 in pediatric and young adult participants with relapsed / refractory AML.                                                                                                                                                                                                                                                                                                           | The recommended phase 2 dose (RP2D) determined by toxicities associated with CPX- 351 in pediatric and young adult participants with relapsed / refractory AML.                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                 | Efficacy                                                                                                                                                                         | The response rate (CR + complete remission with partial platelet recovery [CRp]) after CPX- 351 (Cycle 1) followed by FLAG (Cycle 2) in children with AML in first relapse.                                                                                                                                                                                                                                                                                               | The response rate (CR + complete remission with partial platelet recovery [CRp]) after CPX- 351 (Cycle 1) followed by FLAG (Cycle 2) in children with AML in first relapse.                                                                                                                                                                                                                                                                                               |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                               | Pharmacokine tics (PK)                                                                                                                                                           | The PK of plasma cytarabine and daunorubicin after CPX-351 administration to pediatric and young adult participants with relapsed / refractory AML.                                                                                                                                                                                                                                                                                                                       | The PK of plasma cytarabine and daunorubicin after CPX-351 administration to pediatric and young adult participants with relapsed / refractory AML.                                                                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                               | Efficacy                                                                                                                                                                         | The response rate (CR + CRp + complete remission with incomplete blood count recovery [CRi]) after 1 cycle of CPX-351.                                                                                                                                                                                                                                                                                                                                                    | The response rate (CR + CRp + complete remission with incomplete blood count recovery [CRi]) after 1 cycle of CPX-351.                                                                                                                                                                                                                                                                                                                                                    |
| Database lock                                   | 30 June 2019                                                                                                                                                                     | 30 June 2019                                                                                                                                                                     | 30 June 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30 June 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Results and Analysis                            | Results and Analysis                                                                                                                                                             | Results and Analysis                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description                            | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis population and time point description  | Safety Analysis Set (N=38) for the RP2D and Efficacy Evaluable Set (N=37) for all efficacy endpoints.                                                                            | Safety Analysis Set (N=38) for the RP2D and Efficacy Evaluable Set (N=37) for all efficacy endpoints.                                                                            | Safety Analysis Set (N=38) for the RP2D and Efficacy Evaluable Set (N=37) for all efficacy endpoints.                                                                                                                                                                                                                                                                                                                                                                     | Safety Analysis Set (N=38) for the RP2D and Efficacy Evaluable Set (N=37) for all efficacy endpoints.                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                  | Treatment group                                                                                                                                                                  | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                           | CPX-351                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Number of participants                                                                                                                                                           | Number of participants                                                                                                                                                           | Number of participants                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 37                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Efficacy                                               | CR + CRp (overall response rate) after up to 2 cycles (%)                                                              | 68                                                                           |
|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Efficacy                                               | CR or CRp or CRi (best response rate) after up to 2 cycles (%)                                                         | 81                                                                           |
| Efficacy                                               | CR + CRp + CRi after cycle 1 (CPX-351) (%)                                                                             | 76                                                                           |
| Efficacy                                               | CR or CR or CRi (best response) after receiving Cycle 1 (CPX-351) (%)                                                  | 56.8                                                                         |
| Efficacy                                               | CR or CR or CRi (best response) after receiving Cycle 2 (FLAG) (%)                                                     | 24.3                                                                         |
| Efficacy                                               | Median OS estimate (months)                                                                                            | 32.5                                                                         |
| Descriptive statistics and estimate variability Safety | Treatment-related deaths during the study                                                                              | None                                                                         |
| Descriptive statistics and estimate variability Safety | Dose limiting toxicity (DLT) (n/N)                                                                                     | 1/6                                                                          |
| Descriptive statistics and estimate variability Safety | Serious TEAE (%)                                                                                                       | 55.3                                                                         |
| Descriptive statistics and estimate variability Safety | Most commonly reported serious TEAE (%)                                                                                | Febrile neutropenia (28.9)                                                   |
| Descriptive statistics and estimate variability Safety | TEAE any grade (%)                                                                                                     | 89.5                                                                         |
| Descriptive statistics and estimate variability Safety | Most commonly reported TEAE any grade (%)                                                                              | Febrile neutropenia (47.4) Rash maculo-papular (47.4) QT prolongation (28.9) |
| Descriptive statistics and estimate variability Safety | Mean and median left ventricular shortening fraction (LVSF) and left ventricular ejection fraction (LVEF)LVSF and LVEF | Remained near or within normal limits                                        |
| Notes                                                  |                                                                                                                        |                                                                              |

## Supportive study

The details of this study have been presented previously both in the PK section and Dose response studies section in this report.

## Study Design

Study CPX-MA-1201 was a phase 1, single-center pilot study to assess the PK, toxicity and tolerability of CPX-351 in pediatric and young adult patients with relapsed / refractory hematologic malignancies.

The secondary efficacy objective of this study was to estimate the overall response rate (ORR) to a single course of CPX-351 to young patients with recurrent or refractory hematologic malignancies.

## Study population

A total of 27 patients were enrolled in the study, received at least 1 dose of study drug, and comprised the safety population. A total of 9 patients were included in the Dose Exploration Phase. Of these, 5 patients received a dose of 134 units/m2 CPX-351 and 4 patients received a dose of 100 units/m 2  CPX-351. All 9 patients (100.0%) completed course 1 of therapy and entered the follow-up period.

<div style=\"page-break-after: always\"></div>

Among patients who received 134 units/m 2  CPX-351, 4/5 (80.0%) patients completed the 6-month followup period, and 1/5 (20.0%) subject died during follow-up. Among patients who received 100 units/m 2  CPX351, 2/4 (50.0%) patients completed the 6-month follow-up period, and 2/4 (50.0%) patients died during follow-up.

A total of 18 patients were included in the Expanded Phase, and all received a dose of 100 units/m 2  CPX351. A total of 17/18 patients (94.4%) completed course 1 therapy and entered the follow-up period. One subject went off protocol therapy because of disease progression and pursuit of other therapy. A total of 11/18 (61.1%) patients completed the 6-month follow-up period, and 7/18 (38.9%) patients died during follow-up.

The majority of patients were white (77.8%) and there were slightly more female (51.9%) than male (48.1%) patients. Patients had a mean (SD) age of 6.7 (5.90) years, ranging from 1 to 19 years, with most patients (59.3%) in the age group 2 to &lt; 12 years. No patients aged &lt; 1 year were enrolled. The majority of patients enrolled had AML (23/27 patients, 85.2%) and 4/27 patients (14.8%) had ALL.

## Efficacy

A secondary objective of Study CPX-MA-1201 was to estimate the ORR to a single course of CPX-351.

Among patients with AML who received 100 units/m 2  CPX-351, 3/18 patients (16.7%) achieved CR and 3/18 patients (16.7%) achieved CRi for an ORR of 33.3% (6/18 patients; table 5.4.2.6).

Among patients with AML who received 134 units/m 2  CPX-351, 2/5 patients (40.0%) achieved CR and no patients achieved CRi for an ORR of 40.0% (2/5 patients; Table 5.4.2.6).

No patients with ALL responded to treatment ( Table 28 ).

Table 28. Summary of Response for Patients with AML (Safety Analysis Set)

|                                        | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                        | DoseExplorationPhase        | DoseExplorationPhase        | Expanded Phase              | Overall                     |
|                                        | 100 units/m² N=1            | 134 units/m² N=5            | 100 units/m² N=17           | 100 units/m² N=18           |
| AML (N = 23)                           |                             |                             |                             |                             |
| CR                                     | 0                           | 2 (40.0)                    | 3 (17.6)                    | 3 (16.7)                    |
| CRp                                    | 0                           | 0                           | 0                           | 0                           |
| CRi                                    | 0                           | 0                           | 3 (17.6)                    | 3 (16.7)                    |
| Overall Response Rate (CR + CRp + CRi) | 0                           | 2 (40.0)                    | 6 (35.3)                    | 6 (33.3)                    |
| PR                                     | 0                           | 0                           | 0                           | 0                           |
| TF                                     | 0                           | 3 (60.0)                    | 10 (58.8)                   | 10 (55.6)                   |
| Unevaluable                            | 1 (100)                     | 0                           | 1 (5.9)                     | 2 (11.1)                    |

Abbreviations: AML = acute myeloid leukemia; CR = complete remission; CRi = complete remission with incomplete blood count recovery; CRp = complete remission with partial recovery of platelet count; PR = partial response; TF = treatment failure.

a The overall response rate shown includes the 2 subjects who were unevaluable. Note: Percentages arebased on N.

## 1.6.3. Discussion on clinical efficacy

With  this  application,  the  MAH  was  initially  seeking  approval  for  the  following  indication  for  Vyxeos

<div style=\"page-break-after: always\"></div>

liposomal: ' Vyxeos liposomal is indicated for the treatment of relapsed or refractory AML in paediatric and young adult patients aged 1 to 21 years old. '.  After  receiving the  questions from the CHMP, the MAH decided to not pursue the request for the paediatric indication in Relapse or Refractory Acute Myeloid Leukaemia (R/R AML). Therefore, the MAH is only proposing updated text within Sections 4.4, 4.8, 5.1 and 5.2 of the SmPC. Consequently, the MAH provided responses only to questions related to data proposed to be included in the SmPC.

Clarifications in relation to proposed indication were considered necessary. The data provided could be possibly acceptable for the relapsed, paediatric population. However, there are data currently from only 8 relapsed, young adults. The proposed upper age limit of 21 years was not clinically justified, but rather driven  by  age  range  of  the  available  data.  In  addition  to  that,  no  specific  efficacy  and  safety  results according to different age groups were provided and suitability of the proposed dosing for young adults was questioned. Therefore, the proposed indication (including also young adult relapsed patients) was to be further justified or the wording of the indication to be modified accordingly.

Moreover, the MAH was asked to justify the inclusion of refractory patients into proposed indication because the information with regard to exact number of patients with either relapsed AML or with refractory AML was missing. Specifically, as cytarabine and anthracycline combination therapies are already standard part of  first  line  therapy,  the  MAH  was  asked  to  discuss  whether  patients,  who  were  refractory  to  first  line therapy, may still respond to second line cytarabine-daunorubicine therapy. In its response, the MAH has clarified that all patients were with relapsed AML.  However, the MAH has not provided requested efficacy and  safety  data  per  age  cohort  nor  provided  justification  regarding  the  acceptability  of  the  proposed posology for young adults or refractory paediatric patients. Since the MAH no longer pursuing the indication for paediatric patients with R/R AML these issues are not pursued further.

Acute myeloid leukaemia (AML) is a biologically heterogeneous disease that can be classified into 3 distinct categories based on clinical ontogeny: de novoAML which arises in the absence of an identified exposure or prodromal  stem  cell  disorder  (like  in  MDS).  Secondary  AML  (s-AML)  represents  transformation  of  an antecedent  diagnosis  of  myelodysplastic  syndrome  (AML-MRC)  or  myeloproliferative  neoplasm  (MPN), therapy-related  AML  (tAML)  develops  as  a  late  complication  in  patients  with  prior  exposure  to leukaemogenic therapies.

Long-term survival rates of paediatric AML patients are currently 70% or even higher. Compared to adults, children with AML have superior outcomes due to fewer adverse genetic mutations and the ability to tolerate the  high-intensity  chemotherapy  currently  necessary  for  cure.  Regarding  novel  agents  and  treatment modalities, drugs such as venetoclax, monoclonal antibodies, and cellular therapies are investigated also in paediatric AML.

Relapse after initial AML therapy is associated with poor prognosis and the only consistently curative therapy for relapsed AML is a HSCT.

The MAH has provided data from pivotal phase II study (AAML1421) and supportive phase I study (CPXMA-1201). The dose of CPX-351 used in study AAML1421 was 135 units/m 2  versus 100 unit/m 2  in study CPX-MA-1201, respectively. Due to that, direct comparison of efficacy results (after 1 cycle of CPX-351) between these two studies is not possible.

Study AAML1421 (phase II) enrolled patients paediatric and young adult patients with relapsed AML. Study CPX-MA-1201 (phase I) on the other hand enrolled paediatric and young adult patients with relapsed / refractory hematologic malignancies (AML and ALL).

## Design and conduct of clinical studies

## Study AAML1421

<div style=\"page-break-after: always\"></div>

The efficacy of CPX-351 in paediatric and young adult patients with relapsed AML (up to 21 years old) is based mainly on one, open-label, single-arm study AAML1421. It was conducted and sponsored by the Children's Oncology Group (COG) and the MAH was not involved in the study conduct but received the data from the Sponsors and summarized the results of the study for the purposes of regulatory submission. The study  is  considered  of  adequate  design  with  appropriate  clinical  endpoints  for  the  target  indication  of relapsed, paediatric AML [(with the primary efficacy endpoint of the proportion of patients with CR or CRp after CPX-351 (cycle 1) followed by FLAG (cycle 2)].

This study comprised 2 phases: a dose-finding phase and an efficacy phase. During the dose-finding phase, a  modified  rolling  6  design  was  employed.  Subjects  were  assigned  a  dose  of  CPX-351  at  the  time  of enrollment.  The  starting  dose  was  135  units/m 2 /dose  (i.e.  59  mg/m 2   daunorubicin  and  135  mg/m 2 cytarabine) on Days 1, 3 and 5. If the starting dose was not tolerated, a single dose de-escalation to 100 units/m 2 /dose was allowed.

Targeting HSCT should have been given considerably more value. The only long-term curative treatment option in relapsed AML patients is HSCT (HSCT is recommended as post-remission (CR2) management in all suitable relapsed AML patients). Due to that, all possible patients eligible for this procedure should be offered and targeted to proceed to this treatment.  The MAH has clarified that  prior HSCT was recorded in 10 out of 38 patients (26.3%).

The MAH has used a method from Jung and Kim to calculate the number of responders (both with regard to primary and secondary efficacy endpoints).  However, the response rate has now been presented as a simple proportion of responders and the corresponding Clopper-Pearson confidence interval in the SmPC as requested.

The study inclusion/exclusion criteria reflect the target population of relapsed AML patients. 10 out 38 patients did not complete the study because the physician determined it was in the subject's best interest not to continue in the study. The MAH has clarified that seven patients with CR, CRi, or CRp after cycle 1 had HCT after discontinuing study treatment. One patient had treatment failure and for the remaining two patients there is no further information. The MAH`s response is considered adequate. The MAH`s reasoning that the treatment approach to relapsed/ refractory pediatric AML between US and European investigators is essentially the same, is also acceptable.

Additional data from one phase 1 study has been presented to further support the efficacy of CPX-351: Study CPX-MA-1201. In this phase I (PK, MTD) single arm study, a total of 23 relapsed, pediatric AML patients were treated with single course of CPX-351.

## Efficacy data and additional analyses

A total of 38 subjects were enrolled in this study:

- Six subjects were included in the dose-finding phase, all of whom received a CPX-351 dose of 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine (i.e. 135 units/m 2 /dose). Of the 6 subjects in the dose-finding  phase,  1  subject  experienced  a  DLT  (a  serious  adverse  event  of  Ejection  fraction decreased) at the dose level of 135 units/m 2 /dose. The remaining subjects did not experience DLTs, and 135 units/m 2 /dose (i.e. 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine) was the RP2D.
- Thirty-two subjects were  included  in the Efficacy  Phase,  and  all  received  CPX-351  135 units/m 2 /dose.

In the pivotal study AAML1421, the primary efficacy endpoint (after CPX-351 (Cycle 1) followed by FLAG (Cycle 2)) displayed an ORR (CR + CRp) of 68% and the best response rate (CR + CRp + CRi) of 81%. However, the MAH has used an unconventional method to calculate the number of responders and should

<div style=\"page-break-after: always\"></div>

provide the response rate as a simple proportion of responders and the corresponding Clopper-Pearson confidence interval.

In addition, to justify the potential benefit of the treatment, the MAH was asked to provide data with regard to the use of HSCT as consolidation in patients achieving response. The MAH has not provided the requested data. However, since the MAH no longer pursuing the indication for pediatric patients with R/R AML, this issue is not actual any more.

The secondary efficacy endpoint (after 1 cycle of CPX-351) displayed a response rate (CR + CRp) of 43.2 % and the best response rate (CR + CRp + CRi) of 76%. The same concern applies also here with regard to actual response rates: the MAH was requested to provide the response rate as a simple proportion of responders and the corresponding Clopper-Pearson confidence interval. Thus, while treatment with CPX351 seem to achieve substantial results on its own, the second treatment course with FLAG increases the efficacy  even  further.  However,  there  are  similar  concerns  with  regard  to  missing  information  and contextualisation  of  the  results  as  mentioned  with  the  interpretation  of  results  of  the  primary  efficacy endpoint.

The median OS was estimated as 32.5 months for all 37 efficacy evaluable subjects. The result of this posthoc  exploratory  analysis  should  be  further  contextualised  by  the  MAH.  Updated  follow-up  data  and especially outcome data of patients treated with allo-HSCT as consolidation to establish the clinical benefit of  the  proposed  treatment  with  Vyxeos  liposomal  should  be  provided.  The  MAH  has  not  provided  the requested long-term efficacy data which is acceptable since the MAH is no longer pursuing the indication for paediatric patients with R/R AML.

## Study CPX-MA-1201

With the 100 unit/m 2  dose the ORR was 33.3% and 16.7% of the patients achieved CR. The MAH has only briefly contextualised these results by stating that 'the observed ORR values were consistent with children and young adults with relapsed/refractory AML who were predominantly heavily pre-treated (Gorman 2010; Quarello 2015; Cooper 2017; Jaiswal 2016)'.

Due to limited number of patients in this study, the efficacy results of this small SAT could be regarded descriptive at best.

## 1.6.4. Conclusions on the clinical efficacy

In the pivotal clinical study AAML1421, treatment with CPX-351 resulted in an ORR (CR + CRp) of 68% and the best response rate (CR + CRp + CRi) of 81% in relapsed paediatric patients. The reported CR rate of 54%, supported by the CR/CRp/CRi rate, is considered promising for the high-risk AML study population.

The indication for the treatment of relapsed or refractory AML in paediatric and young adult patients aged 1 to 21 years old is no longer pursued, and only updating the text within Section 4.4, 5.1 and 5.2 of the SmPC  is  proposed.    The  response  rate  is  presented  as  a  simple  proportion  of  responders  and  the corresponding Clopper-Pearson confidence interval.

Since the MAH no longer pursuing the indication for paediatric patients with R/R AML all outstanding issues that were raised during the evaluation of the clinical efficacy are not further pursued.

<div style=\"page-break-after: always\"></div>

## 1.7. Clinical safety

## Introduction

To support this variation, the MAH has submitted safety data from the following 2 studies in paediatric/ young adult subjects  with  AML  (and  ALL)  and  Study AAML1421  and  Study CPX-MA-1201,  described  in Section 1.6 of this report.

For the key baseline demographic patient and disease characteristics and the patient flow for the pivotal study AAML1421, see efficacy section Table 23 and Figure 11 ., respectively.

Pooling of paediatric safety data from the two studies was not performed, because of differences in the characteristics of the two available studies.

## Patient exposure

## Study AAML1421

In Study AAML1421 all 38 subjects (100%) received 1 cycle of therapy with CPX-351 followed by FLAG (Cycle 2). All but 1 subject (37/38 subjects, 97.4%) received 3 CPX-351 doses of 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine; 1 subject received 2 CPX-351 doses of 59 mg/m 2  daunorubicin and 135 mg/m 2 cytarabine. Overall, the mean (SD) cumulative doses of daunorubicin and cytarabine received were 220.1 (106.50) mg and 500.1 (242.04) mg, respectively.

Recommended phase 2 dose: During the Dose-finding Phase, CPX-351 dosing was initiated at 59 mg/m 2 daunorubicin and 135 mg/m 2  cytarabine administered once daily to subjects on Days 1, 3, and 5. A total of 1/6 subjects experienced a DLT (ejection fraction decreased) and this dose was determined to be the RP2D.

## Study CPX-MA-1201

A total of 22 subjects received a CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine (4 in the Dose Exploration Phase and 18 in the Expansion Phase), and 5 subjects (all in the Dose Exploration Phase) received a CPX-351 dose of 59 mg/m 2  daunorubicin and 134 mg/m 2  cytarabine. All 27 subjects (100%)  received  1  course  of  therapy.  Overall,  the  mean  (SD)  cumulative  dose  of  daunorubicin  and cytarabine received were 135.7 (80.41) mg and 308.5 (182.75) mg, respectively.

Maximum tolerated dose: During the Dose Exploration Phase, CPX-351 dosing was initiated at 44 mg/m 2 daunorubicin and 100 mg/m 2  cytarabine in 9 subjects. No DLTs were observed and dosing was escalated to 59 mg/m 2  daunorubicin and 134 mg/m 2  cytarabine. At this dose, 2/5 subjects experienced DLTs (1 DLT of Grade 3 headache and 1 DLT of Grade 3 pain). Therefore, the MTD was declared to be a CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m2 cytarabine administered IV once daily on Days 1, 3 and 5. This dose was used in the Expanded Phase. One subject in the Expanded Phase experienced a DLT PT Platelet count decreased (Grade 4) which resolved in 2 days. The investigator considered the event to be probably related to CPX-351.

## Premedications and Concomitant Medications

## Paediatrics and Young Adults

Subjects were not routinely premedicated for hypersensitivity or for potential infusion-related reactions prior to the first infusion of the first treatment course. If a subject developed a hypersensitivity reaction, then the subject should have been premedicated at subsequent infusions. Subjects were also allowed to

<div style=\"page-break-after: always\"></div>

receive ongoing supportive and palliative care (e.g., pain control) as clinically indicated throughout each study.

As expected, the RR-AML subject populations were heavily pre-treated. For AAML1421, the baseline mean prior anthracycline use is reported as 344.51 (96.461) mg/m 2 . For Study CPX-MA-1201, based on protocol inclusion criteria, all subjects reported receiving prior therapy to treat their AML or ALL. Specifically, all subjects reported receiving chemotherapy; 10/23 subjects with AML (43.5%) and 1/4 subject with ALL (25.0%) reported receiving a transplant; and 1/23 subjects with AML (4.3%) and 3/4 subjects with ALL (75.0%) reported receiving radiation.

Considering  the  study  population  of  subjects  with  RR-AML  undergoing  aggressive  chemotherapy concomitant medications used across the paediatric Studies AAML1421 and CPX-MA-1201 were as expected in this context. For these studies the subjects were allowed to receive ongoing supportive care as clinically indicated throughout the study, however, no data on concomitant medications are available in the datasets.

## Adverse events

A summary of AEs that occurred on or after the first dose of study medication administration is provided below for the pediatric RR-AML studies (AAML1421 and CPX-MA-1201).

Treatment-emergent adverse events that occurred after study medication administration (regardless of relatedness to study medication) were reported for each dose level.

## Study AAML1421

The majority of subjects experienced TEAEs and related TEAEs during the study. More than half of subjects experienced  serious  TEAEs,  and  related  serious  TEAEs.  The  majority  of  subjects  (89.5%)  experienced events  categorized  as  ≥ Grade 3,  with  4 subjects  (10.5%)  experiencing  Grade 4  TEAEs,  and  1 subject (2.6%) experiencing a Grade 5 TEAE. No subjects went off protocol therapy due to unacceptable toxicity.

Table 29. Study AAML1421 Overall Summary of Treatment-emergent Adverse Events (Safety Analysis Set)

|                                         | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|-----------------------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                         | Dose-finding Phase N = 6    | Efficacy Phase N = 32       | Overall N = 38              |
| Subjects with any TEAE                  | 6 (100)                     | 28 (87.5)                   | 34 (89.5)                   |
| Subjects with any Serious TEAE          | 6 (100)                     | 15 (46.9)                   | 21 (55.3)                   |
| Subjects with any Related TEAE          | 5 (83.3)                    | 25 (78.1)                   | 30 (78.9)                   |
| Subjects with any Serious Related TEAE  | 5 (83.3)                    | 15 (46.9)                   | 20 (52.6)                   |
| Subjects with any TEAE by Maximum Grade | 6 (100)                     | 28 (87.5)                   | 34 (89.5)                   |
| Grade 1                                 | 0                           | 0                           | 0                           |
| Grade 2                                 | 0                           | 0                           | 0                           |
| Grade 3                                 | 4 (66.7)                    | 25 (78.1)                   | 29 (76.3)                   |
| Grade 4                                 | 1 (16.7)                    | 3 (9.4)                     | 4 (10.5)                    |
| Grade 5                                 | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Grade 3 to 5                            | 6 (100)                     | 28 (87.5)                   | 34 (89.5)                   |

Abbreviations: AE = adverse event; CRF = case report form; TEAE = treatment-emergent adverse event. Note: A TEAE was defined as any event with an onset date on or after the treatment start date in the eligibility CRF up to 30 days after the last reporting period end date, or any ongoing event that worsened in severity after the date of the first dose of study drug up to and including 30 days after the last reporting period end date.

Note: Adverse event severities were graded by the investigator as Grade 1: mild, 2: moderate, 3: severe or medically significant but not immediately life-threatening, 4: life-threatening, or 5: death. Severity was captured in the CRF question 'AE Grade'.

<div style=\"page-break-after: always\"></div>

Note: Relationship to study drug was identified using a scale of definite, probable, possible, unlikely, and unrelated and was assessed by the investigator and captured in the CRF question 'AE attribution to CPX-351.' A related TEAE was a response of 'possible, probable, and definite' to the CRF question 'AE attribution to CPX-351'.

Note: Percentages are based on N. Note: Subjects received Cycle 1 CPX-351 dose of 59 mg/m 2 daunorubicin and 135 mg/m 2 cytarabine treatment in Dose-finding Phase and Efficacy Phase .

## Study CPX-MA-1201

All subjects experienced TEAEs during the study (Table 30). In the Dose Exploration Phase, all subjects who  received  Dose  Level 1  (CPX-351  dose  of  44 mg/m 2   daunorubicin  and  100 mg/m 2   cytarabine) experienced TEAEs and related TEAEs. A total of 2/4 subjects (50.0%) experienced SAEs and 2/4 subjects (50.0%) experienced related SAEs. No subjects experienced DLTs. Dosing was subsequently escalated to test Dose Level 2 (CPX-351 dose of 59 mg/m 2  daunorubicin and 134 mg/m 2  cytarabine). At this Dose Level all  5 subjects  experienced  TEAEs,  SAEs,  or  related  TEAEs  or  related  SAEs.  Two  subjects  (40.0%) experienced events classified as DLTs. Therefore, all subjects in the Expanded Phase received Dose Level 1 (CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine).

In  the  Expanded  Phase,  all  18 subjects  experienced  TEAEs  and  related  TEAEs.  A  total  of  16 subjects (88.9%)  experienced  SAEs  and  15 subjects  (83.3%)  experienced  related  SAEs.  One  subject  in  the Expanded Phase experienced an event classified as a DLT.

Among the 22 subjects who received a CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine (regardless of whether it was in the Dose Exploration Phase or the Expanded Phase), all experienced TEAEs and  related  TEAEs.  A  total  of  18/22 subjects  (81.8%)  experienced  SAEs,  and  17 subjects  (77.3%) experienced related SAEs.

All subjects experienced Grade 3 and Grade 4 events. No subjects experienced Grade 5 TEAEs.

The AEs/SAEs at a higher dose of CPX-351 dose of 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine (Study AAML1421) were similar to those at a CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m 2 cytarabine (Study CPX-MA-1201) in the pediatric population and young adults up to 21 years of age.

Table 30 . Study CPX-MA-1201 Overall Summary of Treatment-emergent Adverse Events (Safety Analysis Set)

|                                                                           | Number of Subjects, n (%)                                             | Number of Subjects, n (%)                                             | Number of Subjects, n (%)                                             | Number of Subjects, n (%)                                             |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                           | Dose Exploration Phase                                                | Dose Exploration Phase                                                | Expanded Phase                                                        | Overall                                                               |
|                                                                           | 100 units/m 2 N = 4                                                   | 134 units/m 2 N = 5                                                   | 100 units/m 2 N = 18                                                  | 100 units/m 2 N = 22                                                  |
| Subjects with any TEAE i)                                                 | 4 (100)                                                               | 5 (100)                                                               | 18 (100)                                                              | 22 (100)                                                              |
| Subjects with any Serious TEAE Error! Reference source not found.         | 2 (50.0)                                                              | 5 (100)                                                               | 16 (88.9)                                                             | 18 (81.8)                                                             |
| Subjects with any Related TEAE ii)                                        | 4 (100)                                                               | 5 (100)                                                               | 18 (100)                                                              | 22 (100)                                                              |
| Subjects with any Serious Related TEAE Error! Reference source not found. | 2 (50.0)                                                              | 5 (100)                                                               | 15 (83.3)                                                             | 17 (77.3)                                                             |
| Subjects with any DLT                                                     | 0                                                                     | 2 (40.0)                                                              | 1 (5.6)                                                               | 1 (4.5)                                                               |
| Subjects with any TEAE Error! Reference source not found. by Severity     | Subjects with any TEAE Error! Reference source not found. by Severity | Subjects with any TEAE Error! Reference source not found. by Severity | Subjects with any TEAE Error! Reference source not found. by Severity | Subjects with any TEAE Error! Reference source not found. by Severity |
| Grade 1                                                                   | 0                                                                     | 5 (100)                                                               | 4 (22.2)                                                              | 4 (18.2)                                                              |
| Grade 2                                                                   | 1 (25.0)                                                              | 4 (80.0)                                                              | 12 (66.7)                                                             | 13 (59.1)                                                             |
| Grade 3                                                                   | 4 (100)                                                               | 5 (100)                                                               | 18 (100)                                                              | 22 (100)                                                              |
| Grade 4                                                                   | 4 (100)                                                               | 5 (100)                                                               | 18 (100)                                                              | 22 (100)                                                              |

<div style=\"page-break-after: always\"></div>

|              | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|--------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|              | Dose Exploration Phase      | Dose Exploration Phase      | Expanded Phase              | Overall                     |
|              | 100 units/m 2 N = 4         | 134 units/m 2 N = 5         | 100 units/m 2 N = 18        | 100 units/m 2 N = 22        |
| Grade 5      | 0                           | 0                           | 0                           | 0                           |
| Grade 3 to 5 | 4 (100)                     | 5 (100)                     | 18 (100)                    | 22 (100)                    |

Abbreviations: AE = adverse event, CRF = case report form; DLT = dose limiting toxicity; TEAE = treatment-emergent adverse event. Error! Reference source not found. A TEAE was defined as any event with onset date on or after the first dose of study drug until 30 days after the last dose, or any ongoing event that worsened in severity after the date of the first dose of study drug up to and including 30 days after the last dose of study drug.  ii )   A TEAE was classified as related based  on  a  response  of  'Possible',  'Definite',  'Probably'  to  the  CRF  question  'AE  attribution  to  CPX-351'.  Note: Percentages were based on N.

Note: 1 unit CPX-351 = 1 mg cytarabine and 0.44 mg daunorubicin. Note: Treatment-emergent adverse event severity was graded by the investigator as Grade 1: mild, 2: moderate, 3: severe or medically significant but not immediately life-threatening, 4: life-threatening, or 5: death. Maximum grade was captured in the CRF.

## Common Adverse Events

## Study AAML1421

Overall (N = 38 subjects), the reported TEAEs were most frequently categorized in the SOCs Infections and Infestations  (20 subjects,  52.6%),  Blood  and  Lymphatic  System  Disorders  (19 subjects,  50.0%), Investigations  (18 subjects,  47.4%),  and  Skin  and  subcutaneous  (SC)  Tissue  Disorders  (18 subjects, 47.4%) ( Table 31 . ). The most frequently reported TEAEs (i.e., those occurring in ≥ 25% of subjects) listed by  decreasing  frequency  were  Febrile  neutropenia,  Rash  maculopapular,  and  Electrocardiogram  QT prolonged.

The high incidences of TEAEs related to myelosuppression were expected given the known consequences of intensive chemotherapy and are consistent with the known safety profile for this agent. Of note, subjects were on concomitant therapy with other drugs known to prolong the QT interval (e.g., azole antifungal prophylaxis).

Table 31. Study AAML1421 Treatmentemergent Adverse Events Reported in ≥ 5% of Subjects, by System Organ Class and Preferred Term (Safety Analysis Set)

|                                   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|-----------------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred Term | Dose-finding Phase N = 6    | Efficacy Phase N = 32       | Overall N = 38              |
| Subjects with any TEAE            | 6 (100)                     | 28 (87.5)                   | 34 (89.5)                   |
| Infections and Infestations       | 4 (66.7)                    | 16 (50.0)                   | 20 (52.6)                   |
| Skin infection                    | 1 (16.7)                    | 3 (9.4)                     | 4 (10.5)                    |
| Sepsis                            | 1 (16.7)                    | 2 (6.3)                     | 3 (7.9)                     |
| Device related infection          | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Lung infection                    | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Mucosal infection                 | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Upper respiratory tract infection | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Anorectal infection               | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Escherichia infection             | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Septic shock                      | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Staphylococcal infection          | 1 (16.7)                    | 0                           | 1 (2.6)                     |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                    | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                      | Dose-finding Phase N = 6    | Efficacy Phase N = 32       | Overall N = 38              |
| Blood and Lymphatic System Disorders                 | 3 (50.0)                    | 16 (50.0)                   | 19 (50.0)                   |
| Febrile neutropenia                                  | 3 (50.0)                    | 15 (46.9)                   | 18 (47.4)                   |
| Investigations                                       | 2 (33.3)                    | 16 (50.0)                   | 18 (47.4)                   |
| Electrocardiogram QT prolonged                       | 2 (33.3)                    | 9 (28.1)                    | 11 (28.9)                   |
| Alanine aminotransferase increased                   | 0                           | 3 (9.4)                     | 3 (7.9)                     |
| Aspartate aminotransferase increased                 | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Ejection fraction decreased                          | 1 (16.7)                    | 1 (3.1)                     | 2 (5.3)                     |
| Gamma-glutamyltransferase increased                  | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Streptococcus test positive                          | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Skin and Subcutaneous Tissue Disorders               | 1 (16.7)                    | 17 (53.1)                   | 18 (47.4)                   |
| Rash maculopapular                                   | 1 (16.7)                    | 17 (53.1)                   | 18 (47.4)                   |
| Metabolism and Nutrition Disorders                   | 2 (33.3)                    | 7 (21.9)                    | 9 (23.7)                    |
| Hypokalaemia                                         | 2 (33.3)                    | 3 (9.4)                     | 5 (13.2)                    |
| Hyperglycemia                                        | 0                           | 3 (9.4)                     | 3 (7.9)                     |
| Decreased appetite                                   | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Gastrointestinal Disorders                           | 1 (16.7)                    | 4 (12.5)                    | 5 (13.2)                    |
| Colitis                                              | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Dysphagia                                            | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Respiratory, Thoracic and Mediastinal Disorders      | 1 (16.7)                    | 4 (12.5)                    | 5 (13.2)                    |
| Epistaxis                                            | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Hypoxia                                              | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| General Disorders and Administration Site Conditions | 2 (33.3)                    | 2 (6.3)                     | 4 (10.5)                    |
| Pyrexia                                              | 1 (16.7)                    | 1 (3.1)                     | 2 (5.3)                     |
| Death                                                | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Nervous System Disorders                             | 1 (16.7)                    | 2 (6.3)                     | 3 (7.9)                     |
| Hemiparesis                                          | 1 (16.7)                    | 0                           | 1 (2.6)                     |

Abbreviations: CRF = case report form; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SOC = system organ class; TEAE = treatment-emergent adverse event. Note: A TEAE was defined as any event with an onset date on or after the treatment start date in the eligibility CRF up to 30 days after the last reporting period end date, or any ongoing event that worsened in severity after the date of the first dose of study drug up to and including 30 days after the last reporting period end date. Note: Multiple entries for an individual subject under each SOC / PT are only counted once. Note: Some SOCs may have achieved the 5% threshold, but if no underlying PTs achieved the 5% threshold, the SOC is not displayed. Note: Percentages of subjects are based on N. Note: Subjects received Cycle 1 CPX-351 dose of 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine treatment in Dose-finding Phase and Efficacy Phase. Note: MedDRA version 21.0.

<div style=\"page-break-after: always\"></div>

Table 32. TEAEs in ≥ 25% of Subjects at 134 units/m2, by grades 3 -5, SOC and PT

| System Organ Class Preferred Term      | Grade 3   | Grade4   |   Grade5 | Any Grade   |
|----------------------------------------|-----------|----------|----------|-------------|
| Subjects with any TEAE                 | 5 (100)   | 5 (100)  |        0 | 5 (100)     |
| Blood and Lymphatic System Disorders   | 5 (100)   | 0        |        0 | 5 (100)     |
| Anaemia                                | 5 (100)   | 0        |        0 | 5 (100)     |
| Febrile neuhropenia                    | 5 (100)   | 0        |        0 | 5 (100)     |
| Investigations                         | 3 (60.0)  | 5 (100)  |        0 | 5 (100)     |
| Platelet coumt decreased               | 1 (20.0)  | 4 (80.0) |        0 | 5 (100)     |
| Neuhophil coumt decreased              | 0         | 4 (80.0) |        0 | 4 (80.0)    |
| Lymphocyte coumt decreased             | 0         | 3 (60.0) |        0 | 3 (60.0)    |
| White blood cell coumt decreased       | 0         | 3 (60.0) |        0 | 3 (60.0)    |
| Skin and Subeutaneous Tissue Disorders | 1 (20.0)  | 0        |        0 | 5 (100)     |
| Rash maculo-papular                    | 1 (20.0)  | 0        |        0 | 5 (100)     |
| Cardiac Disorders                      | 0         | 0        |        0 | 4 (80.0)    |
| Sinus tachyeardia                      | 0         | 0        |        0 | 4 (80.0)    |
| Vascular Disorders                     | 0         | 0        |        0 | 3 (60.0)    |
| Hypertension                           | 0         | 0        |        0 | 3 (60.0)    |
| Metabolism and Nutrition Disorders     | 2 (40.0)  | 0        |        0 | 2 (40.0)    |
| Decreased appetite                     | 2 (40.0)  | 0        |        0 | 2 (40.0)    |
| Hypokalaemia                           | 2 (40.0)  | 0        |        0 | 2 (40.0)    |

Overall, related  TEAEs were  experienced  by  30/38 subjects  (78.9%).  As  expected  in  this  patient population, related TEAEs occurred most frequently in the SOCs Blood and Lymphatic System Disorders (18 subjects,  47.4%)  and  Skin  and  Subcutaneous  Tissue  Disorders  (16 subjects,  42.1%).  The  most frequently reported related TEAEs (occurring in ≥ 25% of subjects) by listed by decreasing frequency, were Febrile neutropenia and Rash maculopapular.

## Study CPX-MA-1201

Among subjects who received a CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine in the Dose Exploration Phase, the reported TEAEs were most frequently associated with the SOCs Investigations (4 subjects,  100%),  Blood  and  Lymphatic  System  Disorders  (3 subjects,  75%),  and  Metabolism  and Nutrition Disorders (3 subjects, 75%). The most frequently reported TEAEs by PT (i.e., those occurring in ≥ 75% of subjects) by decreasing frequency were Platelet count decreased, white blood cell (WBC) count decreased, Anemia, and Febrile neutropenia.

Among subjects who received CPX-351 dose of 59 mg/m 2  daunorubicin and 134 mg/m 2  cytarabine in the Dose Exploration Phase, the reported TEAEs were most frequently associated with the SOCs Investigations (5 subjects, 100%), Blood and Lymphatic System Disorders (5 subjects, 100%), Skin and Subcutaneous Tissue  Disorders  (5 subjects,  100%),  and  Cardiac  Disorders  (4 subjects,  80%)  ( Table  33 ).  The  most frequently reported TEAEs by PT (i.e., those occurring in ≥ 75% of subjects) by decreasing frequency were Platelet  count  decreased,  Anemia,  Febrile  neutropenia,  Rash  maculopapular,  Sinus  tachycardia  and Neutrophil count decreased.

Among subjects who received CPX-351 dose of 44 mg/m 2  daunorubicin and 100 mg/m 2  cytarabine in the Expanded  Phase  (n = 18),  the  reported  TEAEs  were  most  frequently  associated  with  the  SOCs Investigations (18 subjects, 100%), Blood and Lymphatic System Disorders (18 subjects, 100%), and Skin and Subcutaneous Tissue Disorders (14 subjects, 77.8%) ( Table 33 ). The most frequently reported TEAEs by PT (i.e., those occurring in ≥ 75% of subjects) by decreasing frequency were Platelet count decreased, Anemia, Febrile neutropenia, and Rash maculopapular.

<div style=\"page-break-after: always\"></div>

Overall,  among  subjects  who  received  a  CPX-351  dose  of  44 mg/m 2   daunorubicin  and  100 mg/m 2 cytarabine  (regardless  of  whether  it  was  in  the  Dose  Exploration  Phase  or  the  Expanded  Phase),  the reported TEAEs were most frequently associated with the SOCs Investigations (22 subjects, 100%), Blood and  Lymphatic  System  Disorders  (21 subjects,  95.5%),  and  Skin  and  Subcutaneous  Tissue  Disorders (16 subjects,  72.7%).  The  most  frequently  reported  TEAEs  by  PT  (i.e.,  those  occurring  in  ≥ 75%  of subjects) by decreasing frequency were Platelet count decreased Anemia, and Febrile neutropenia.

Table 33. Study CPX-MA-1201 Treatmentemergent Adverse Events Reported in ≥ 25% of Subjects, by System Organ Class and Preferred Term (Safety Analysis Set)

|                                        | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                        | Dose Exploration Phase      | Dose Exploration Phase      | Expanded Phase              | Overall                     |
| System Organ Class Preferred Term      | 100 units/m 2 N = 4         | 134 units/m 2 N = 5         | 100 units/m 2 N = 18        | 100 units/m 2 N = 22        |
| Subjects with any TEAE                 | 4 (100)                     | 5 (100)                     | 18 (100)                    | 22 (100)                    |
| Investigations                         | 4 (100)                     | 5 (100)                     | 18 (100)                    | 22 (100)                    |
| Platelet count decreased               | 4 (100)                     | 5 (100)                     | 17 (94.4)                   | 21 (95.5)                   |
| White blood cell count decreased       | 3 (75.0)                    | 3 (60.0)                    | 13 (72.2)                   | 16 (72.7)                   |
| Lymphocyte count decreased             | 2 (50.0)                    | 3 (60.0)                    | 12 (66.7)                   | 14 (63.6)                   |
| Neutrophil count decreased             | 2 (50.0)                    | 4 (80.0)                    | 9 (50.0)                    | 11 (50.0)                   |
| Blood bilirubin increased              | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Ejection fraction decreased            | 0                           | 2 (40.0)                    | 2 (11.1)                    | 2 (9.1)                     |
| Electrocardiogram QT prolonged         | 0                           | 1 (20.0)                    | 2 (11.1)                    | 2 (9.1)                     |
| Gamma-glutamyltransferase increased    | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Blood creatinine increased             | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Blood and Lymphatic System Disorders   | 3 (75.0)                    | 5 (100)                     | 18 (100)                    | 21 (95.5)                   |
| Anemia                                 | 3 (75.0)                    | 5 (100)                     | 16 (88.9)                   | 19 (86.4)                   |
| Febrile neutropenia                    | 3 (75.0)                    | 5 (100)                     | 16 (88.9)                   | 19 (86.4)                   |
| Skin and Subcutaneous Tissue Disorders | 2 (50.0)                    | 5 (100)                     | 14 (77.8)                   | 16 (72.7)                   |
| Rash maculopapular                     | 2 (50.0)                    | 5 (100)                     | 14 (77.8)                   | 16 (72.7)                   |
| Metabolism and Nutrition Disorders     | 3 (75.0)                    | 2 (40.0)                    | 9 (50.0)                    | 12 (54.5)                   |
| Hypokalaemia                           | 2 (50.0)                    | 2 (40.0)                    | 6 (33.3)                    | 8 (36.4)                    |
| Hyperglycemia                          | 2 (50.0)                    | 1 (20.0)                    | 3 (16.7)                    | 5 (22.7)                    |
| Decreased appetite                     | 0                           | 2 (40.0)                    | 4 (22.2)                    | 4 (18.2)                    |
| Hypophosphatasemia                     | 1 (25.0)                    | 0                           | 2 (11.1)                    | 3 (13.6)                    |
| Acidosis                               | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Hypomagnesaemia                        | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Hypoalbuminemia                        | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Hypocalcaemia                          | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Hyponatraemia                          | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |

<div style=\"page-break-after: always\"></div>

|                                                 | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|-------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                 | Dose Exploration Phase      | Dose Exploration Phase      | Expanded Phase              | Overall                     |
| System Organ Class Preferred Term               | 100 units/m 2 N = 4         | 134 units/m 2 N = 5         | 100 units/m 2 N = 18        | 100 units/m 2 N = 22        |
| Infections and Infestations                     | 2 (50.0)                    | 3 (60.0)                    | 5 (27.8)                    | 7 (31.8)                    |
| Lung infection                                  | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Skin infection                                  | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Sinusitis                                       | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Respiratory, Thoracic and Mediastinal Disorders | 1 (25.0)                    | 1 (20.0)                    | 5 (27.8)                    | 6 (27.3)                    |
| Hypoxia                                         | 1 (25.0)                    | 0                           | 4 (22.2)                    | 5 (22.7)                    |
| Gastrointestinal Disorders                      | 2 (50.0)                    | 2 (40.0)                    | 2 (11.1)                    | 4 (18.2)                    |
| Stomatitis                                      | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Abdominal pain                                  | 1 (25.0)                    | 1 (20.0)                    | 0                           | 1 (4.5)                     |
| Nausea                                          | 1 (25.0)                    | 1 (20.0)                    | 0                           | 1 (4.5)                     |
| Vomiting                                        | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Vascular Disorders                              | 1 (25.0)                    | 3 (60.0)                    | 3 (16.7)                    | 4 (18.2)                    |
| Hypertension                                    | 1 (25.0)                    | 3 (60.0)                    | 3 (16.7)                    | 4 (18.2)                    |
| Cardiac Disorders                               | 0                           | 4 (80.0)                    | 2 (11.1)                    | 2 (9.1)                     |
| Sinus tachycardia                               | 0                           | 4 (80.0)                    | 1 (5.6)                     | 1 (4.5)                     |
| Musculoskeletal and Connective Tissue Disorders | 1 (25.0)                    | 1 (20.0)                    | 1 (5.6)                     | 2 (9.1)                     |
| Osteonecrosis                                   | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |
| Osteoporosis                                    | 1 (25.0)                    | 0                           | 0                           | 1 (4.5)                     |

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SOC = system organ class;

TEAE = treatment-emergent adverse event.

Note: Percentages of subjects are based on N.

Note: 1 unit CPX-351 = 1 mg cytarabine and 0.44 mg daunorubicin.

Note: A subjects who experienced multiple events within a SOC or PT was counted once for that class and once for the PT.

MedDRA version 21.0

<div style=\"page-break-after: always\"></div>

Table 34. Study 1201 TEAEs in ≥ 10% of Subjects at 100 units/m2, by grades 3-5, SOC and PT

| System Organ Class Preferred Term                | Grade 3   | Grade 4   | Grade 5   | Any Grade   |
|--------------------------------------------------|-----------|-----------|-----------|-------------|
| Subjeets with any TEAE                           | 22 (100)  | 22 (100)  | 0         | 22 (100)    |
| Investigations                                   | 12 (54.5) | 22 (100)  | 0         | 22 (100)    |
| Platelet coumt decreased                         | 0         | 21 (95.5) | 0         | 21 (95.5)   |
| Whitebloodcell coumt decreased                   | 4 (18.2)  | 12 (54.5) |           | 16 (72.7)   |
| Lyuphocyte coumt decreased                       | 4 (18.2)  | 10 (45.5) | 0         | 14 (63.6)   |
| Neuhrophil coumt decreased                       | 1 (4.5)   | 10 (45.5) | 0         | 11 (50.0)   |
| Blood and Lymphatie SystemDisorders              | 21 (95.5) | 0         | 0         | 21 (95.5)   |
| Anaemia                                          | 19 (86.4) | 0         | 0         | 19 (86.4)   |
| Febrile neutropenia                              | 19 (86.4) | 0         | 0         | 19 (86.4)   |
| Slin and Subcutaneous Tissue Disorders           | 10 (45.5) | 0         | 0         | 16 (72.7)   |
| Rash maculo-papular                              | 10 (45.5) | 0         |           | 16 (72.7)   |
| Metabolism and Nutrition Disorders               | 11 (50.0) | 4 (18.2)  | 0         | 12 (54.5)   |
| Hypokalaemia                                     | 4 (18.2)  | 4 (18.2)  | 0         | 8 (36.4)    |
| Hyperglycaemia                                   | 5 (22.7)  | 0         | 0         | 5 (22.7)    |
| Decreased appetite                               | 4 (18.2)  | 0         | 0         | 4 (18.2)    |
| Hypophosphataemia                                | 2 (9.1)   | 1 (4.5)   | 0         | 3 (13.6)    |
| Infections and Infestations                      | 6 (27.3)  | 1 (4.5)   | 0         | 7 (31.8)    |
| Sepsis                                           | 3 (13.6)  | 1 (4.5)   | 0         | 4 (18.2)    |
| Respiratory, Thoracic and Mfediastinal Disorders | 3 (13.6)  | 2 (9.1)   | 0         | 6 (27.3)    |
| Hypoxia                                          | 2 (9.1)   | 2 (9.1)   | 0         | 5 (22.7)    |
| Waseular Disorders                               | 3 (13.6)  | 1 (4.5)   | 0         | 4 (18.2)    |
| Hypertension                                     | 3 (13.6)  | 1 (4.5)   | 0         | 4 (18.2)    |

## Serious adverse events/deaths/other significant events

## Serious Adverse Events

Study AAML1421

Serious TEAEs (SAEs) occurred in 21/38 subjects (55.3%). The majority of SAEs were reported in the SOCs Blood and Lymphatic System Disorders and Infections and Infestations (11/38 subjects, 28.9% in each class). As expected in this subject population, and consistent with results of other studies of CPX-351, the most commonly reported SAE was febrile neutropenia (11/38 subjects, 28.9%; Table 35 ).

Table 35. Study AAML1421 Serious Treatmentemergent Adverse Events Reported in ≥ 5% of Subjects, by Preferred Term in Order of Decreasing Frequency (Safety Analysis Set)

|                                   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|-----------------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred Term | Dose-finding Phase N = 6    | Efficacy Phase N = 32       | Overall N = 38              |
| Subjects with any Serious TEAE    | 6 (100)                     | 15 (46.9)                   | 21 (55.3)                   |
| Febrile neutropenia               | 2 (33.3)                    | 9 (28.1)                    | 11 (28.9)                   |
| Rash maculopapular                | 0                           | 6 (18.8)                    | 6 (15.8)                    |
| Pyrexia                           | 1 (16.7)                    | 1 (3.1)                     | 2 (5.3)                     |
| Anorectal infection               | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Death                             | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Dysphagia                         | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Ejection fraction decreased       | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Escherichia infection             | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Hemiparesis                       | 1 (16.7)                    | 0                           | 1 (2.6)                     |

<div style=\"page-break-after: always\"></div>

|                                   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|-----------------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred Term | Dose-finding Phase N = 6    | Efficacy Phase N = 32       | Overall N = 38              |
| Hypoxia                           | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Sepsis                            | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Septic shock                      | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Staphylococcal infection          | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Streptococcus test positive       | 1 (16.7)                    | 0                           | 1 (2.6)                     |

Abbreviations: CRF = case report form; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; TEAE = treatment-emergent adverse event. Note: A TEAE was defined as any event with onset date on or after the treatment start date in eligibility CRF up to 30 days after last reporting period end date, or any ongoing event that worsened in severity after the date of the first dose of study drug up to and including 30 days after last reporting period end date. Note: Multiple entries for an individual subject under each PT are only counted once. Note: Subjects received Cycle 1 CPX-351 dose of 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine in  Dose-finding  Phase and Efficacy Phase. Note: This table displays TEAEs with onset dates in Cycle 1, Cycle 2, or Follow-up. Note: Percentages of subjects are based on N. Note: MedDRA version 21.0

An examination of SAEs with onset dates during Cycle 1 only, and with onset dates during Cycle 1 and Cycle 2 only, that were reported in ≥ 5% of subjects by SOC and PT revealed a display similar to what is presented in Table 5.5.5.

Treatment-related SAEs occurred in 20/38 subjects (52.6%). The majority of treatment-related SAEs were reported in the SOCs Blood and Lymphatic System Disorders (11/38 subjects, 28.9%) and Infections and Infestations (9/38 subjects, 23.7%). The most commonly reported treatment-related SAE by PT was Febrile neutropenia (11/38 subjects, 28.9%; Table 36 ).

Table 36. Study AAML1421 Related Serious Treatmentemergent Adverse Events Reported in ≥ 5% of Subjects, by System Organ Class and Preferred Term (Safety Analysis Set)

| System Organ Class Preferred Term                    | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred Term                    | Dose-finding Phase N = 6    | Efficacy Phase N = 32       | Overall N = 38              |
| Subjects with any Related Serious TEAE               | 5 (83.3)                    | 15 (46.9)                   | 20 (52.6)                   |
| Blood and Lymphatic System Disorders                 | 2 (33.3)                    | 9 (28.1)                    | 11 (28.9)                   |
| Febrile neutropenia                                  | 2 (33.3)                    | 9 (28.1)                    | 11 (28.9)                   |
| Infections and Infestations                          | 4 (66.7)                    | 5 (15.6)                    | 9 (23.7)                    |
| Anorectal infection                                  | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Escherichia infection                                | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Sepsis                                               | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Staphylococcal infection                             | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Skin and Subcutaneous Tissue Disorders               | 0                           | 6 (18.8)                    | 6 (15.8)                    |
| Rash maculopapular                                   | 0                           | 6 (18.8)                    | 6 (15.8)                    |
| Investigations                                       | 2 (33.3)                    | 2 (6.3)                     | 4 (10.5)                    |
| Ejection fraction decreased                          | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Streptococcus test positive                          | 1 (16.7)                    | 0                           | 1 (2.6)                     |
| Gastrointestinal disorders                           | 0                           | 3 (9.4)                     | 3 (7.9)                     |
| Colitis                                              | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| General disorders and administration site conditions | 0                           | 2 (6.3)                     | 2 (5.3)                     |
| Metabolism and nutrition disorders                   | 0                           | 2 (6.3)                     | 2 (5.3)                     |

Abbreviations: CRF = case report form; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SOC = system organ class; TEAE = treatment-emergent adverse event. Note: A TEAE was defined as any event with onset date on or after the treatment start date in eligibility CRF up to 30 days after last reporting period end date, or any ongoing event that worsened in severity after the date of

<div style=\"page-break-after: always\"></div>

the first dose of study drug up to and including 30 days after last reporting  period end date. Note: Multiple entries for an individual subject under each SOC / PT are only counted once. Note: Subjects received Cycle 1 CPX-351 dose of 59 mg/m 2  daunorubicin and 135 mg/m 2  cytarabine treatment in Dose-finding Phase and Efficacy Phase.  Note: Percentages of subjects are based on N. Note: MedDRA version 21.0

An examination of treatment-related SAEs with onset dates during Cycle 1 only, and with onset dates during Cycle 1 and Cycle 2 only, that were reported in ≥ 5% of subjects by SOC and PT revealed a display similar to the presentation in Table 36 .

## Study CPX-MA-1201

Overall,  among  subjects  who  received  a  CPX-351  dose  of  44 mg/m 2   daunorubicin  and  100 mg/m 2 cytarabine  (regardless  of  whether  it  was  in  the  Dose  Exploration  Phase  or  the  Expanded  Phase), 18/22 subjects (81.8%) reported SAEs ( Table 37 ). The majority of SAEs were reported in the SOCs Blood and Lymphatic System Disorders (17/22 subjects, 77.3%) and Infections and Infestations (6/22 subjects, 27.3%). The most commonly reported SAE was Febrile neutropenia (17/22 subjects, 77.3%).

Table 37. Study CPX-MA-1201 Serious Treatment-emergent Adverse Events by Preferred Term in Order of Decreasing Frequency (Safety Analysis Set)

|                                              | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   | Number of Subjects, n (%)   |
|----------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                              | Dose Exploration Phase      | Dose Exploration Phase      | Expanded Phase              | Overall                     |
| Preferred Term                               | 100 units/m 2 N = 4         | 134 units/m 2 N = 5         | 100 units/m 2 N = 18        | 100 units/m 2 N = 22        |
| Subjects with any Serious TEAEs              | 2 (50.0)                    | 5 (100)                     | 16 (88.9)                   | 18 (81.8)                   |
| Febrile neutropenia                          | 1 (25.0)                    | 4 (80.0)                    | 16 (88.9)                   | 17 (77.3)                   |
| Hypoxia                                      | 1 (25.0)                    | 0                           | 3 (16.7)                    | 4 (18.2)                    |
| Sepsis                                       | 0                           | 1 (20.0)                    | 3 (16.7)                    | 3 (13.6)                    |
| Hypertension                                 | 0                           | 0                           | 2 (11.1)                    | 2 (9.1)                     |
| Lung infection                               | 1 (25.0)                    | 0                           | 1 (5.6)                     | 2 (9.1)                     |
| Stridor                                      | 0                           | 0                           | 2 (11.1)                    | 2 (9.1)                     |
| Acidosis                                     | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Glaucoma                                     | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Infection                                    | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Pain                                         | 0                           | 1 (20.0)                    | 1 (5.6)                     | 1 (4.5)                     |
| Posterior reversible encephalopathy syndrome | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Pulmonary oedema                             | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Seizure                                      | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Skin infection                               | 0                           | 0                           | 1 (5.6)                     | 1 (4.5)                     |
| Bacteraemia                                  | 0                           | 1 (20.0)                    | 0                           | 0                           |
| Cellulitis                                   | 0                           | 1 (20.0)                    | 0                           | 0                           |
| Colitis                                      | 0                           | 1 (20.0)                    | 0                           | 0                           |
| Headache                                     | 0                           | 1 (20.0)                    | 0                           | 0                           |
| Nausea                                       | 0                           | 1 (20.0)                    | 0                           | 0                           |
| Osteomyelitis                                | 0                           | 1 (20.0)                    | 0                           | 0                           |

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SOC = system organ class;

TEAE = treatment-emergent adverse event.

Note: Percentages are based on N.

Note: 1 unit CPX-351 = 1 mg cytarabine and 0.44 mg daunorubicin.

Note: A TEAE was defined as any event with onset date on or after the first dose of study drug until 30 days after the last dose, or any ongoing event that worsened in severity after the date of the first dose of study drug up to and including 30 days after the last dose of

<div style=\"page-break-after: always\"></div>

study drug. TEAE severity was graded by the investigator as Grade 1, 2, 3, 4, or 5. Maximum grade was captured in the case report form.

Note: A subject who experienced multiple events within an SOC or PT was counted once for that class and once for the PT.

Note: MedDRA version 21.0

## Deaths

## Study AAML1421

No deaths occurred while subjects received protocol therapy. A total of 12 deaths occurred during the protocol-defined Follow-up Phase (i.e., after subjects had completed the Treatment Phase of the study); none of these were considered related to protocol therapy. A total of 8 deaths were due to progressive disease and 4 were due to other causes. Half of the deaths (6/12 deaths) were reported within the 6-month Follow-up  Period  (FU 1),  4 deaths  were  reported  within  the  1-year  FU 2,  and  death  was  reported  for 1 subject each at the 2-year (FU 3) and 3-year (FU 4) periods.

## Study CPX-MA-1201

No deaths occurred while subjects received protocol therapy. A total of 10 subjects died during the protocoldefined follow-up period and were due to disease progression.

## Adverse Events of Special Interest

Study AAML1421 and study CPX MA 1201 : there were no AEs of special interest (AESIs) prespecified for the RR-AML paediatric studies.

## Laboratory findings

According to the MAH, routine laboratory monitoring of haematology, electrolytes, blood chemistry and urine and regular assessments of vital signs and physical condition were performed by Investigators for monitoring the safety of all subjects but were not collected as part of the study data. These routine laboratory assessments were recorded in the subjects' medical record. AEs identified from laboratory parameters were to be reported on the AE CRF. Therefore, routine lab results are not included or discussed in the CSRs.

## Hematology

Transfusions of platelets and red blood cells can ameliorate the worst consequences of thrombocytopenia and anaemia in most, but not all cases; during the CPX-351 clinical program transfusions were administered frequently.

## Absolute Neutrophil Count

## Study AAML1421

Although ANC values were not provided in the datasets for AAML1421, responses were verified based on data available in the CRF, including marrow blast percentage and threshold levels for ANC and platelet counts at the end of induction (ANC ≥ 1 × 10 9 /L versus &lt; 1 × 10 9 /L and platelets ≥ 100 × 10 9 /L versus &lt; 100 × 10 9 /L, respectively).

Additionally, the time to peripheral ANC recovery is as follows: at the end of Cycle 1, the mean (SD) time to ANC recovery overall among subjects with CR or CRp was 44.3 (7.21) days. The mean time to ANC recovery was similar for subjects participating in the Dose-finding Phase and the Efficacy Phase.

<div style=\"page-break-after: always\"></div>

At the end of Cycle 2, the mean (SD) time to ANC recovery overall among subjects with CR or CRp was 74.2 (11.16) days.

## Study CPX-MA-1201

Among  subjects  who  received  a  CPX-351  dose  of  44 mg/m 2   daunorubicin  and  100 mg/m 2   cytarabine (regardless of whether it was in the Dose Exploration Phase or the Expanded Phase), most subjects had Grade 4 abnormal ANC levels. The exceptions included 1 subject with Grade 0 ANC levels (within normal limits) at baseline and during treatment, and 2 subjects with abnormal Grade 4 ANC levels at baseline who improved to Grade 2 and Grade 3 during treatment.

During  treatment,  among  subjects  who  received  CPX-351  at  a  dose  of  59 mg/m 2   daunorubicin  and 134 mg/m 2  cytarabine in the Dose Exploration Phase, all subjects had Grade 4 abnormal ANC levels.

## Platelet Count

## Study AAML1421

Although laboratory values for AAML1421 are not presented in the datasets, of note, hematologic DLTs were defined as failure to recover a peripheral ANC &gt; 500/μL and n on-transfusion dependent platelet count &gt; 20,000/μL due to documented bone marrow aplasia/hypoplasia (that is, not due to malignant infiltration) for ≥ 50 days from the start of the therapeutic cycle. Failure to recover peripheral counts due to disease involvement of the bone marrow were not considered dose-limiting.

In the Efficacy Phase, if after Cycle 1 a subject had a hypoplastic bone marrow for ≥ 60 days and failure to recover a peripheral ANC &gt; 500/μL and a non -transfusion dependent platelet count &gt; 20,000/μL not due to  malignant  infiltration  or  severe  infection  (defined  as  ≥ Grade 3  infection),  they  were  considered  a treatment failure and went off protocol therapy.

## Study CPX-MA-1201

Among  subjects  who  received  a  CPX-351  dose  of  44 mg/m 2   daunorubicin  and  100 mg/m 2  cytarabine (regardless of whether it was in the Dose Exploration Phase or the Expanded Phase), 6 subjects had normal platelet levels at baseline. Three subjects had Grade 4 abnormal platelet levels at baseline, and all but 1 of these subjects improved to Grade 3 during study treatment.

During treatment, among subjects who received a CPX-351 dose of 59 mg/m 2  daunorubicin and 134 mg/m 2 cytarabine i n the Dose Exploration Phase, most subjects had ≤ Grade 2 abnormal platelet levels at baseline. During study treatment, platelet levels remained relatively stable for most subjects, with the exception of 1 subject who had Grade 1 abnormal platelet levels at baseline and had Grade 3 abnormal platelet levels during treatment.

## Hemoglobin

## Study AAML1421 and Study CPX-MA-1201

Regular assessments of haemoglobin were performed by Investigators to monitor subject safety, but were not collected as part of the study data. These routine assessments were recorded in the subject medical records. Adverse Events identified from assessments of haemoglobin were to be reported on the AE CRF but were not reported in the laboratory datasets.

## Clinical Chemistry

## Serum Creatinine

<div style=\"page-break-after: always\"></div>

## Study AAML1421 and Study CPX-MA-1201

Serum creatinine levels were performed by Investigators to monitor the safety of all subjects but were not collected as part of the study data. These routine laboratory assessments were recorded in the subjects' medical records. Adverse event identified from the assessments of serum creatinine were to be reported on the AE CRF. Therefore, these results are not included or discussed for Study AAML1421 and Study CPX-MA-1201.

## Serum Bilirubin

## Study AAML1421 and Study CPX-MA-1201

Serum bilirubin levels were performed by Investigators for monitoring the safety of all subjects, but were not collected as part of the study datasets for AAML1421 and Study CPX-MA-1201. These routine laboratory assessments were recorded in the subjects' medical record. Adverse Events identified from assessments of serum bilirubin were to be reported on the AE CRF. Therefore, these results are not included or discussed for these studies.

## Urinalysis

Urinalysis was conducted in each of the clinical trials within the CPX-351 clinical development program. No remarkable findings of any clinical concern were reported.

## Serum Copper

Since CPX-351 contains copper encapsulated in the liposome, which acts as a chelating agent to maintain a slow release rate for daunorubicin, subjects were monitored for serum copper concentrations during each of the clinical studies conducted in the CPX-351 development program.

## Study AAML1421

Serum copper values were not reported for AAML1421.

## Study CPX-MA-1201

Serum copper levels increased from Baseline by Day 5 up to a mean of 800 μg/dL. Of note, the upper limit of  quantitation  of  serum  copper  concentration  by  the  clinical  laboratory  assay  was  800 μg/dL.  Values ≥ 800 μg/dL were reported as 800 μg/dL. Serum copp er levels generally returned to baseline levels by the completion of course 1.

## Vital Signs, Physical Findings, and Other Observations Related to Safety

## Vital Sign Data

For the paediatric studies AAML1421 and CPX-MA-1201, regular assessments of vital signs and physical condition were performed by Investigators for monitoring subject safety, but were not collected as part of the study data. These routine assessments were recorded in the subjects' medical record. Adverse events identified  from  assessments  of  vital  signs  and  physical  condition  were  to  be  reported  on  the  AE  CRF. Therefore, these results were not available for inclusion or discussion in this submission.

## Electrocardiogram Data

Inclusion criteria in both studies required adequate cardiac function, defined as: Shortening fraction of ≥ 27% by echocardiogram, or Ejection fraction of ≥ 50% by radionuclide angiogram or echocardiogram. Study 1421 additionally required a Bazett's corrected QT (QTcB) interval &lt; 500 msecs.

<div style=\"page-break-after: always\"></div>

## Study AAML1421

Measures of left ventricular ejection fraction (LVEF) and left ventricular shortening Fraction (LVSF) over time were assessed by ECHO. In addition, QT interval was assessed by ECG over 2 cycles of therapy and follow-up. The highest corrected QT interval (QTc) was summarized. Measures of cardiac function revealed limited impact of CPX-351 during the course of the study. Mean and median LVSF and LVEF values assessed during ECHO remained near or within normal limits.

## Study AAML1421 Corrected QT Interval

Treatment with CPX-351 did not significantly impact QTc intervals during the course of the study. While a trend towards increasing mean and median QTcs was seen through Follow-up 1, values returned to baseline (study entry) by the time of Follow-up. Results of mean and median QTcs at Follow-up 3 and Follow-up 4 should be interpreted with caution due to the low number of subjects with ECG evaluations.

There were 7 events of QTc prolongation in the Cycle 1 reporting period; all were Grade 1, and 3/7 were related to study medication. One subject recorded a corrected QT &gt; 500 msec during Follow-up 1. The event was reported as an AE (CTCAE Grade 3) with the PT Electrocardiogram QT prolonged. Eight additional subjects recorded a corrected QT ≥ 480 msec and 11/38 subjects overall (28.9%) experienced TEAEs with the PT Electrocardiogram QT prolonged. None of these 11 events was ≥ Grade 3.

Of note, subjects were on concomitant therapy with other drugs known to prolong the QT interval (e.g., azole antifungal prophylaxis). Three events (2 unrelated and 1 related) occurred during concurrent infection events (pneumonia in 2 subjects and mucosal infection in 1 subject).

Table 38. Cardiac Evaluation Summary: Highest Corrected QT Interval Over Time (Safety Analysis Set)

|                    | Proportion of Subjects with ECG Evaluated, n (%)   |   n | Mean (SD)     |   Median | Min, Max   |
|--------------------|----------------------------------------------------|-----|---------------|----------|------------|
| Study Entry        | 35 (92.1)                                          |  35 | 416.8 (34.38) |      424 | 306, 456   |
| Cycle 1            | 33 (86.8)                                          |  33 | 426.4 (32.69) |      435 | 328, 477   |
| Cycle 2            | 20 (52.6)                                          |  20 | 444.0 (25.08) |      441 | 405, 494   |
| Follow-up 1 (6 mo) | 20 (52.6)                                          |  20 | 444.8 (38.94) |      440 | 389, 524   |
| Follow-up 2 (1 yr) | 9 (23.7)                                           |   9 | 424.8 (49.80) |      418 | 340, 499   |
| Follow-up 3 (2 yr) | 2 (5.3)                                            |   2 | 407.0 (7.07)  |      407 | 402, 412   |
| Follow-up 4 (3 yr) | 1 (2.6)                                            |   1 | 497.0 (NC)    |      497 | 497, 497   |

Abbreviations: ECG = electrocardiogram; Max = maximum; Min = minimum; mo = month; NC = not calculated; SD = standard deviation; yr = year.

## Safety in special populations

## Intrinsic Factors

## Exposure-response in Pediatrics and Young Adults

An exposure-response (ER) analysis of safety was performed to include the paediatric population based on data from a total of 46 (18.5%) paediatric subjects (1 to 17 years old) from Study CPX-MA-1201 and Study AAML1421  and  204 (81.5%)  adults  (≥ 18 years)  from  Study 101,  Study  206,  and  Study 301. Subjects  were  dosed  with  either  44 mg/m 2   daunorubicin  and  100 mg/m 2   cytarabine  or  59 mg/m 2 daunorubicin and 135 mg/m 2  cytarabine. Exposure-response analysis in this combined adult and paediatric

<div style=\"page-break-after: always\"></div>

population determined the impact of drug exposure on the probability of the most frequent TEAEs reported which included the PT Neutropenia reported in 141/178 (79.2%) subjects with the 'blood and lymphatic system  disorders'  SOC  and  the  PT  Rash  reported  in  79/203 (38.9%)  of  subjects  with  'skin  and subcutaneous tissue disorders' SOC. The effect of cytarabine maximum concentration (Cmax) or area under the concentration-time curve 0 to 48 (AUC0-48) on the probability of neutropenia were statistically significant (p = 0.0011 and p = 0.0354, respectively). The odds ratio for the Cmax of cytarabine was 1.015, which suggests  that  the  odds  of  response  increased  by  approximately  1.5%  for  each  1 unit  increment  of cytarabine  Cmax  (i.e.  1 µg/mL).  The  Cmax  and  AUC0-48  of  cytarabine  was  also  a  statistically  significant predictor of the probability of rash (p = 0.0092 and p = 0.0354, respectively), with and odds ratio of 1.012.

These results suggest that both the Cmax or AUC0-48 of cytarabine are predicative of neutropenia and rash. Similar to what observed in previous ER analysis for safety, when assessing the probability of any Grade 3 to 5 TEAE in the paediatric population only (Study CPX-MA-1201 and Study AAML1421), no apparent ER relationship was observed. Additionally, in the paediatric population, no statistically significant effect of cytarabine Cmax was observed on the time to recovery of ANC or time to platelet recovery.

## Use in Pregnancy and Lactation

No clinical data are available regarding the safety of CPX-351 during pregnancy or lactation.

Women of childbearing potential  should  avoid  becoming  pregnant  while  receiving  CPX-351.  Women  of childbearing  potential  should  use  effective  contraception  while  they  or  their  male  partner  undergo treatment. Women of childbearing potential should not receive treatment until pregnancy is excluded.

Women of childbearing potential should undergo pregnancy testing before initiation of CPX-351. Men with sexual partners of reproductive potential, and women should use effective contraception during treatment and for 6 months following the last dose of CPX-351.

## Extrinsic Factors

Specific data extrinsic factors were not collected during clinical studies of CPX-351. A relationship between these factors and CPX-351 exposure is unknown.

## Safety related to drug-drug interactions and other interactions

No formal assessments of pharmacokinetic drug-drug interactions between CPX-351 and other agents have been conducted.

## Discontinuation due to adverse events

In study AAML1421 , there were no TEAEs leading to discontinuation.

In study CPX-MA-1201, AE data was not collected to enable reporting of discontinuations due to TEAEs.

## Post marketing experience

## Paediatric and young adult patients

## None

## Adults

<div style=\"page-break-after: always\"></div>

Estimated cumulative exposure in ongoing and completed Jazz Pharmaceuticals, Inc.-sponsored interventional  clinical  trials  is  Vyxeos  (CPX-351)  n = 475  through  02 August 2020.  Vyxeos  Periodic Benefit-risk Evaluation Report (PBRER), dated 06 October 2020, is the 6 th  semi-annual report submitted to the US and the 4 th  PBRER (PSUR) submitted to the EU. It summarizes the cumulative safety profile from clinical trials and post marketing data covering the period 03 February 2020 through 02 August 2020 (MAA EMEA/H/C/004282 SN-0039, submitted 09 October 2020). The PBRER details benefit-risk information for Vyxeos  including  a  cumulative  and  interval  summary  tabulation  of  serious  and  non-serious  adverse reactions from post marketing data sources.

As of the current PBRER (dated 03 April 2020), no actions (e.g., failure to obtain or apply for marketing approval renewal, withdrawal or suspension of a marketing approval, or suspension of supply) by Jazz Pharmaceuticals, Inc. due to a safety reason have been taken.

## Literature search

Given that the cytarabine and daunorubicin components of CPX-351 have been marketed for over 40 years, a literature search (March 2017 using EMBASE, MEDLINE; via Embase.com) was conducted by the MAH to summarize the known safety contributions of the individual agents. The following summarizes specific areas of literature search regarding known safety effects of cytarabine and daunorubicin.

## Myelosuppression

Administration of anthracyclines is associated with significant bone marrow suppression, frequent infections (as a result of neutropenia), increased risk for bleeding events (resulting from thrombocytopenia) (Atallah et el 2007) (Moreau et al. 2009) (Gupta et al. 2010).

## Cardiotoxicity

Administration of anthracyclines is associated with cardiac toxicity (specifically associated with higher doses of daunorubicin administered for longer durations) (Volkova, 2011), (Von Hoff, 1979). Total cumulative doses  of  greater  than  550mg/m2  have  been  associated  with  an  increased  incidence  of  drug  induced congestive  heart  failure.  This  limit  appears  lower  in  patients  who  received  radiation  therapy  to  the mediastinum.

Total cumulative doses of daunorubicin greater than 550mg/m2 have been associated with an increased incidence  of  drug  induced  congestive  heart  failure  (Tan  2015).  Prior  therapy  with  anthracyclines,  preexisting cardiac disease, previous mediastinal radiotherapy or concomitant use of cardiotoxic drugs may increase the risk of daunorubicin induced cardiac toxicity. (Volkova, 2011; Menna 2012).

The use of adjuvant chemotherapeutic agents known to be cardio-toxic increases the risk of heart failure among radiation-treated patients (Senkus-Konefka and Jasseem 2007) History of chest irradiation is a cardiac risk factor (Anderson and. Sawyer 2008).

Risk factors for cardiotoxicity include cumulative dose and concomitant treatment with cyclophosphamide, trastuzumab or paclitaxel (Volkova, 2011).

## Myocarditis

Rare  instances  of  pericarditis-myocarditis,  not  dose-related,  can  occur  with  the  use  of  anthracyclines. Clinically,  early  cardiac  side  effects  are  typically  reversible  and  self-limiting  and  include  dysrhythmia, repolarization changes in the electrocardiogram, pericarditis, and less frequently myocarditis (Senkus and Jassem 2011). These complications do not preclude further anthracycline use (Suter and Ewer 2013).

<div style=\"page-break-after: always\"></div>

## Renal and Hepatic Impairment

Significant hepatic or renal impairment may increase the risk of toxicity associated with cytarabine and daunorubicin. Renal insufficiency is a risk factor in the development of cerebral toxicity during cytarabine treatment (Hasle 1990) (Damon et al. 1989). Anthracyclines are primarily metabolized by the liver with approximately 50% excreted via bile (Barker et al. 2016).

## Hyperuricemia

Metabolic abnormalities characteristic of Tumour lysis syndrome (TLS) include abnormally high serum uric acid  levels  (hyperuricemia).  TLS  typically  occurs  after  the  initiation  of  anticancer  therapies,  including cytotoxic  drugs,  biological  agents,  corticosteroids,  hormones,  and  radiation  therapy,  in  patients  with hematologic  malignancies  or  solid  tumours  that  are  highly  treatment  sensitive.  Daunorubicin  has  a nephrotoxic potential (Mughal et al. 2010)

## Tissue Necrosis

Anthracyclines  can  persist  in  tissues  for  weeks  or  even  months  after  extravasation.  The  local  area  of extravasation is at high risk of infection, because of both the local necrosis and in general by the impaired immunological  state  of  most  patients  receiving  this  kind  of  treatment.  For  significant  anthracycline extravasations, there is a high risk of ulceration and a possible need for surgery (Langer et al. 2009, Jordan et al. 2009)

## Hypersensitivity and Rash

Hand-foot syndrome (palmoplantar erythrodysesthesia) may result from liposomal anthracyclines (Reyes et al. 2014)). Studies show that liposomal formulations of anticancer drugs are less toxic than the nonencapsulated formulations, although some liposome-specific adverse effects such as various skin reactions, and also hypersensitivity reactions have been reported (Slingerland et al. 2012).

Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with daunorubicin and cytarabine (Cytarabine PI; Daunorubicin PI).

## Gastrointestinal events

Administration of anthracyclines is associated with GI side effects (such as nausea, vomiting and diarrhoea). Chemotherapy-Induced Nausea and Vomiting (Hesketh 2008; Peric and Reeves, 2015.)

## 1.7.1. Discussion on clinical safety

In support of this variation and safety, the MAH submitted two paediatric studies. Study AAML1421 was a phase 1/2, open label, single-arm, dose escalating study of CPX-351 followed by fludarabine, cytarabine and filgrastim (FLAG) in 38 paediatric and young adult patients (age range from 1 to 21 years) with RRAML; study CPX-MA-1201 was a phase 1, open label, single arm, dose escalating, pilot study of CPX-351 in paediatric and young adult patients (age range from 1 to 19 years), with RR-AML or acute lymphocytic leukaemia (ALL).

In general, the safety findings in paediatric studies were relatively consistent with those observed in adult patients. Within serious and serious related TEAEs, febrile neutropenia occurred at a significantly higher rate in both paediatric studies than in the adult studies: in study 1421, frequency was 28.9%, all were considered related, whereas in the pooled adult population, frequency was 10.1%, considering induction only 5.3%. The MAH further clarified, that no new or unexpected safety findings were evident from the

<div style=\"page-break-after: always\"></div>

analysis of the paediatric data compared to safety data obtained from adult studies and the post marketing experience.

Increasing the intensity of induction chemotherapy to enhance overall survival often comes at the cost of high treatment-related toxicity. As such, mortality rates following initiation of therapy are considered important measures of SAEs. Specifically, mortality rates at day 30 and day 60 are generally considered as markers of early death associated with treatment.

No deaths occurred while subjects received protocol therapy. In study AAML1421 total of 12 deaths occurred during the protocol-defined Follow-up Phase (i.e., after subjects had completed the Treatment Phase of the study); none of these were judged to be related to protocol therapy. A total of 8 deaths were due to progressive disease and 4 were due to other causes. Half of the deaths (6/12 deaths) were reported within the 6-month Follow-up Period, 4 deaths were reported within the 1 year, and death was reported for 1 subject each at the 2 year and 3-year periods.

The MAH clarified that all deaths appeared not to be related to treatment with Vyxeos. Clustering on any certain age strata was not clearly evident.

According to the MAH, in study AAML1421, there were no TEAEs leading to discontinuation and such data was not accrued in the pilot study.

Administration of anthracyclines is associated with cardiac toxicity, specifically with higher doses of daunorubicin administered for longer period of time. Rare instances of pericarditis-myocarditis, not doserelated, can also occur. It can also be associated with reduction in left ventricular ejection fraction (LVEF) and congestive heart failure. Acknowledging the inherent high morbidity of the patients under study, the results of ECHO and ECG measurements appeared not to cause any specific, major concerns in this limited study sample (study AAML1421). ECG and QT results suggest only a minor effect on the QTc interval with 1 QT prolongation &gt;500ms (grade 3) at the 135 U/m² dose of CPX-351 in paediatrics, which overall confirms conclusions in adults. Regarding cardiac function it appeared that LVSF remained stable, whereas LVEF appeared to decrease slightly from BL. Nearly 25% of patients (8 of 35) experienced reduced LVEF ≤ 50% during the study. However, follow-up data are from 1-2 patients only. 1 SAE of decreased ejection fraction (36%, grade 3) was reported as DLT during cycle 1. Overall, frequency of cardiac/QT-related TEAEs was higher in both paediatric studies than in adult studies. It is deemed appropriate to explore exposure-response for cardiotoxicity-related TEAEs, also considering cumulative doses. Further, for study 1201 cardiac no ECG and ECHO results are available.

Furthermore, drug-induced prolongation of the QT/QTc interval is usually asymptomatic, and an increased rate of certain adverse events in patients taking an investigational agent can signal potential proarrhythmic effects. In study AAML1421 one event was reported as an TEAE (CTCAE Grade 3) with the PT Electrocardiogram QT prolonged. Eight additional subjects recorded a corrected QT ≥ 480 msec and 11/38 subjects overall (28.9%) experienced TEAEs of QT prolongation. None of these 11 events was ≥ Grade 3. Firm conclusions on the basis of the results, including the incidences of AE/SAE on cardiac safety, cannot, however, be made. Confounding by concomitant therapy with other drugs known to prolong the QT interval may, according to the MAH, also be present.

Available evidence of the cardiotoxic potential of Vyxeos liposomal has been reflected in the product information which states that  cardiac disorders (including sinus tachycardia, QT prolongation and ejection fraction decreased ) were observed in studies in anthracycline pre-treated children with relapsed or refractory AML treated with a single induction cycle (Cycle 1) of Vyxeos liposomal.  Several other longterm studies of treatment with anthracycline/ anthracenedione in children suggest that congestive cardiomyopathies with a latency of many years may occur

Patients with AML or ALL suffer from impaired hematopoietic function and often present with anaemia, thrombocytopenia and abnormal neutrophil counts prior to receiving treatment. Due to the nature of the

<div style=\"page-break-after: always\"></div>

disease, treatment-related myelosuppression is an important safety concern monitored by evaluation of laboratory parameters including absolute neutrophil count (ANC) and platelet counts. Reductions in ANC and platelet production directly influence the frequency of acute myelosuppression-related downstream AEs, such as susceptibility to infections and increased risk of bleeding/anaemia. Furthermore, due to the nature of the disease and intensive treatment required, monitoring renal and hepatic function enables optimization of treatment and clinical management of patients with AML.

The impact of intrinsic factors including demographic subgroups of age, race, gender, renal impairment and hepatic impairment on the safety of CPX-351 were not evaluated in the paediatric patients. Also, any possible relationship between extrinsic factors and CPX 351 exposure is unknown, as specific data were not collected during the clinical studies. No data on transfusions were provided other than that they were frequent. Furthermore, there were no AEs of special interest (AESIs) prespecified for the RR-AML paediatric studies.

Further uncertainties remain with respect the safety of Vyxeos liposomal in the treatment of paediatric and young adult patients with RR-AML. Even acknowledging the orphan status of Vyxeos liposomal, the overall numbers of patients under study are small and derive mainly from a sole phase 1/2 study AAML1421. The open label, single arm design also limits the interpretation of the safety results. In addition, the long-term safety data derives mainly from this single, open label, single arm, phase 1/2 study and are, to date, partly pending, as the LTE of this study is still ongoing. The MAH clarified that the current CSR is to be considered as the final one. A sentence on lack of long-term data especially on cardiac safety has been added to the PI and is acceptable. The requested text on the lack of overall paediatric safety data beyond the duration of the provided clinical trials has also been added, on request.

The effects of Vyxeos liposomal on growth and maturation was not evaluated in the submitted studies. A sentence on the lack of these data has been added to the SmPC.

The number of reported AEs and SAEs is high; however, high toxicity can be expected in the target population given the known consequences of intensive chemotherapy in a heavily pre-treated patient population. Based on the provided data from these 2 investigator-initiated trials, the overall clinical safety of CPX 351 seems tolerable and acceptable for the treatment of paediatric patients &gt; 1 years with R/R AML, notwithstanding the limitations of the provided safety data. It is advantageous that both drug substances in non-liposomal intravenous formulations are known and used for years in the treatment of paediatric AML. Safety concerns pertains also to the question of anthracycline pre-treatment and maximal cumulative dose of daunorubicin to prevent long-term cardiotoxicity. Studies excluded patients above certain pre-dose thresholds, but it is unclear whether current recommendations for upper limits were followed.

It is, furthermore, noted that at the time of the original MAA the data submitted was not considered sufficient for the indication of adult RR-AML. This inherently means that there is no adequate trial for Vyxeos liposomal with a positive benefit-risk in the treatment of adults with RR-AML. Text on this issue has been adequately added to the SmPC.

Some question concerning safety were raised based on the original documentation submitted to support the extension of the Vyxeos indication to paediatric and young adult patients with RR-AML. The MAH chose mostly not to answer these questions on the basis that it was no longer pursuing the extension of the indication and these data are thus not needed.

The current paediatric safety data concern a different indication compared to the approved adult indication. However, relevant safety information has been reflected in Sections 4.4 and 4.8 of the SmPC.

On the basis of the submitted data on the safety profile of Vyxeos liposomal in the treatment of RR-AML in paediatric patients no major objections concerning safety were raised. All open safety issues, OCs,

<div style=\"page-break-after: always\"></div>

have been resolved; no unresolved issues remain thus, this variation  is considered approvable from the safety point of view.

## 1.7.2. Conclusions on clinical safety

The safety  profile  of  Vyxeos  liposomal  in  the  paediatric  pre-treated  R/R  AML  population,  appeared,  in general,  to  be  comparable  to  that  of  the  treatment-naïve  adult  population.  There  are  no  outstanding concerns regrading the safety of the product from the available data and thus the variation of the marketing authorisation for Vyxeos liposomal to update sections 4.8, 5.1 and 5.2 of the SmPC is considered from a safety point of view, approvable.

## 1.7.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 1.8. Risk management plan

The MAH submitted an updated RMP version 1.1 with this application. As the new proposed indication was withdrawn the submitted updated RMP is no longer applicable.

## 1.9. Update of the Product information

As a consequence of this variation, sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2. Benefit-Risk Balance

## 2.1.1. Disease or condition

The proposed indication was initially for the treatment of relapsed or refractory AML in paediatric and young adult patients aged 1 to 21 years old. The aim of treatment for patients with relapsed AML is to prolong survival.

## 2.1.2. Available therapies and unmet medical need

Long-term survival rates of pediatric AML patients are currently 70% or even higher. Current first line treatment strategy that includes four to five courses of intensive myelosuppressive chemotherapy, mainly based on anthracyclines and cytarabine with or without (HSCT).

Regarding  novel  agents,  treatment  modalities,  targeted  therapies  and  drugs  such  as  venetoclax, monoclonal antibodies, and cellular therapies are investigated in AML.

However,  up  to  40%  of  the  children  the  AML  relapses,  with  a  probability  of  long-term  survival  of approximately 40%. These poor outcomes indicate the need for improved treatment, including innovative drugs and treatment modalities.

<div style=\"page-break-after: always\"></div>

For patients who relapse, or are refractory to first-line therapy there is a limited number of effective agents available. For the reinduction therapy, several agents have used, including re-introduction of anthracyclines and  cytarabine.  Other  possibilities  include  use  of  mitoxantrone  (alone  or  in  combination  therapy), clofarabine (alone or in combination therapy) and FLAG (alone or in combination therapy).

Optimal treatment for paediatric relapsed AML is not well defined, regarding optimal chemotherapy, the need for allo-HSCT, the timing of an allo-HSCT and risk group stratified treatment based on prognostic factors.  However,  allo-HSCT  in  second  complete  remission  (CR2)  after  reinduction  chemotherapy  is associated with better outcome than chemotherapy only, and once paediatric patient relapses, working toward an allo-HSCT is currently a rule.

Relapsed paediatric AML carries a poor prognosis and represents an unmet medical need.

## 2.1.3. Main clinical studies

Study AAML1421 was a phase 1/2, multicenter study of CPX-351 for children with AML in first relapse, conducted and sponsored by Children's Oncology Group (COG). The primary objectives of this study were to determine a recommended phase 2 dose (RP2D) and the toxicities associated with CPX-351 in pediatric and  young  adult  patients  with  relapsed/refractory  AML  and  to  estimate  the  response  rate  (complete remission [CR] + complete remission with partial platelet recovery [CRp]) after CPX-351 (Cycle 1) followed by fludarabine/cytarabine/G-CSF (FLAG; Cycle 2) in children with AML in first relapse. The MAH was not involved in the study conduct, but received the data from the Sponsors and summarised the results of the study for the purposes of current regulatory submission.

This study comprised 2 phases: a dose-finding and an efficacy phase and altogether 38 patients were included into the study (6 in the dose-finding and 32 in the efficacy phase). In both phases of the study, Cycle 1 treatment consisted of 2 doses of intrathecal (IT) cytarabine (age-based dosing) along with CPX351 administered IV over 90 minutes on Days 1, 3, and 5. Cycle 2 of therapy consisted of FLAG. All patients were treated at the same CPX-351 dose, namely 135 units/m2/dose (i.e. 59 mg/m2 daunorubicin and 135 mg/m2 cytarabine).

## 2.2. Favourable effects (study AAML1421)

The primary efficacy endpoint displayed an overall response rate (CR + CRp) of 68% and the best response rate (CR + CRp + CRi) of 81% after CPX-351 (cycle 1) followed by FLAG (cycle 2).

The secondary efficacy endpoint displayed a response rate (CR + CRp) of 43.2% and the best response rate (CR + CRp + CRi) of 76% after CPX-351 (cycle 1).

The median OS was 32.5 months for all 37 efficacy evaluable patients and 10.1 months for the 7 nonresponders, respectively. In all 26/37 subjects (70.3%) were alive at the time of analysis, or were censored before or at the time of analysis.

## 2.3. Uncertainties and limitations about favourable effects

The efficacy claims are based on a single, uncontrolled, phase I/II pivotal study.

Because of the unconventional method to calculate the number of responders (both with regard to primary and secondary efficacy endpoint) used in this SAT, the MAH should provide the response rate as a simple proportion of responders with the corresponding Clopper-Pearson confidence interval.

<div style=\"page-break-after: always\"></div>

Due to the large heterogeneity of the targeted population and the low sample size being included into the single pivotal study (n=37), uncertainties regarding efficacy in subgroups of clinically relevant prognostic value remain due to incomplete information provided:

- age groups '≥ 1 to &lt;2 ' vs '≥ 2 to &lt;12 ' vs '≥ 12 to &lt;18'
- relapsed vs refractory AML setting
- prior allogeneic HSCT status
- prior therapy with cytarabine/daunorubicin
- time-to-relapse

CR rate and CR/CRi/CRp rate are not considered established or validated surrogate markers for OS in AML. The clinical relevance of CR/CRp/CRi is based on the fact that blast reduction is a prerequisite of a HSCT after  (re-)induction  therapy,  being  the  only  therapeutic  option  with  curative  intent  in  a  high-risk  AML setting. Data on patients proceeding to a HSCT is incomplete, and follow-up data on OS was not provided, and therefore it was not possible to assess the clinical relevance of the reported outcomes.

## 2.4. Unfavourable effects

In study AAML1421, the majority of subjects experienced TEAEs and related TEAEs during the study. More than  half  of  subjects  experienced  serious  TEAEs,  and  related  serious  TEAEs.  The  majority  of  subjects (89.5%)  experienced  events  categorized  as  ≥ Grade 3,  with  4 subjects  (10.5%)  experiencing  Grade 4 TEAEs, and 1 subject (2.6%) experiencing a Grade 5 TEAE.

The most frequently reported TEAEs by PT (those occurring in ≥ 25% of subjects) were febrile neutropenia, maculopapular rash and electrocardiogram QT prolonged. Frequency of TEAEs related to myelosuppression, such as anaemia, were seen more often at both doses in the chemotherapy pre-treated paediatrics than in treatment  naïve  adult  patients.  The  most  common  TEAE  was  febrile  neutropenia.  Cardiac  TEAEs  (QT prolongation, sinus tachycardia, ejection fraction decreased) and rash occurred more often at the higher dose.

For related TEAEs in study 1421, febrile neutropenia was observed at comparable frequency (44.7% vs. 48.3%) whereas rash was more frequent than in adults (42.1% vs. 32.3%).

Serious TEAEs (SAEs) occurred in 21/38 subjects (55.3%). The majority of SAEs were reported in the SOCs Blood and Lymphatic System Disorders and Infections and Infestations (11/38 subjects, 28.9% in each class).  The  most  commonly  reported  SAE  was  febrile  neutropenia  (11/38 subjects,  28.9%).  Rash maculopapular was reported in 6 subjects (15,8%) and pyrexia in 2 subjects (5.3%).

Treatment-related SAEs occurred in 20/38 subjects (52.6%). The majority of treatment-related SAEs were reported in the SOCs Blood and Lymphatic System Disorders (11/38 subjects, 28.9%) and Infections and Infestations (9/38 subjects, 23.7%). The most commonly reported treatment-related SAEs by PT were febrile neutropenia (11/38 subjects, 28.9%), rash maculopapular (6/38 subjects, 15.8%) and colitis (2/38 subjects, 5.3%).

Within serious and serious related TEAEs, febrile neutropenia occurred at a significantly higher rate in both paediatric studies than in the adult studies: in study 1421, frequency was 28.9%, all were considered related, whereas in the pooled adult population, frequency was 10.1%, considering induction only 5.3%.

LVEF appeared to decrease slightly from BL. Nearly 25% of patients (8 of 35) experienced reduced LVEF ≤ 50% during the study. 1 SAE of decreased injection fraction (36%, grade 3) was reported as DLT during cycle 1.

<div style=\"page-break-after: always\"></div>

No deaths occurred while subjects received protocol therapy in either study. A total of 12 deaths occurred during the protocol-defined Follow-up Phase (i.e., after subjects had completed the Treatment Phase of the study); none of these were considered related to protocol therapy.

## 2.5. Uncertainties and limitations about unfavourable effects

- Acknowledging the orphan status of AML, the numbers of paediatric patients are small and derive mainly from a sole, single arm, open label study, with 38 paediatric patients (from 1 to 21 years of age)  with  relapsed  AML  (phase  1/2  study  AAML1421).  Consequently,  numbers  in  the  different paediatric age strata are also small.
- No paediatric safety data have been presented, analysed or discussed according to the age strata.
- Long-term safety data derives from this single study: only preliminary data has been provided for the events of death and cardiovascular safety. According to the MAH further data is not available.
- Long-term data on subsequent treatments are not available. These data are prerequisite for the interpretation of long-term safety.
- Considering cumulative exposure to anthracyclines, studies excluded patients above certain predose thresholds, but due to missing data it is unclear whether current recommendations for upper limits, i.e. higher than the Vyxeos-SmPC-recommended maximal cumulative anthracycline dose, were followed.

<div style=\"page-break-after: always\"></div>

## 2.6. Effects Table

Table 8.6.1. Study AAML1421: Effects Table for Vyxeos liposomal in paediatric and young adult patients from 1 year of age to 21 years of age in the treatment of relapsed AML (data cut-off: 30.6.2019)

| Effect                                                   | Short descripti on                                  | Unit                 | Result                               | Uncertainties / Strength of evidence                                                                                                                              | References (Clinical study report)   |
|----------------------------------------------------------|-----------------------------------------------------|----------------------|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| ORR (CR + CRp) Primary efficacy endoint                  | After CPX- 351 (Cycle 1) followed by FLAG (Cycle 2) | %                    | 68%                                  | very limited data of previous therapies including HSCT, no data with regard the use of HSCT as consolidation in patients achieving CR, no long-term efficacy data | Study AAML1421                       |
| Unfavourable Effects                                     | Unfavourable Effects                                | Unfavourable Effects | Unfavourable Effects                 | Unfavourable Effects                                                                                                                                              | Unfavourable Effects                 |
| Number of patients, all                                  |                                                     | N                    | 38                                   | Safety Analysis set                                                                                                                                               | Study AAML1421                       |
| Any related TEAE                                         | Number of patients                                  | (n)%                 | 30 (78.9)                            | Single arm, open label study, with small numbers, limited/pending long term data.                                                                                 | Study AAML1421                       |
| Any Grade 3 TEAEs                                        | Number of patients                                  | (n)%                 | 29 (76.3)                            | Single arm, open label study, with small numbers, limited/pending long term data.                                                                                 | Study AAML1421                       |
| Any Grade 4 TEAEs                                        | Number of patients                                  | (n)%                 | 4 (10.5)                             | Single arm, open label study, with small numbers, limited/pending long term data.                                                                                 | Study AAML1421                       |
| Any Grade 5 TEAEs                                        | Number of patients                                  | (n)%                 | 1 (2.6)                              | Single arm, open label study, with small numbers, limited/pending long term data.                                                                                 | Study AAML1421                       |
| Any SAE - febrile                                        | Number of patients                                  | (n)%                 | 21 (55.3)                            |                                                                                                                                                                   | Study AAML1421                       |
| neutropenia -maculopapular rash -pyrexia Any Related SAE | Number of                                           |                      | 11 (28.9) 6 (15.8) 2 (5.3) 30 (52.6) |                                                                                                                                                                   | Study AAML1421                       |

Abbreviations: PP, per protocol. AE, adverse event; SAE, serious adverse event; TEAE, treatment emergent adverse event; Notes:

## 2.7. Benefit-risk assessment and discussion

## 2.7.1. Importance of favourable and unfavourable effects

Vyxeos liposomal has demonstrated that majority of study population (study AAML1421) with relapsed AML achieved substantial response and ended up with CR. This is important given the extremely poor prognosis of these patients and their unmet medical need. Secondary endpoint supports the primary outcome.

There is no direct clinical relevance of CR in AML treatment. Its clinical relevance is based on the fact, that CR/CRp/CRi  is  normally  aimed  for  as  the  basis  for  HSCT  after  (re-)induction  therapy,  being  the  only therapeutic  option  with  curative  intent  in  a  high-risk  AML  setting  as  RR  AML.  However,  while  it  is acknowledged that targeting CR2 is of utmost importance, the long-term outcome and contextualisation of the observed efficacy results is difficult. This is due limited data available regarding the use of HSCT as consolidation in patients achieving response (CR2). Importantly, chemotherapy on its own is not likely to have major long-term benefit in patients with relapsed AML.

<div style=\"page-break-after: always\"></div>

Since the MAH is no longer pursuing the indication for paediatric patients with R/R AML, it has not provided the requested data to assess the clinical relevance of the efficacy results nor provided the requested longterm efficacy data. Thus, while this data would be of interest, these issues are not pursued further.

The pivotal study (study AAML1421) included also patients 18-21 years. This issue somewhat complicates the assessment of the efficacy because for these 'young adult' patients there are possible therapeutic options, like gilteritinib, available. Efficacy results have not been presented by age category, and therefore B/R  cannot  currently  be  assessed.  PopPK  analyses  suggested  that  exposures  increased  significantly  in young adults 18-21 years. Based on current PK data, the proposed dose is questionable for young adults aged 18-21 years. However, since the MAH is no longer pursuing the indication for paediatric patients with R/R AML the acceptability of the proposed indication (wording, patient population, posology) is not relevant anymore.

Considering the limitations of the current paediatric data, deriving mainly from a small, single arm study, with limited long-term data and the lack of adequate safety data in adult RR-AML patients, the interpretation and  contextualisation  of  the  submitted  paediatric  safety  data  is  somewhat  restricted.  However,  the adequacy and sufficiency of the totality of the submitted data for the assessment of the overall safety of Vyxeos liposomal in the treatment of paediatric patients with RR-AML is considered acceptable, in the current setting of a PI texts variation, to inform the prescriber, as per guidance, of the availability of the such data.

## 2.7.2. Balance of benefits and risks

Benefit-risk balance of Vyxeos liposomal in paediatric and young adult patients from 1 year of age to 21 years  of  age  in  the  treatment  of  relapsed  or  refractory  AML  is  negative  but  remains  positive  for  the treatment of adults with newly diagnosed, therapy-related   acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

## 2.7.3. Additional considerations on the benefit-risk balance

The MAH has withdrawn the application for the 1-year additional data marketing exclusivity.

## 2.8. Conclusions

The overall B/R of Vyxeos liposomal remains positive for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AMLMRC).

## 3. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, by consensus the variation to the terms of the Marketing Authorisation, concerning the following changes:

<div style=\"page-break-after: always\"></div>

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC to include relevant information in paediatric patients based on results from the paediatric clinical study AAML1421. The Package leaflet is updated accordingly.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan EMEA-001858-PIP02-16-M03 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## 4. EPAR changes

The EPAR will be updated following Commission Decision for this group of variations. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Vyxeos Liposomal-H-C-0004282-II-0018'